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General introduction and objectives 

General introduction
In the Netherlands, on average 1100 new patients are diagnosed annually with
esophageal cancer. The prognosis of esophageal cancer is poor with a 5-year 
survival of 10-15% (1, 2). A surgical resection is currently the primary treatment for 
esophageal cancer if a patient is fit enough to undergo surgery and the tumor is
considered resectable without evidence of distant metastases. More than 50% of 
patients with esophageal cancer have an inoperable disease at presentation due to 
locally advanced or metastatic disease, or severe co-morbidity. For these patients
restoration of the ability to eat is the only possible therapy. Since most of these
patients live no longer than 6 months, the aim of palliative treatment is to relieve 
dysphagia rapidly with minimal or no hospital stay and to maintain the ability to
swallow during life thus improving or maintaining quality of life.
Treatment options most commonly used for palliation of malignant dysphagia 
include self-expanding metal stent placement (3-7), laser therapy (8, 9), external
beam radiation in combination with brachytherapy (10, 11), and brachytherapy as a 
single treatment (12-15). A disadvantage of laser therapy is that repeated treatment
sessions are required to achieve and maintain adequate palliation (8, 9). A combined 
treatment of external beam radiation with brachytherapy is often too intensive for
patients with metastatic disease and a poor medical condition. Therefore, in many
patients with inoperable disease, placement of a self-expanding metal stent or single 
dose brachytherapy are used for the palliation of dysphagia (16). Both these
treatment modalities have been proven to be effective in relieving dysphagia with a
low complication rate (4-7, 12-15), however, their relative effectiveness is unknown. 
A self-expanding metal stent is a flexible tube made of a metal mesh with a plastic
coating. This stent can be inserted into the esophagus during an endoscopic 
procedure to restore a normal food passage to the stomach. The stent can be 
deployed through the stenosis and will gradually expand within 24 hours after
placement. Several types of metal stents are available, of which the Ultraflex stent, 
the Flamingo Wall stent and the Z-stent are most commonly used. These 3 types of 
stents were compared in a randomized study with 100 patients in our hospital. No
major differences existed in effectiveness, occurrence of complications and recurrent 
dysphagia between these stents (4). We therefore decided to use the Ultraflex stent 
as this stent is most commonly used worldwide. 
Brachytherapy (intraluminal radiotherapy) is a local intraluminal radiation. During 
endoscopy a guide wire is left, over which a flexible applicator with a radioactive
source is passed down the esophagus. A radiation dose between 7.5-20 Gy can be
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administered to the esophageal tumor in 1 to 3 treatment sessions. A major
advantage of single dose brachytherapy in comparison to external beam radiation is 
the ability to deliver a maximum radiation dose directly to the tumor without
damaging the healthy surrounding tissue. Based on the literature (12) and the
experience of radiotherapists we decided to use a single dose of 12 Gy 
brachytherapy.
Both treatments (stent placement and single dose brachytherapy) are frequently
used in the Netherlands for the palliation of dysphagia of esophageal carcinoma, 
however, these treatments have never been compared in a randomized trial. In 
addition, a longitudinal extensive investigation of health related quality of life after
these palliative treatments has never been performed. Also, treatment costs and total
medical costs are important outcome measures because of the high initial costs of 
metal stents.
Objectives of this thesis:
Primary objective 
 To compare stent placement and single dose brachytherapy with respect to
relief of dysphagia, complications, treatment for persistent or recurrent
dysphagia, health related quality of life, and costs.
Secondary objectives
 To survey the diagnostic procedures and treatment strategies currently
employed in hospitals for patients with esophageal carcinoma.
 To evaluate the outcome of single dose brachytherapy performed in a 10 year-
period in our hospital. 
 To investigate specific stent related problems, including the influence of prior 
treatment with radiation and/or chemotherapy on the outcome of stent 
placement and occurrence and causes of recurrent dysphagia after stent
placement and the outcome of re-intervention for recurrent dysphagia. 
 To evaluate the outcome of a new type of metal stent to prevent gastro-
esophageal reflux.
12
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Palliative treatment of esophageal carcinoma
2.1 INTRODUCTION 
Annually, cancer of the esophagus and gastro-esophageal junction is diagnosed 
worldwide in more than 400,000 patients, which makes it the 8th most common 
malignancy and 6th on the list of cancer mortality causes (1). It is somewhat difficult
to determine its true incidence, since cancer of the gastro-esophageal junction is 
sometimes classified as gastric cancer and sometimes as esophageal cancer. In 
clinical practice, this distinction is not very important since for both cancer of the
esophagus and cancer of the gastro-esophageal junction, the curative and palliative
options for treatment are the same.
Cancer of the esophagus and gastro-esophageal junction carries a poor prognosis 
with a 5-year survival rate of 10-15% (2). This is partly due to the fact that more than
50% of patients with carcinoma of the esophagus or gastro-esophageal junction have 
already inoperable disease at presentation. Most of these patients require palliative
treatment to relieve progressive dysphagia.
This chapter will focus on the epidemiology and pathogenesis of inoperable cancer
of the esophagus and gastro-esophageal junction. The two most commonly used 
methods for palliation of dysphagia due to inoperable cancer of the esophagus,
namely single dose brachytherapy and stent placement, will be discussed.
2.2 EPIDEMIOLOGY 
Squamous cell carcinoma 
The incidence of squamous cell carcinoma varies from country to country, and also
within a country it may be more often detected in certain regions. About two-third
of new cases of squamous cell carcinoma are detected in China (47%) and Central
Asia (19%). This is called the ‘Central Asia Esophageal Cancer Belt’. The incidence of 
squamous cell carcinoma in this area varies from 19 per 100,000 in Azerbaijan to 340 
per 100,000 in the northern part of China. The incidence of squamous cell carcinoma
in Western Europe and the USA is much lower, i.e., 3-6 per 100,000. In Western
countries, squamous cell carcinoma of the esophagus is mainly found in the older
age group with the highest incidence between 50 and 70 years. The distribution
between males and females is 3-4 to 1 (3).
Adenocarcinoma
Until about 1970, more than 90% of esophageal cancers were squamous cell 
carcinomas. However, population based studies have shown a large increase in the
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incidence of adenocarcinoma of the esophagus and gastro-esophageal junction over 
the last 30 years in North America and Western Europe, especially among white
males (4, 5). In males, the incidence of adenocarcinoma of the esophagus and gastro-
esophageal junction has now surpassed that of squamous cell carcinoma (6). In the
USA, the annual rates per 100,000 population for esophageal adenocarcinoma rose 
from 0.7 during 1974-1976 to 3.2 during 1992-1994, an increase of >350% (5). The 
same trend, although less rapidly, has been reported in other countries, such as 
Australia, New Zealand, and in Western Europe (7). 
Many believe that the increase in (esophageal) adenocarcinoma is related to an 
increase in the incidence of Barrett’s esophagus. In a report from Scotland, Prach et 
al. (8) found that the incidence of new diagnoses of Barrett’s esophagus increased 
from 1 per 100,000 in 1980 to 48 per 100,000 in 1992. The rate of Barrett’s esophagus
detection increased over the same years from 1.4 to 42.7 (16.5 if only cases with
histological conformation were included) per 1000 endoscopical procedures.
Multiple reports confirm that adenocarcinoma of the esophagus and gastro-
esophageal junction occurs more frequently in white males. The distribution
between males and females is 4 to 1. Most patients with esophageal adenocarcinoma
are older individuals with a peak incidence around 65 year (9). The world-wide 
distribution of esophageal cancer (for males) is shown in Figure 1. 
2.3 PATHOGENESIS
Squamous cell carcinoma 
 Smoking and alcohol. The most important risk factors for squamous cell 
carcinoma in Western Europe and the USA are smoking and alcohol intake. The 
squamous cell carcinoma risk is increased by a factor 5 for moderate smokers
and a factor 10 for heavy smokers. It has been shown that alcohol intake and 
smoking are independent risk factors for the development of esophageal
squamous cell carcinoma (10). 
 Food. In Hong Kong, a correlation has been established between the use of
pickled vegetables and the development of squamous cell carcinoma. It was 
found that this was caused by herbs that were used for these vegetables, which
were often contaminated with toxic fungi (11). 
 Prior radiation therapy has been associated with an increased squamous cell
carcinoma risk. A recent study demonstrated that patients who underwent
18
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radiation therapy for breast cancer more than 10 years ago had an increased risk 
of developing squamous cell carcinoma in the esophagus (12). 
 Hot drinks, particularly tea in certain areas in Asia, are associated with an
increased risk of developing squamous cell carcinoma. The suggested 
mechanism is chronic irritation of the esophageal mucosa caused by these hot 
drinks (13).
 The role played by human papillomavirus (HPV) is unclear. In South Africa,
where the incidence of squamous cell carcinoma is high, HPV DNA was
detected in more than 50% of cancers (14). In contrast, in the Netherlands, the 
presence of HPV in squamous cell carcinoma is rare (15). 
Disorders associated with an increased squamous cell carcinoma risk 
 Achalasia. In a cohort study from Sweden, in which 1062 patients with achalasia 
were followed, the risk of squamous cell carcinoma was increased by a factor 16
after a follow-up of 9864 patient-years (16). Since most tumors were detected at
an advanced stage, a ‘curative’ resection was only possible in a minority of the
patients.
 Caustic ingestion. The incidence of esophageal squamous cell carcinoma is
increased by a factor 1000-3000 in patients with a stricture in the esophagus
caused by a caustic ingestion. The risk of developing a malignancy is probably 
highest after the ingestion of lye (17). The mean time between ingestion of a 
corrosive agent and the development of squamous cell carcinoma is 30-40 years.
 Head and neck cancer. Squamous cell carcinoma of the esophagus and the 
(hypo-) pharynx are both associated with smoking and alcohol intake.
Therefore, it is not surprising that 1-8% of the patients with head and neck
cancer also have esophageal cancer or will develop it at a later stage (18). This 
means that the risk of esophageal cancer is increased by a factor 3-10 in patients
with head and neck cancer. 
Adenocarcinoma
 Gastro-esophageal reflux disease. A direct association between reflux and 
adenocarcinomas rather than the presumed sequence of reflux disease leading 
to Barrett’s esophagus and this condition leading to adenocarcinoma was found 
by Lagergren et al. (19). The esophageal adenocarcinoma risk was 7.7 times
increased in persons with heartburn and acid reflux occurring at least once per
week. For those with severe symptoms for 20 years or longer, the risk was 43.5 
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times increased for esophageal adenocarcinoma, but only 4.4 times increased for 
adenocarcinoma of the gastric cardia. There was no correlation with squamous 
cell carcinoma.
 Barrett’s esophagus. Barrett’s esophagus is a disorder of the distal esophagus, in 
which the squamous epithelium is replaced by metaplastic columnar
epithelium. Barrett’s esophagus is a complication of long-standing gastro-
esophageal reflux disease (GERD) (20). A causal relationship between Barrett’s
esophagus and the development of esophageal adenocarcinoma has been
established.
In older reports, the risk of esophageal adenocarcinoma in long segment
Barrett’s esophagus was 30-52 times greater than that of the normal population.
In other words, cancer was diagnosed at a median rate of about 1 per 100
patient-years of follow-up. However, these reports were often based on a short 
period of follow-up with the possibility of including prevalent cancers as
incidence cases and therefore may have overestimated the cancer risk. More
recent reports with longer follow-up found one cancer per 180-200 patients-
years of follow-up (21). The prevalence of Barrett’s esophagus in consecutive 
patients undergoing endoscopy for any clinical indication varies between 0.3% 
and 2% (22). Several studies have shown that Barrett’s esophagus is a disorder
of whites and is mainly found in Western Europe. The distribution between
males and females is 2.5-4 to 1 (9).
2.4 TREATMENT 
A surgical resection is currently the primary treatment for esophageal cancer if a
patient is fit enough to undergo surgery and the tumor is considered resectable 
without evidence of distant metastases. Resection of the esophagus with a gastric
pull-up or a colonic interposition is however an invasive procedure with significant
morbidity and mortality, and most patients have recurrent tumor growth within the
first few years after treatment (23). Neo-adjuvant chemotherapy or chemoradiation
may improve the results of surgery and may prevent patients from recurrent disease 
(24-26). In the past decade, endoscopic methods have been developed to remove
early cancers in the esophagus via a non-surgical endoscopic way.
In patients with inoperable esophageal cancer due to locally advanced or metastatic
disease, or severe co-morbidity, restoration of the ability to eat is the only possible
therapy. Since most of these patients live no longer than 6 months, the aim of 
palliative treatment is to relief dysphagia rapidly with minimal or no hospital stay,
20
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to maintain swallowing during life and to avoid serious complications. It is 
important to realize that treatment of incurable esophageal cancer should be 
individualized and based on tumor stage, medical condition and performance status
of the patient, and the patient’s personal wishes. In addition, both the available
expertise and equipment, and the results of prospective, randomized studies should
be taken into consideration.
There is a wide variety of palliative techniques currently available (Table 1). 
Treatment options most commonly used for palliation of dysphagia include self-
expanding metal stent placement (27-31), laser therapy (32, 33), external beam
radiation in combination with brachytherapy (34, 35), and brachytherapy as a single 
treatment (36-39). A disadvantage of laser therapy is that repeated treatment
sessions are required to achieve and maintain adequate palliation (32, 33). For 
patients with extensive local-regional tumor growth and a good clinical condition, a 
combined treatment of brachytherapy with external beam radiotherapy might result
in good local tumor regression and relief of dysphagia (34, 35, 38). The treatment
schedule most often used involves a total of 50 Gy external beam radiation delivered
in 25 fractions combined with one or two session of brachytherapy (10-15 Gy). This 
schedule is often too intensive for inoperable patients with metastases or a poor 
general condition. Therefore, in many patients with inoperable disease, single dose 
brachytherapy or placement of a self-expanding metal stent are used for the 
palliation of dysphagia (40).
Palliative chemotherapy may result in local and distant tumor control and possibly
also in prolonged survival. Chemotherapy most commonly consists of combination
regimes of cisplatin with paclitaxel and/or 5-FU, etoposide or another agent for both 
squamous cell carcinoma and adenocarcinoma. Response rates (including complete
and partial responses) range from 25 to 45% for metastatic disease with acceptable
toxicity, however, the effect on survival remains undetermined (41-43). Several new 
agents and combination of agents are currently under investigation.
21
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Table 1: Palliative modalities for esophageal carcinoma 
Modality
Non-Endoscopic techniques 
Surgery
Radiation therapy 
External beam radiotherapy 
Intraluminal radiotherapy (brachytherapy) 
Chemotherapy
Endoscopic Techniques 
Stent placement 
Self-expanding metal stents
Laser therapy
Thermal (Nd:YAG) 
Photodynamic therapy 
Dilation
Electrocoagulation (BICAP probe) 
Chemical Injection Therapy
Nutritional Support
Nasoenteric feeding tube 
Percutaneous endoscopic gastrostomy (PEG)
2.5 SINGLE DOSE BRACHYTHERAPY 
Since 1980, brachytherapy (intraluminal radiotherapy) in combination with external
beam radiation has been used for the treatment of esophageal carcinoma. In 1987,
brachytherapy as a single treatment has been introduced for the palliation of 
dysphagia caused by inoperable esophageal carcinoma due to metastatic disease or 
a poor medical condition.
In the past, the most commonly used source for brachytherapy was caesium (137Cs),
but nowadays, iridium (192Ir) has replaced the heavy caesium. Brachytherapy can be 
delivered at different dose rates. These are classified as low dose rate (LDR) 
delivering a dose of 0.4-2 Gy per hour, medium dose rate (MDR) with a dose of >2-
12 Gy per hour, and the most recently developed high dose rate (HDR), with a dose 
of more than 12 Gy per hour. The treatment time is substantially shorter with HDR
brachytherapy, resulting in a much more patient-friendly treatment which can be
carried out as an outpatient procedure (44).
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Single dose brachytherapy is frequently used in Western Europe, South Africa,
Japan and to a lesser extent in the USA. To date, ten studies have reported that in
the majority of patients dysphagia can effectively be palliated by brachytherapy in 
doses varying between 7.5 and 20 Gy given in 1-3 treatment sessions (34, 37, 39, 45-
53) (Table 2). An advantage of brachytherapy (from the old Greek language 
meaning from a short distance) in comparison to external beam radiation is the
ability to deliver a maximum radiation dose directly to the tumor without damaging 
the healthy surrounding tissue. In addition, in particular with HDR brachytherapy,
time of treatment is short, approximately 20-30 minutes.
2.5.1 Description of brachytherapy procedure 
Prior to brachytherapy, an endoscopy is performed. If needed, the stricture is 
dilated to a maximum of 11 mm by dilation with a Savary-Miller Esophageal Dilator
(Wilson-Cook Medical, Winston-Salem, NC, USA). The proximal and distal tumor
margins are marked by injecting radiographic contrast medium into the submucosa 
of the esophageal wall through a sclerotherapy needle. Then a guide wire is left. For 
brachytherapy, a flexible applicator (Bonvoisin-Gérard Esophageal Applicator,
Nucletron, Veenendaal, The Netherlands) with a diameter of 10 mm is passed down 
the esophagus (Figure 2A). In some patients a feeding tube (charrière 14) can be 
used as applicator for brachytherapy. A thread with ‘dummy loads’ is introduced
into the applicator. A chest X-ray is made, to check the position of the applicator
with the ‘dummy loads’ (Figure 2B). A dose of 7.5-20 Gy is administered with the
radioactive source 192Iridium at 1 cm from the source axis of the applicator in 1-3 
sessions. In our center, a single dose of 12 Gy is the most commonly used treatment.
The dose distributed to the surface of the tumor (5 mm from the source axis) will
amount 200% of the prescribed dose. The dose administrated at 12.5 mm from the
source axis is then 65% (at 7.5 mm depth inside the tumor). The standard active
length of the application is the tumor length plus two centimeters extra at both ends
of the tumor. The mean application time of the procedure is 15-20 minutes. It is
advisable to prescribe sucralfate (Ulcogant£, E. Merks Nederland, Amsterdam) for a
period of 4 weeks after single dose brachytherapy as a prophylactic measure for 
odynophagia (54). 
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Table 2: Overview of studies using brachytherapy for palliation of patients with an 
inoperable esophagogastric carcinoma.
Author N Dose Dysphagia
Improved
Complications Recurrent
dysphagia
Survival
Giles
Rowland et al.
1985 (46)
40 15Gy/1x 65% 12.5% esophagitis ? ?
Low et al.
1992 (51)
12 15Gy/1x 83% 33% esophagitis, 17% 
pain, 17% pyrexia, 8% 
bleeding
30% ?
Harvey et al.
1993 (47)
A: 10 
B: 12 
20Gy/3x
12.5Gy/1x
90%
92%
30%
80% esophagitis
30%
39%
4 months
5.8 months
(mean)
Brewster et al.
1995 (37)
197 7.5-
20Gy/1x
54% 2% severe
complications
? 136 days
(median)
Jager et al. 
1995 (48)
88 15Gy/1x 67% 34% retrosternal pain,
1% hematemesis, 6%
fistulae
37% 5.5 months
(median)
Kulhavy et al.
1995 (49)
A:12
B:14
C:14
D:11
10Gy/1x
12Gy/1x
15Gy/1x
18Gy/1x
3/4
8/8
6/6
3/7
0%
0%
0%
9% fistulae
17%
14%
7%
27%
?
Leung et al.
1995 (50)
10 7.1-
60Gy/1x
90% 0% 10% 3 months
(median)
Sur et al. 1998 
(52)
A: 36 
B: 68 
C: 68 
12Gy/2x
16Gy/2x
18Gy/3x
? 14% strictures, 20% 
fistulae
25% strictures, 3% 
fistulae
42% strictures, 11% 
fistulae
? 10%, 1 year 
22%, 1 year 
35%, 1year 
Sur et al. 2002 
(39)
A: 112 
B: 120 
16Gy/2x
18Gy/3x
? 11% strictures, 10% 
fistulae
12%
persistent
disease,
35%
additional
treatment
237 days
(median)
Sharma et al.
2002 (53)
58* 6Gy/2x 48% 15% strictures, 10% 
ulceration, fistulae 5%
? 7 months
(median)
*of which 20 patients received a combination of 20-30 Gy external beam radiation and brachytherapy, no
separate data were given for the group treated only with brachytherapy.
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Figure 2: Esophageal applicator for single dose brachytherapy (left) and chest X-ray before 
start of the brachytherapy to check the position of the applicator (right). 
2.5.2. Complications and recurrent dysphagia
Major complications after single dose brachytherapy mainly consist of fistula
formation, hemorrhage, aspiration pneumonia, fever and severe pain. Recurrent 
dysphagia following single dose brachytherapy is most commonly caused by tumor
persistence, tumor recurrence and stricture formation. Minor complications are
mainly mild retrosternal pain and radiation esophagitis (Table 2). 
Fistula formation
Tumors that infiltrate into surrounding tissue, most commonly the respiratory tract
and occasionally the aorta, mediastinum or pleura, are most likely prone to develop
a fistula. Patients with evidence of deep ulceration of the tumor or macroscopic
growth into the tracheal lumen should therefore be excluded from brachytherapy. 
Fistula formation has been reported to occur in around 3-10% of patients (Table 2). 
Treatment of a fistula should be instantly, as fistula formation is a life-threatening
complication, which in case of esophagorespiratory fistulas can result in serious 
pulmonary infection from aspiration pneumonia. Placement of a covered metal stent
is the treatment of choice (55-57).
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Hemorrhage
Hemorrhage most commonly occurs as a late complication. It is often unsure 
whether this is due to the treatment or progression of the disease. Hemorrhage after 
brachytherapy has been reported in up to 5% of patients (Table 2). Treatment
consists of blood transfusions, sometimes in combination with a short course of
external beam radiotherapy.
Tumor persistence and tumor recurrence
Tumor persistence and tumor recurrence are the most predominant causes of an 
additional treatment after single dose brachytherapy (Table 2). Reported incidences 
vary widely between 10-40%. Treatment most commonly consists of a second dose 
of brachytherapy or placement of a metal stent. 
Radiation esophagitis
Radiation esophagitis is a frequently reported early complication after radiation
therapy with incidence rates up to 80%. Radiation esophagitis is more commonly
observed with high radiation doses or combined external and intraluminal
radiotherapy. It is advisable to prescribe prophylactic oral sucralfate for a period of
4 weeks to prevent radiation esophagitis (54). It is thought that sulcralfate coats the
mucosa and in that way promotes the healing of radiation induced ulcers and 
edema (54). In our experience, radiation esophagitis is only a minor problem if 
single dose brachytherapy with a radiation dose of 12-15 Gy is used in combination
with sulcralfate.
2.6 SELF-EXPANDING METAL STENTS
Placement of a self-expanding metal stent is a frequently used method for palliation
of malignant dysphagia. Since 1990, more then 75 studies have been published on
the outcome of metal stent placement for the palliation of esophageal carcinoma 
(summarized in (58-60)). 
2.6.1 Metal Stents versus Prosthetic Tubes
Metal stents have several advantages over the previously used prosthetic tubes, 
since they can be inserted with a minimum of dilation, the diameter of the delivery 
catheters being only 7-11 mm. After placement of a metal stent, the stent expands
gradually, which potentially decreases the occurrence of subsequent procedure-
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related complications. Moreover, the larger lumen achieved from 16 to 24 mm, and
the flexibility of metal stents should improve the quality of swallowing compared to
prosthetic tubes. An advantage of prosthetic tubes is the low cost compared to the 
more expensive metal stents.
Several randomized trials have been performed comparing metal stents with
prosthetic tubes (61-66). In summary, these studies have demonstrated that
placement of a metal stent is associated with fewer procedure-related complications
than a prosthetic tube (62, 63, 65, 66). In one study, metal stents were also more
effective in improving dysphagia (64). Studies on cost-effectiveness have shown 
that, despite the high initial purchase costs, metal stents were more cost-effective 
than prosthetic tubes because of a shorter hospital stay for procedures for stent-
related complications (61, 62, 64, 67). 
2.6.2 Currently Available Metal Stents
Special stent characteristics are needed for the effective palliation of tumors of the
distal esophagus and the gastric cardia. The ideal stent would have the following
characteristics:
- it would have a large internal diameter to ensure the passage of a normal diet; 
- it would be flexible and non-traumatic while still achieving full expansion; 
- it would not migrate, yet could be repositioned or removed if necessary. 
Although this ideal stent does not exist, all available covered metal stents do meet
some of these criteria (Table 3). 
The Ultraflex stent (Boston Scientific, Natick, Massachusetts, USA) consists of a
knitted nitinol wire tube, and the covered version has a polyurethane layer which 
covers the midsection of the stent extending to within 1.5 cm of either end of the
stent (Figure 3). The stent has a proximal flare with two sizes: 28 mm (distal
diameter 23 mm) and 23 mm (distal diameter 18 mm). The stent has an easy-to-use
delivery system, and can be deployed gradually either from the proximal to the
distal end or vice versa. It is important to remember that the degree of shortening
after stent placement is 30–40%. The radial force of the Ultraflex stent is the lowest
amongst the currently available metal stents. Partial obstruction of the stent may
occur in stents that are sharply angulated after crossing the gastro-esophageal
junction.
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The Wallstent (Boston Scientific) is made from cobalt-based alloy and is formed into
a tubular mesh and is available in two designs: the Wallstent II and the Flamingo 
Wallstent (available only in Europe) (Figure 3). Stents of both designs are easy to 
place. The Wallstent can be repositioned during the procedure because recapturing 
remains possible when less than 50% of the stent is expanded. The degree of 
shortening after placement is about 20-30%. Both designs have a high radial force. 
The Wallstent II flares to 28 mm at both ends with a diameter of 20 mm at its
midsection. It is covered with a silicone polymer layer, with 2 cm left unexposed at
the proximal and distal ends. The Flamingo Wallstent is designed specifically for 
use in the distal esophagus/gastric cardia, however it can be used in the more 
proximal part of the esophagus as well. This conical shaped stent is designed to 
apply a variable radial force throughout the length of the stent to address
anatomical differences in the distal esophagus and gastric cardia. The stent is
covered by a polyurethane layer, which is applied from the inside, extending to
within 2 cm of either end of the stent. Both a large-diameter stent (proximal and 
distal diameters 30 and 20 mm) and a small-diameter stent (proximal and distal
diameters 24 and 16 mm) are available. The Wallstent II and the Flamingo Wallstent
are both very pliable, with the diameter of the stent being unaffected even when
angulated.
The Z-stent (Wilson-Cook Medical, Winston-Salem, North Carolina, USA) with a 
Korean modification, the Choo stent (M.I. Tech, Seoul, Korea), consists of a wide 
“Z”-mesh of stainless steel covered over its entire length by a polyethylene layer 
(Figure 3). The Z-stent is available with (Europe) or without (U.S.A.) fixing barbs in 
the central segment. The introduction system is more complex than that of the 
(Flamingo) Wallstent and the Ultraflex stent. The stent does not shorten on release
and is the least flexible of the currently available metal stents. The Z-stent flares to 
25 mm at both ends with a diameter at its midsection of either 18 mm or 22 mm.
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Figure 3: Currently available covered metal stents, from left to right: Ultraflex stent, 
Flamingo Wallstent, Wallstent II, and Z-stent. The Song stent is not shown, but has a 
design which is comparable to the Z-stent. 
2.6.3 Comparison of different types of metal stents 
There are two retrospective studies and two prospective randomized trials 
comparing the outcome of different types of metal stents. A retrospective study,
including 96 patients, compared the uncovered Ultraflex, covered and uncovered 
versions of the Wallstent, and the covered Z-stent. No differences were found in 
outcome and complication rate between these stent types (68). Covered versions of
the Wallstent and the Ultraflex stent were compared in another retrospective study, 
showing a higher early complication rate with the Wallstent, but a higher re-
intervention rate with the Ultraflex stent (69). In a prospective trial, 100 patients
were randomized to one of three types of covered metal stents, the Ultraflex stent,
the Flamingo Wallstent, and the Z-stent. There were no significant differences in
dysphagia improvement, and the occurrence of complications or recurrent 
dysphagia, although there was a trend towards more complication with the Z-stent
(Ultraflex stent: 8/34 (24%), Flamingo Wallstent: 6/33 (18%) and Z stent: 12/33 (36%); 
p=0.23) (28). In another prospective trial, the Ultraflex stent and the Flamingo
Wallstent were compared in patients with distal esophageal cancer. The two stent 
types were equally effective in the palliation of dysphagia in this patient group, and 
the complication rate associated with their use was also comparable (Ultraflex stent: 
7/31 (23%) and Flamingo Wallstent: 5/22 (23%)) (70). 
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From these data, it can be concluded that there are only minor differences between 
the most commonly used stent types. The choice of stent should therefore be 
determined by the location and the anatomy of the malignant stricture on the one
hand and the specific characteristics of the stent on the other hand (Table 3).
2.6.4 Description of the Stent Placement Procedure 
Placement of a metal stent is usually done with the patient under sedation. When
fluoroscopy is used, the proximal and distal margins of the stricture are demarcated 
endoscopically by skin markers, tissue clips, or the intramucosal injection of a 
radiopaque contrast agent. Injection of the lipid-soluble contrast agent lipiodol 
results in a persistent mark. Accurate placement of the Ultraflex stent is also
possible under endoscopic guidance without the aid of fluoroscopy. This can be 
done by the application of an external marker at the level of the proximal
radiopaque marker on the stent, allowing the stent to be placed under direct 
endoscopic visualization (71). This technique is at present only feasible with the
Ultraflex stent release system. Finally, metal stents can be placed under fluoroscopy 
guidance alone, without the use of endoscopy (72). 
In most institutions, a stenotic malignant stricture is dilated to a diameter of 9–10
mm prior to stent placement, to measure stricture length and to accurately place a
guide wire. Dilation may increase the risk of perforation. There is however no 
consensus on whether one or more dilation sessions preceding stent placement will 
lower this risk of perforation. The next step is to place a stiff guidewire, for example 
a 0.038 inch Savary guidewire, across the stricture into the stomach or, preferably,
the duodenum and withdraw the endoscope.
A pre-mounted Ultraflex stent or Wallstent (either a Wallstent II or a Flamingo
Wallstent) is then advanced over the wire. The Wallstent is deployed by retracting
the constraining outer sheath, whereas the Ultraflex stent is deployed by pulling a 
ring attached to the suture ring.
As a first step prior to insertion, the Z-stent needs to be back-loaded into its delivery 
catheter. Then, the Z-stent is deployed by removing a peel-away sheath and pulling
a compression catheter back over a pushing catheter. 
Both the Ultraflex stent and the Wallstent shorten during expansion, which must be
taken into consideration when positioning the introduction system. In order to 
prevent migration of the stent upon release from the introduction system, the 
system should not be advanced too far distally. An advantage of the Wallstent is
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that it can be recaptured (if not expanded over more than 50%) by advancing the
constraining sheath and repositioning the entire stent. The stent should be 2-4 cm 
longer than the stricture to allow for a 1-2 cm extension above and below the
proximal and distal tumor margins. For stents placed across the gastro-esophageal 
junction, stent length is guided by the rule that the proximal covered portion of the 
stent should lie at least 1-2 cm above the tumor margin, whereas the distal covered 
portion should not overlap the tumor margin by more than 1 cm, to prevent
ulceration of the posterior wall of the stomach by the distal end of the stent. There is 
no objection to confirm endoscopically that the upper end of the stent is positioned 
proximal to the upper tumor margin (Figure 4). However, the endoscope should not
be passed through the stent to avoid stent dislodgment from friction with the 
endoscope.
Thanks to their mechanical properties, both the Ultraflex stent and the Wallstent,
whether fully expanded, partially expanded, unexpanded or migrated after release 
from the introduction system, are easier to reposition or remove endoscopically than 
the Z-stent. This is done by pulling at the upper rim of the Wallstent or at the lasso 
attached inside the proximal flange of the Ultraflex stent, causing the radial
diameter of the stent to decrease. Stent expansion can best be confirmed by a chest 
radiograph. Currently, stent placement is an outpatient procedure. Placement of a 
metal stent takes about 15–20 minutes.
Figure 4: Endoscopic view of the Ultraflex stent immediately after placement. 
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2.6.5 Complications and recurrent dysphagia
Procedure-related complications after metal stent placement mainly consist of 
perforation, aspiration pneumonia, fever, bleeding and severe pain, and occur in 5-
15% of patients. Delayed complications and recurrent dysphagia following stent 
placement include hemorrhage, fistula formation, gastroesophageal reflux, stent 
migration, tumor over- or ingrowth, and food-bolus obstruction, and occur in 30-
45% of patients. Minor complications are mild retrosternal pain and gastro-
esophageal reflux, which are reported by 10-20% of patients.
Perforation
Perforation occasionally occurs after stent placement; sometimes following dilation
of an obstructing tumor to facilitate placement of the stent. Perforation is treated
with conservative treatment including naso-duodenal tube feeding, nil per mouth
and antibiotics. Placement of a second stent to seal the perforation is sometimes
indicated.
Fever
Fever which occurs without evidence of aspiration pneumonia or perforation is 
most likely to be caused by a mechanical effect of the stent on the tumor, possibly by 
releasing toxic products from the tumor. Patients usually recover uneventfully after
prophylactic treatment with antibiotics.
Hemorrhage
Hemorrhage, including hematemesis and melena, mostly occurs as a late
complication of stent placement. It is often unsure whether this is due to the stent
placement, progression of the disease, or to a cause unrelated to the tumor and its
treatment. During endoscopy the precise source of blood loss is often not
discovered. Treatment consists of blood transfusions in case of severe hemorrhage,
sometimes in combination with a short course of external beam radiotherapy (e.g. 5 
sessions of 4 Gray).
Retrosternal pain
(Transient) retrosternal pain is a frequently reported complication after stent
placement, particularly after prior radiation and/or chemotherapy. Golder et al. (73) 
recorded the daily opioid analgesic requirements of 52 patients from 3 days before
until 7 days after stent placement. Twenty-six (50%) patients needed opiates for 
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chest pain within 48 hours of the procedure compared to 11 (21.2%) patients before
stent placement (p<0.001). In other studies, figures ranging from 5-50% for chest
pain after stent placement have been reported (44, 81, 90, 94). In our experience,
mild retrosternal after stent placement can effectively be treated with
acetaminophen or one of the non-steroidal anti-inflammatory drugs. Only rarely, 
opiates are indicated for a period of a few days to maximal 1-2 weeks. Severe pain
after stent placement occurs in 1-2% of all patients. In these patients, removal of the 
stent is sometimes indicated to relief the pain.
Gastro-esophageal reflux
Gastro-esophageal reflux is a common problem among patients with distally located
tumors where the distal end of the stent is placed through the lower esophageal 
sphincter. As a preventive measure, proton-pump inhibitors are prescribed in many 
institutions to patients with a stent passing the lower esophageal sphincter.
Recently, metal stents with an anti-reflux mechanism have been developed to
prevent gastro-esophageal reflux. At the distal end of the stent, the cover of the stent 
is extended beyond the lower metal cage so as to form a “wind sock”-type valve.
The first results of this anti-reflux stent were reported in a study including 11 
patients. The authors concluded that the anti-reflux stent was effective in preventing 
gastro-esophageal reflux (74). A study comparing anti-reflux stents (25 patients)
with standard open stents (25 patients) showed that 3/25(12%) versus 24/25 (96%) 
patients, respectively, reported symptoms of gastro-esophageal reflux (p<0.001),
whereas no differences in dysphagia improvement, complications, or reintervention
rate were found (75). These results are promising and will likely reduce the
prescription rate of proton-pump inhibitors in these patients.
Stent migration
Stent migration is a common complication with reported incidence rates varying 
between 5-15% (28, 31, 76, 77). The most frequently used method for re-intervention
after stent migration is placement of a second stent. In certain cases, repositioning of
a distally migrated stent is possible with the use of a forceps or a snare (78), or 
placing the endoscope in a retroflexed position (79). We do not recommend using 
the latter technique, since esophageal perforation may occur. In addition, this
method may result in damage to the endoscope (80). If repeated episodes of stent 
migration occur in the same patient, other palliative treatments such as
brachytherapy or laser therapy need to be considered. 
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From our own experience and from others (77), it is important to realize that stent
retrieval after migration is often not indicated, because perforation or obstruction of 
the digestive tract is uncommon. If a migrated stent causes obstruction of the 
pylorus or symptoms of pain, or if successful placement of a second stent is
impossible, than stent removal should be performed. Several methods of stent
retrieval have been described. In case of an Ultraflex stent, this can be done by
collapsing the stent with a grasping forceps using the purse string suture attached to
the proximal flange of the stent. The most frequently described method however is
by decreasing the diameter of the stent with a polypectomy snare at 2-5 cm from the
proximal end of the stent (81, 82). Others have used a biopsy forceps in combination
with a snare, which requires passage of a double-channel therapeutic endoscope 
(83). Apart from a snare, one can use endoloops, which may have a greater
constriction force than a polypectomy snare (84).
Tumor overgrowth
Tumor overgrowth is the result of progression of the malignancy rather than a
failure or a complication of the stent. It affects both ends of the stent at a similar rate
and is seen in 10-20% of patients after a mean period of 2-4 months after stent
placement (28, 68, 76, 85). Tumor overgrowth can be prevented, at least temporarily,
by inserting a stent that is, after expansion, approximately 2-4 cm longer than the
malignant stricture to allow for a 1-2 cm extension above the proximal and below
the distal end of the tumor. 
The most frequently used method for the treatment of tumor overgrowth is
placement of a second stent. In addition, laser therapy or argon plasma coagulation
can be used to debulk the tumor. In case of placement of a second stent, the stent is 
placed proximal or distal to the previously placed stent with a part of the second 
stent overlapping the primary stent.
In our experience, recurrent dysphagia due to nonmalignant obstructive tissue, such 
as granulation tissue, reactive hyperplasia and fibrosis at the proximal or distal end 
of the stent is an unlikely event. Mayoral et al. (86) however reported this cause of 
recurrent dysphagia in more than 30% of their patients at a mean interval of 22 
weeks after stent placement. We observed the development of this nonmalignant 
tissue in a number of patients undergoing endoscopy for reasons other than 
recurrent dysphagia. It was predominantly found at the proximal end of the stent 
but did not appear to cause dysphagia.
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Other causes of recurrent dysphagia
Food bolus obstruction occurs fairly common with reported rates of 5-15% (28, 68,
76, 85). It can successfully be treated by endoscopic stent clearance. However, care 
should be taken to prevent the stent from migrating while doing this. Prevention of
food bolus obstruction can be achieved by providing eating instruction, including
chewing the food thoroughly and drinking sparkling drinks during and after a 
meal.
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Diagnostic procedures and treatment strategies for esophageal cancer 
ABSTRACT
Objective: To survey the diagnostic procedures and treatment strategies currently
employed in hospitals in the Netherlands for patients with esophageal carcinoma.
Methods: A questionnaire was sent to all clinicians working in the field of
gastroenterology in the Netherlands. This questionnaire focused on clinical 
preferences regarding diagnostic procedures and treatment strategies for 
esophageal cancer. Also, hypothetical patient vignettes were presented to 
investigate which factors affected choice of treatment, in particular surgical 
treatment.
Results: The response rate was 64%. Almost 90% of the clinicians treated fewer than
20 patients annually, mostly in their own hospital. Computer tomography was the
most frequently used staging procedure; endoscopic ultrasound was less frequently 
used (42% used it in less than half of patients). The treatment choice for the patients
vignettes varied widely among clinicians. Factors influencing the choice to operate 
or not were metastases, loco-regional tumor ingrowth, poor general health, and
advanced age, with 8%, 22%, 20%, and 53% respectively of the clinicians still
considering surgery in the presence of one of these factors as opposed to 99% if none 
of these factors were present. Surgeons opted more often for operation than 
internists and gastroenterologists. Stent placement was the most frequently chosen 
method to palliate malignant dysphagia. 
Conclusions: There is a wide variation in the use of diagnostic procedures and 
treatment strategies for patients with esophageal cancer in the Netherlands. This
stresses the need for scientifically based practice guidelines, taking into account
specific patient and tumor characteristics.
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INTRODUCTION
Esophageal cancer is a disease with a high mortality, as reflected by a 5-year
survival rate of 10% (1). Annually, almost 400,000 new patients are diagnosed
worldwide, of which 1100 patients are diagnosed in the Netherlands. This makes
esophageal cancer the eighth most common cancer, and sixth on the list of cancer 
mortality causes (2). In the industrialized world, in spite of a stable or even falling 
incidence of squamous cell carcinoma of the esophagus, the total incidence of 
esophageal carcinoma has risen in recent years as the result of a marked rise in the 
incidence of adenocarcinoma (3-5).
Optimal staging of the disease is important to determine the most suitable treatment
strategy, either curative or palliative. In addition, this information may predict the
prognosis for individual patients. Furthermore, uniform treatment strategies are
important in optimizing patient care. As general guidelines for the diagnosis and 
treatment of esophageal cancer have not been established in many countries, 
including the Netherlands, we investigated whether this affects the currently used 
diagnostic procedures and treatment strategies amongst Dutch clinicians working in 
the field of gastroenterology. This included also the frequency of diagnostic 
procedures with which these are applied and the criteria in choosing between 
specific curative and palliative treatment strategies.
METHODS
In April 2001, a written questionnaire was sent to all Dutch clinicians (internists,
gastroenterologists and surgeons) working in the field of gastroenterology, listed as 
MD-members of the Netherlands Society of Gastroenterology (n=667). After 4 weeks 
a reminder was sent.
A total of 426 (64%) questionnaires were returned. Twenty-seven questionnaires 
were returned unanswered because the clinician had retired or was no longer 
working in a hospital. Sixty-three clinicians were not involved in the care for
patients with esophageal cancer. These questionnaires were excluded, leaving 336 
questionnaires for analysis.
The questionnaire included 7 questions, all multiple choice (see Appendix). The first
four questions involved general characteristics of the clinicians, including their
specialization, the type of hospital (university or general hospital) where they 
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worked, the number of new patients with esophageal cancer they saw annually, and 
whether such patients were generally treated in the clinicians’ own hospital or were
referred to another (university) hospital. Question 5 investigated the type of 
diagnostic procedures and the frequency with which these were applied. Question 6
investigated which treatment the clinician would have chosen for specific categories 
of patients with esophageal cancer presenting with dysphagia. These categories 
were presented as patient vignettes (Table 1), and the therapeutic options comprised
commonly applied curative and palliative treatments. Patient vignettes were chosen 
with varying variables, such as age (55 or 80 years), general health (good or poor),
and tumor characteristics (presence of loco-regional tumor ingrowth or metastases).
The final question examined the forms of palliative treatment used in treating
malignant dysphagia. 
We analyzed the influence of specialization, the type of hospital the clinician was 
working and the number of patients treated annually by each clinician, on the use of
various staging procedures and palliative treatments with the Kruskal Wallis test,
and, if appropriate, with logistic regression (Question 5 and 7). The X2 test was used 
for analyzing the influence of specialization, type of hospital, and number of 
patients treated annually, on the preferred treatment option for each patient vignette
(Question 6). The number of clinicians who chose for surgery on the basis of the
various patient vignettes was compared with the McNemar’s test. 
Table 1: Description of the variables in patient vignettes described in question 6; all 
patients were described as having esophageal cancer causing dysphagia.
Question Age General
condition
Loco-regional tumor 
ingrowth (T4)
Metastases
6A 55 Good No No
6B 55 Good No Yes
6C 55 Good Yes No
6D 55 Poor No No
6E 80 Good No No
6F 80 Good Yes No
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Table 2: General characteristics of the clinicians with completed questionnaires (n=336). 
N (%) 
Clinicians registration
Internal medicine 
Gastroenterology
Surgery
111 (33) 
117 (35) 
108 (32) 
Hospital
University Hospital 
General Hospital 
Both
75 (22) 
259 (77) 
2 (1) 
Number of new patients with esophageal cancer treated by clinician 
annually
<5 patients 
5-20 patients 
20-50 patients 
>50 patients 
94 (28) 
197 (59) 
32 (10) 
13 (4) 
Hospital where staging and treatment of patients is performed 
Never referred to other (university) hospital 
Sometimes (<50%) referred to other (university) hospital 
Mostly (>50%) referred to other (university) hospital 
Always referred to other (university) hospital 
153 (46) 
104 (31) 
44 (13) 
33 (10) 
RESULTS
The number of analyzable questionnaires from the three groups of specialists
(internal medicine, gastroenterology and surgery) was similar (Table 2). Eighty-
seven percent of the clinicians treated 20 patients or less with esophageal cancer
annually. Overall 77% of the total number of clinicians, and 73% of the clinicians
treating less than 20 patients annually, preferred treating patients with esophageal
cancer in their own hospital. 
Diagnostic procedures
The frequency distribution of the various diagnostic and staging procedures
employed by the clinicians is shown in Figure 1. Computer tomography (CT) was
the most frequently used procedure for tumor staging, while endoscopic ultrasound
(EUS) was far less often employed. Clinicians in university hospitals employed more 
often EUS for staging than those working in general hospitals (p<0.001). On the
other hand, abdominal ultrasound was more frequently used in general hospitals
(p=0.001). All three specialist groups used the various diagnostic and staging
procedures with equal frequency.
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Figure 1: The use of different diagnostic and staging procedures for patients with 
esophageal cancer by clinicians in the Netherlands (Question 5, n=336). 
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Preferred treatment for patient vignettes with specific characteristics 
There was considerable divergence in the treatments chosen on the basis of various 
patient vignettes (Table 3). The first case of a 55-years-old patient in a good general
condition without evidence of metastatic disease (Question 6A) was the only case in 
which there was a large concordance for the preferred therapy, being surgical 
esophagectomy. For the other patients a considerable variation existed in preferred 
treatment choice. For instance, for a 55-year-old patient in a good general condition
with loco-regional tumor ingrowth (Question 6C), 39% preferred a combination of 
external beam and intraluminal radiation, but surgery (22%), chemotherapy (19%), 
stent placement (27%), and external beam radiation alone (15%) were also frequently
chosen.
Surgeons more often preferred surgery, despite evidence of loco-regional tumor 
ingrowth (p<0.001), a poor general condition (p<0.001), or a higher age of the patient
(p<0.001) than internists and gastroenterologists (Figure 2). The treatment choices of 
clinicians working in university hospitals did not differ from those working in 
general hospitals. However, clinicians treating less than 20 patients annually more 
often chose stent placement for elderly patients in a good general condition without
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evidence of metastatic disease than did clinicians treating more than 20 patients
annually (22% versus 7%, p=0.009), who more often opted for surgery for this type
of patient (70% versus 50%, p=0.03). For the other patient vignettes no major
differences were found between clinicians treating more or less than 20 patients
annually.
It was clear that metastatic disease had a major influence on the decision whether to 
operate or not, with only 8% preferring surgery for a 55-year-old patient in a good 
general condition with metastases compared to 99% for the 55-year-old patient
without metastases (p<0.001) (Table 3). Other factors that made the decision to
operate less likely in patients without metastatic disease were loco-regional tumor
ingrowth with a reduction to 22% (p<0.001), a poor general condition with a
reduction to 20% (p<0.001), and advanced age with a reduction to 53% (p<0.001). For 
a patient with loco-regional tumor ingrowth without metastases, the 22% preference
for surgery for a 55-year-old patient was reduced to 6% for an 80-year-old patient
(p<0.001). From these results it can be concluded that metastatic disease influenced 
the choice against surgery far more than loco-regional tumor ingrowth or a poor
general condition, and that the factor advanced age alone influenced the choice 
least, with 8%, 22%, 20%, and 53%, respectively, still preferring surgery (p<0.001). 
Palliative treatments
Stent placement was the preferred palliative treatment for malignant dysphagia 
(Figure 3). Sixty percent of the clinicians opted for stent placement in the majority of
their patients with inoperable esophageal cancer and dysphagia. External beam
radiation, intraluminal radiation or their combination were less frequently used for 
palliation, only 22% using any form of radiotherapy in the majority of their patients.
Dilation as sole palliative treatment was infrequently used, 77% of the clinicians 
never or only rarely (0-10%) used this technique for palliation.
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Table 3: Treatment options chosen by clinicians (n=336) in the Netherlands for specific 
patients vignettes with esophageal carcinoma, in percentages*.
Patient vignette Surgery Chemo-
therapy
Stent ERT ILT ERT+
ILT
Dilata-
tion
6a: 55 yr, good general cond, 
no metastases 
99 6 0 0.3 0 0.3 0
6b: 55 yr, good general cond,
cervical lymph node 
metastases
8 24 41 13 16 37 2
6c: 55 yr, good general cond,
tumor growth into pleura (T4) 
22 19 27 15 8 39 1
6d: 55 yr, poor general cond,
no metastases 
20 5 40 8 14 31 2
6e: 80 yr, good general cond,
no metastases 
53 1 20 4 7 26 0.3
6f: 80 yr, good general cond,
tumor growth into pleura (T4) 
6 4 58 10 12 27 2
ERT = external beam radiation, ILT = intraluminal radiation 
* Because clinicians could select more than one treatment option, total amount can exceed 
100%
Figure 2: The frequency of considering surgery for specific patient groups with esophageal 
cancer by surgeons (n=108), internists (n=111), and gastroenterologists (n=117). * p<0.001 
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*
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Figure 3: The use of various palliative treatments for patients with malignant dysphagia 
(ERT = external beam radiation, ILT = intraluminal radiation) (Question 7, n=336). 
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DISCUSSION
Clinicians in the Netherlands were found to use a wide variety of strategies in
staging and treating patients with esophageal cancer. Since 87% of the clinicians see 
less than 20 patients with esophageal carcinoma annually and the majority treats
these patients in their own hospital, it is our opinion that consensus on the use of 
diagnostic procedures and treatment modalities for patients with esophageal cancer
is highly desirable.
Not surprisingly, endoscopy was performed by all clinicians for diagnosing the
tumor and sampling of biopsies. Nowadays, endoscopic ultrasound (EUS) is
considered the most accurate pre-operative procedure for tumor T-staging (local 
tumor extension) and N-staging (regional lymph node involvement) (6-10). 
However, only 35% of the clinicians used EUS regularly despite the fact that this
technique is available in all regions in the Netherlands (Figure 1). EUS was 
employed far less frequently in general hospitals than in university hospitals. This 
can be explained by the fact that experience is essential to perform EUS and,
consequently, its use in the Netherlands is mainly limited to hospitals with a critical
number of patients with esophageal carcinoma, which are, in general, the university
hospitals and some f the larger general hospitals.
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Computer tomography (CT) and abdominal ultrasound are both widely used in 
determining the possible presence of metastases (M-stage) from esophageal cancer 
(11-14). This could also be concluded from the answers of our questionnaire.
However, new versions of the CT have a higher sensitivity and specificity to
determine metastases and, for the future, CT will therefore probably be preferable to
abdominal ultrasound (15, 16).
It was reassuring to find that surgery was unanimously selected as treatment of 
choice in the young (55-year-old), uncomplicated patient. The divergence of opinion 
in the more complicated cases reflects our current state of ignorance as to the 
optimal treatment for patients with extensive and/or metastatic disease. A practice
guideline for diagnosing, staging and treating esophageal cancer was published by 
the American College of Gastroenterology in 1999 (17). This report gave an 
overview of the diagnostic and treatment modalities for esophageal carcinoma and 
concluded that due to the many uncertainties and the generally unsatisfactory state
of the current management options, patients should be encouraged to enter clinical
trials in order to improve the staging and treatment strategies. Guidelines were also 
published in France recommending clear decision-tree models for determining
therapeutic strategies (18). The authors concluded that there was no standard 
treatment for the majority of patients and several options were presented. In these 
guidelines, treatment options depended on tumor stage. However, from our survey 
it can be concluded that patient characteristics, such as age and general condition,
should also be taken into consideration in determining therapeutic strategy.
Although guidelines based on the literature can go some way in standardizing the
management of individual patients, there remains an urgent need for randomized 
trials for various tumor stages and age groups, comparing surgery to non-surgical 
and palliative treatments, both from the point of view of survival and of quality of
life.
For patients judged to be inoperable, several treatment modalities are available. The 
results of palliative chemotherapy are improving, particularly through the use of
new agents and new combinations (19). However, chemotherapy at present does not
appear to be popular with Dutch clinicians (the use of chemotherapy varied
between 1-24% for the different patient vignettes). External beam radiation alone or 
in combination with intraluminal radiation is a rather demanding treatment, usually
involving 25 treatment sessions of external beam radiation in combination with 2
treatment sessions of intraluminal radiation. This treatment is usually reserved for
patients in a good clinical condition, however being inoperable because of local-
regional tumor ingrowth. A median survival of 8-13 months has been reported for 
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this treatment modality (20-22). For the majority of patients with inoperable
esophageal carcinoma stent placement or intraluminal radiation are considered the
most practical and effective options to improve dysphagia (23-27). Our survey
indicates that of these two palliative modalities, stent placement is the most
frequently used method in the Netherlands. 
In conclusion, this survey indicates that at present there are wide variations in the 
strategies for diagnosis, staging and treatment of patients with esophageal cancer in
the Netherlands. There is a need for more evidence-based approaches to both the
use of diagnostic procedures and the choice of treatment. Based on the recently
published guideline ‘Esophageal carcinoma’ of the Comprehensive Cancer Center
and the guideline of the Dutch Institute for Healthcare (CBO) which is currently
being developed (publication expected in the fall of 2004), a more uniform and 
successful management of esophageal cancer in the Netherlands will be achieved. It
would be interesting to repeat this survey within 1-2 years after publication of these
guidelines, which would clarify if guidelines are the optimal instrument to achieve 
this goal. 
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APPENDIX
Questionnaire
1. What is your clinician registration?
O Internal medicine
O Gastroenterology 
O Surgery 
2. Are you working in a university hospital or general hospital? 
O University hospital
O General Hospital
3. How many new patients with esophageal carcinoma do you treat annually? 
O 0 (end of questionnaire) 
O < 5
O 5-20 
O 20-50 
O > 50
4. Is staging and treatment of esophageal carcinoma being performed in your own hospital 
or are such patients referred to another (university) hospital? 
O Patients are never be referred 
O Patients are sometimes (<50%) referred 
O Patients are often (>50%) referred 
O Patients are always referred 
5. How often do you use the following diagnostic and staging procedures to establish 
further treatment? 
a) Endoscopy 0-10% / 10-49% / 50-90% / >90% 
b) Endoscopic ultrasound 0-10% / 10-49% / 50-90% / >90% 
c) Abdominal ultrasound 0-10% / 10-49% / 50-90% / >90% 
d) Ultrasound of the neck 0-10% / 10-49% / 50-90% / >90% 
e) CT thorax 0-10% / 10-49% / 50-90% / >90% 
f) CT abdomen 0-10% / 10-49% / 50-90% / >90% 
g) Cytological/histological confirmation 0-10% / 10-49% / 50-90% / >90% 
of metastases (if appropriate) 
h) Laparoscopy 0-10% / 10-49% / 50-90% / >90% 
i) Other …..…………………………… 0-10% / 10-49% / 50-90% / >90% 
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6. Which therapy do you prefer for the following type of patients with esophageal cancer 
causing dysphagia?
a) a 55-year old patient in a good general condition and without metastases.
O surgery 
O chemotherapy 
O metal stent placement 
O external beam radiation 
O intraluminal radiation (brachytherapy) 
O external beam +intraluminal radiation 
O (several) dilation (sessions) 
O other ……………………………..
b) a 55-year old patient in a good general condition and with metastases in the cervical 
lymph nodes.
See answering categories as in question 6A 
c) a 55-year old patient in a good general condition and with tumor growth into the 
pleura (stage T4), without metastases. 
See answering categories as in question 6A 
d) a 55-year old patient in a poor general condition due to severe COPD, without
metastases.
See answering categories as in question 6A
e) an 80-year old patient in a good general condition and without metastases.
See answering categories as in question 6A 
f) an 80-year old patient in a good general condition and with tumor growth into the 
pleura (stage T4), without metastases.
See answering categories as in question 6A 
7. How often do you use the following palliative treatments for malignant dysphagia?
a) metal stent placement 0-10% / 10-49% / 50-90% / >90% 
b) external beam radiation 0-10% / 10-49% / 50-90% / >90% 
c) intraluminal radiation (brachytherapy) 0-10% / 10-49% / 50-90% / >90% 
d) external beam+intraluminal radiation 0-10% / 10-49% / 50-90% / >90% 
e) (several) dilation (sessions) 0-10% / 10-49% / 50-90% / >90% 
f) other ……………………………… 0-10% / 10-49% / 50-90% / >90% 
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Brachytherapy for the palliaton of esophageal cancer 
ABSTRACT
Background and purpose: High dose rate (HDR) brachytherapy is a commonly
used palliative treatment for esophageal carcinoma. We evaluated the outcome of 
HDR brachytherapy in patients with malignant dysphagia.
Material and methods: A retrospective analysis over a 10-year period was 
performed of 149 patients treated with HDR brachytherapy, administered in one or
two sessions, at a median dose of 15 Gy. Patients were evaluated for functional
outcome, complications, recurrent dysphagia, and survival.
Results: At 6 weeks after HDR brachytherapy, dysphagia scores had improved from
a median of 3 to 2 (n=104; p<0.001), however dysphagia had not improved in 51 
(49%) patients. Procedure-related complications occurred in 7 (5%) patients. Late
complications, including fistula formation or bleeding, occurred in 11 (7%) patients.
Twelve (8%) patients experienced minor retrosternal pain. Median survival of the
patients was 160 days with a 1-year survival rate of 15%. Procedure-related
mortality was 2%. At follow-up, 55 (37%) patients experienced recurrent dysphagia.
In 34 (23%) patients a metal stent was placed to relief persistent or recurrent
dysphagia.
Conclusion: HDR brachytherapy is a moderately effective treatment for the 
palliation of malignant dysphagia. The incidence of early major complications is
low, however, persistent and recurrent dysphagia occur frequently, and require
often additional treatment.
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INTRODUCTION
Over 50% of patients with a carcinoma of the esophagus or gastric cardia have 
inoperable disease at presentation due to advanced local tumor progression, 
metastases or a poor general condition. Most patients require palliative treatment
for dysphagia. 
Treatment options presently available for palliation include self-expanding metal
stent placement, laser therapy, external beam radiation sometimes in combination
with high dose rate (HDR) brachytherapy, and HDR brachytherapy as a single
treatment (1). The disadvantage of laser therapy is that repeated treatment sessions
are required to achieve and maintain adequate palliation. Self-expanding metal stent
placement has achieved wide popularity, but metal stents are expensive (2-6). For 
patients with extensive local-regional tumor growth and a good clinical condition, a 
combined treatment of HDR brachytherapy with external beam radiotherapy might
result in good local tumor regression and relief of dysphagia (7-12). The treatment
schedule mostly involves a total of 50 Gy external beam radiation delivered in 25 
fractions combined with one or two session of HDR brachytherapy (10-15 Gy), and 
is often too intensive for inoperable patients with metastases or a poor general
condition. A single treatment with HDR brachytherapy could be an attractive
alternative for the palliation of malignant dysphagia in these patients.
To date, ten studies have been published reporting that in the majority of patients
dysphagia can be palliated by a single session of HDR brachytherapy with doses
varying between 7.5 and 20 Gy, including two studies of which the results have only
been presented in abstract form (13-22). The majority of these studies were small
and results varied widely. Therefore, we performed a retrospective analysis of
patients treated by HDR brachytherapy over a 10-year period. Patient records were
evaluated for functional outcome, complications, recurrent dysphagia, and survival.
MATERIALS AND METHODS
From 1-1-1990 to 31-12-1999, 310 patients with an inoperable carcinoma of the
esophagus were treated by HDR brachytherapy. Patients were excluded from 
analysis if they had received HDR brachytherapy in combination with external
beam radiotherapy (n=148), or if they had tumor recurrence after a surgical 
esophageal resection (n=13). The remaining 149 patients, treated by HDR 
brachytherapy only, were selected for analysis. These patients had been judged to be 
inoperable and ineligible for external beam radiation with curative intent because of
a poor medical condition (47%), or metastases (53%).
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Prior to HDR brachytherapy, the proximal and distal ends of the tumor were 
identified endoscopically and a guide wire was left, over which the flexible 
applicator was passed down the esophagus. Dilation up to 10 mm was necessary in 
20 (13%) patients. In 31 (21%) patients a feeding tube (Charrière 14) was used as
applicator for HDR brachytherapy. A median dose of 15 (range 6-20) Gy was 
administered with the radioactive source 192Iridium at 1 cm from the source axis of 
the applicator in one (87%) or two (13%) sessions. The dose distributed to the 
surface of the tumor (5 mm from the source axis) amounted 200% of the prescribed
dose. The dose administrated at 12.5 mm from the source axis was 65% (at 7.5 mm
from the surface of the tumor). The mean application time of the procedure was 995 
± 416 seconds (16 min 35 sec, range 190 - 2378 sec). The standard active length of
application was the tumor length plus two centimeters extra at both ends of the 
tumor. The mean active length was 13.6 ± 2.8 cm (range 7.0 –23.0 cm). Sucralfate was
prescribed for a period of 4 weeks after HDR brachytherapy as a prophylactic
measure for odynophagia (23). 
For evaluation, dysphagia was scored according to Ogilvie et al. (24) as: grade 0:
ability to eat a normal diet; grade 1: ability to eat some solid food; grade 2: ability to
eat some semisolids only; grade 3: ability to swallow liquids only; grade 4: complete
dysphagia. Accurate dysphagia scoring on the day of the first session of HDR
brachytherapy and at 6 weeks after therapy was possible in 104 patients.
Complications, recurrent dysphagia and survival were analyzed for the total group
of 149 patients. The results are expressed as means ± SD; dysphagia score and 
survival are expressed as medians. Dysphagia scores before treatment and 6 weeks 
after treatment were compared with Wilcoxon signed-ranks test. Survival was
analyzed with the Kaplan-Meier method.
RESULTS
Clinical characteristics
The mean age of patients was 74 (range 43-93) years, 44% were female (Table 1). The 
mean tumor length was 6.8 (range 1-17) cm. Some more squamous cell carcinoma
(56%) than adenocarcinoma (42%) were identified.
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Table 1: Clinical characteristics of 149 patients with an inoperable esophagogastric 
carcinoma treated with HDR brachytherapy.
Age (y) 74 ± 11 
Gender (M / F) 83 / 66 
Mean Tumor Length (cm) 6.8 ± 3.3 
Tumor Histology
Squamous cell carcinoma
Adenocarcinoma
Other
83 (56%) 
63 (42%) 
3 (2%) 
Location of Tumor (distance from incisors) 
Proximal (< 25cm) 
Middle (25-35 cm) 
Distal (> 35 cm) 
Cardia
18 (12%) 
79 (53%) 
41 (28%) 
11 (7%) 
Total dose of radiation (Gy) 
6 ǂ 7.5 
10 ǂ 12 
15
16 ǂ 20 
5 (3%) 
22 (14%) 
115 (77%) 
8 (6%) 
Outcome and survival 
At 6 weeks after HDR brachytherapy, the dysphagia score had improved from a
median of 3 to 2 (n=104; p<0.001). Dysphagia improved in 53 (51%) of the 104 
patients; 67 (64%) of these patients were able to eat solids or semi-solids (Figure 1).
The median survival of the patients was 160 days with a 3, 6, and 12 months
survival rate of 72%, 43% and 15%, respectively. The procedure-related mortality
was 2% (see below). The majority of the remaining patients (81%) died from tumor 
progression, 7% from unrelated causes, and in 10% of the patients the cause of death
was unknown. One person was still alive at 27 months after HDR brachytherapy.
Complications and recurrent dysphagia
Major complications occurred in 18 (12%) patients, 7 (5%) of these occurred in the 
first week after HDR brachytherapy (Table 2). Two early complications were fatal.
One patient suffered from severe esophageal edema necessitating a feeding tube, 
and died 19 days later from respiratory failure caused by aspiration pneumonia.
Another patient developed stridor and dyspnea at the day after treatment. At the 
request of the patient and his family, no further procedures were performed. This 
patient died 24 hours after admission from respiratory failure. 
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Figure 1: Dysphagia scores of patients with esophagogastric carcinoma before and 6 weeks 
after treatment with HDR brachytherapy (n=104).
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One patient developed hematemesis 3 days after HDR brachytherapy, which
resolved spontaneously. Another patient developed an esophagorespiratory fistula
following dilation for persisting complete dysphagia, three days after HDR
brachytherapy. The fistula was closed by placement of two coated metal stents. One 
week later, this patient died from cardiac failure. Three patients reported severe 
chest pain after HDR brachytherapy, but the pain gradually diminished after some 
weeks.
Six patients suffered late hematemesis and/or melena after a median of 8 months 
(range 2-17 months), all in the presence of recurrent tumor growth. Three of these
patients died from massive hematemesis. Of the three survivors one received 
another session of HDR brachytherapy, which stopped the bleeding. Another
patient had recurrent non-fatal episodes of hematemesis at 4 and 8 months after a
second treatment of HDR brachytherapy. The third patient only needed a blood
transfusion. Five patients developed an esophagorespiratory fistula after a median
of 11 months (range 6-15 months). Of these, one developed a fistula at two weeks
after a second episode of HDR brachytherapy (11 months after the initial treatment)
and died one week later from this complication. One patient who underwent four 
dilation sessions over a period of 4 months for tumor recurrence, had a fistula 
diagnosed one week after the last dilation. Another patient developed a fistula after
a palliative resection for persistent tumor, followed by external beam radiation and
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Table 2: Complications and recurrent dysphagia in 149 patients with an inoperable 
esophagogastric carcinoma treated with HDR brachytherapy
N (%) 
Major Complications
d 7 days
Bleeding
Fistula
Aspiration pneunomia 
Stridor
Severe pain 
> 7 days
Bleeding
Fistula
18 (12%)
1
1
1
1
3
6
5
Minor Complications
Mild pain 
12 (8%) 
12
Recurrent Dysphagia
Tumor recurrence 
Late radiation effects 
Food bolus obstruction
Strictures (unknown cause) 
55 (37%)
40
6
4
5
dilation. The two remaining fistulas developed in the presence of recurrent tumor
growth in the esophagus 1 year and 15 months, respectively, after HDR 
brachytherapy.
Minor complications (Table 2) consisted of temporary mild chest pain, which was
reported by twelve (8%) patients following HDR brachytherapy. Almost all these 
patients required, at least temporary, analgesics. 
HDR brachytherapy failed to improve the dysphagia score in 51 (49%) of the 104 
patients with documented 6 week dysphagia scores (Figure 1). Twenty-one (41%) of 
these patients were then treated with the placement of a conventional
endoprosthesis or a self-expanding metal stent (n=12), a feeding tube (n=3), a PEG
(n=3), dilation (n=2), or a palliative resection (n=1). Twenty (39%) patients were not
treated and remained on a semi-solid or liquid diet. In another 4 patients, the 
dysphagia score improved after the evaluation at 6 weeks, while in 6 patients
persistent dysphagia was due to a variety of reasons, in three of whom endoscopic 
examination showed no evidence of a stricture.
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Fifty-five of 149 (37%) patients developed recurrent dysphagia (Table 2), after a
median of 3 months (range 1-26 months), due to tumor recurrence (n=40), late
radiation effects such as fibrosis, necrosis or ulceration (n=6), food bolus obstruction 
(n=4), or a stricture in the esophagus due to an unknown cause (n=5). Recurrent
dysphagia was treated by stent placement (n=22), dilation (n=12), a second course of 
HDR brachytherapy (n=6), placement of a feeding tube or a PEG (n=3), or no further
treatment (n=12). 
DISCUSSION
HDR brachytherapy is a commonly used treatment modality for palliation of
malignant dysphagia. The group of patients in this study was considered to be 
ineligible for a combination treatment of external beam radiation and HDR 
brachytherapy, due to poor general condition or metastases. Patients were 
predominantly treated with a single session of HDR brachytherapy of 15 Gy. In the
majority of patients the procedure could be performed as a day-case procedure, 
which minimized hospitalization in this group of patients with a short live
expectancy.
Because of the retrospective nature of the study, it is possible that the incidence of 
complications and recurrent dysphagia were underestimated. However, most 
patients remained under out-patient surveillance during the remainder of their life. 
Accurate dysphagia scoring on both the day of the first HDR brachytherapy session
and at 6 weeks after therapy was possible in 104 patients. Thirteen of the other 45 
patients died before the 6 weeks follow-up after brachytherapy, and for the
remaining 32 patients the 6 weeks dysphagia scores were missing or not well 
documented. However, the dysphagia scores at the time of HDR brachytherapy 
(day 0) of these 45 patients, were not significantly different from those of the group 
with accurate 6 weeks data (data not shown).
The dysphagia score improved in only 51% of these patients. This is a disappointing
result, because dysphagia is usually the indication for palliation. In a retrospective
study by Giles Rowland and Pagliero (15), reporting the results of palliation with
HDR brachytherapy in 40 patients (Table 3), improvement of dysphagia occurred in
65% of the patients. In a retrospective study performed by Brewster et al. (13), 
improvement of the dysphagia score occurred in 54% of 197 patients, which is 
comparable to our results. In a prospective study by Jager et al. (17), the dysphagia
score improved in 67% of 88 patients, but these authors included 7 (8%) patients
with early stage disease, and these patients were treated with a combination of
internal and external beam radiation.
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Table 3: Overview of studies using HDR brachytherapy for palliation of patients with an 
inoperable esophagogastric carcinoma.
Author N Dose Dysphagia
Improved
Complications Recurrent
dysphagia
Survival
Giles Rowland
et al. 1985 (15)
40 15Gy/1x 65% 12.5% esophagitis ? ?
Low et al. 1992 
(20)
12 15Gy/1x 83% 33% esophagitis, 17% 
pain, 17% pyrexia, 8% 
bleeding
30% ?
Harvey et al.
1993 (16)
22 10: 20Gy/3x
12:
12.5Gy/1x
90%
92%
30%
80% esophagitis
30%
39%
4 months
5.8 months
(mean)
Brewster et al.
1995 (13)
197 7.5-20Gy/1x 54% 2% severe
complications
? 136 days
(median)
Jager et al. 1995 
(17)
88 15Gy/1x 67% 34% retrosternal pain,
1% hematemesis,
6% fistulae
37% 5.5 months
(median)
Kulhavy et al.
1995 (18)
A:12
B:14
C:14
D:11
A: 10Gy/1x 
B: 12Gy/1x 
C: 15Gy/1x 
D: 18Gy/1x 
3/4
8/8
6/6
3/7
0%
0%
0%
9% fistulae
17%
14%
7%
27%
?
Leung et al.
1995 (19)
10 7.1-60Gy/1x 90% 0% 10% 3 months
(median)
Sur et al. 1998 
(21)
A: 36 
B: 68 
C: 68 
A: 12Gy/2x 
B: 16Gy/2x 
C: 18Gy/3x 
? 14% strictures, 20% 
fistulae
25% strictures, 3% 
fistulae
42% strictures, 11% 
fistulae
? 10%, 1 year 
22%, 1 year 
35%, 1year 
Present series 149 6-20Gy/1-2x 51% 12% severe
complications,
8% mild retrosternal
pain
37% 160 days
(median)
Were these disappointing results caused by an insufficient radiation dosage? Sur et 
al. (21) compared different doses of HDR brachytherapy in 172 patients with
advanced esophageal cancer. Patients were randomized to receive 12 Gy in 2
sessions, 16 Gy in 2 sessions or 18 Gy in 3 sessions. A preliminary analysis of 68 
patients showed that patients who received 12 Gy in 2 sessions did significantly
worse than the other two groups in terms of dysphagia-free survival and persistent
tumor obstructing the esophageal lumen after treatment. The 12 Gy in 2 sessions
arm was therefore discontinued. The authors concluded that the optimal radiation
dose ranged between 16 Gy in two sessions and 18 Gy in three sessions. Kulhavy et 
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al. (18) compared different doses of HDR brachytherapy given in a single fraction.
Fifty-one patients received 10, 12, 15 or 18 Gy. From the results of 25 evaluable
patients, they concluded that doses of 12-15 Gy were likely to give the best results in
terms of relief of dysphagia with minimal morbidity. In our study 137 (92%) patients
received 15 Gy in a single fraction. Other doses or fractionation of HDR 
brachytherapy were chosen for specific reasons such as a greater tumor length,
ulceration, or an increased risk of fistula formation. Because of the small number of 
patients, it was not possible to analyze the influence of dose or fractionation on the
outcome of HDR brachytherapy. It is very well possible that a fractionated and/or
higher dosage would have improved the results. This question needs further 
investigation.
Mild esophagitis manifested as pain and increased dysphagia during the first days 
after treatment is a commonly reported side effect of external beam radiation (12, 23, 
25, 26). Data on the occurrence of early esophagitis after HDR brachytherapy vary
greatly (Table 3). Jager et al. (17) reported that HDR brachytherapy was well 
tolerated by their patients with no or very little acute toxicity. Brewster et al. (13)
reported that acute symptomatic esophagitis occurred in 3 (2%) patients. In the
study by Giles Rowland and Pagliero (15), 5 (12.5%) patients had symptomatic
esophagitis for 5-10 days. These results are in contrast with the results from smaller 
studies by Low et al. (20) and Harvey et al. (16) reporting esophagitis to occur in
more than 30% of their patients. Symptoms of esophagitis were not often mentioned
by our patients. Radiotherapy can also cause late radiation effects such as ulceration, 
fibrosis and necrosis, causing strictures in the esophagus (12, 25, 26). This occurred
in 6 (4%) of our patients, and was treated by dilation.
The occurrence of early major complications (during or in the first week after HDR
brachytherapy) was low in our cohort. Only 7 (5%) major complications were
observed, this included three patients with severe pain after HDR brachytherapy
which resolved spontaneously. Two early complications were fatal. Other studies
have also reported very low major complication rates (Table 3). Recurrent dysphagia
after HDR brachytherapy occurred in 37% of our patients, which is similar to the
findings of Jager et al. (17). However, Giles Rowland and Pagliero (15) reported only 
two (5%) patients needing re-treatment after 30 weeks for recurrent dysphagia. In 
the present study, 34 (23%) patients received a stent for persistent or recurrent 
dysphagia to improve dysphagia.
Placement of self-expanding metal stents as a first treatment for palliation of
dysphagia is nowadays commonly used. An advantage of metal stents could be the 
rapid improvement of dysphagia in the majority of patients, and the lower
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frequency of recurrent dysphagia compared to HDR brachytherapy (2-6). However, 
major complications seem to occur more frequently after stent placement. A 
randomized study comparing HDR brachytherapy with the nowadays commonly
used placement of a self-expanding metal stent as a first treatment for the palliation
of malignant dysphagia is therefore warranted, in order to define the specific 
indications for both these types of palliation.
HDR brachytherapy in combination with laser therapy could possibly increase the
effectiveness. Prior laser therapy should reduce the tumor bulk, thus both speeding
up and increasing the improvement of the dysphagia score. In four non-randomized
studies, laser plus HDR brachytherapy was studied prospectively and proved to be
both safe and effective (27-30). Laser plus HDR brachytherapy was compared with
laser therapy alone in two prospective, randomized studies in 39 and 22 patients (31,
32). These studies showed a prolonged dysphagia-free interval after the 
combination of laser and HDR brachytherapy but there was no difference in 
survival.
The result of palliative chemotherapy are improving, particularly through the use of 
new combinations and new agents (33). This can be offered in addition to the
treatment to relief dysphagia (HDR brachytherapy or stent placement) for specific 
patients.
In conclusion, the results of this retrospective study suggest that HDR 
brachytherapy alone is a safe, but not a very effective treatment for the palliation of 
malignant dysphagia. The incidence of early major complications is low, however, 
the occurrence of persistent and recurrent dysphagia leaves much to be desired. 
Whether results can be improved by higher and/or fractionated radiation doses 
without jeopardizing safety remains to be studied.
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ABSTRACT
Background: Single dose brachytherapy is a commonly used palliative treatment
modality for esophageal carcinoma, however a considerable number of patients 
need additional treatment for persistent or recurrent dysphagia. We aimed to
establish predictors for an unfavorable outcome after single dose brachytherapy.
Methods: Between December 1999 and July 2002, 95 patients with dysphagia from
inoperable esophageal carcinoma were treated with single dose (12 Gy)
brachytherapy. Patients were followed prospectively by monthly home visits by a
specialized research nurse. We investigated which patient and tumor characteristics
influenced the risk of persistent dysphagia (continuing dysphagia within 4 weeks
after treatment necessitating a second treatment) or recurrent dysphagia (occurring
more than 4 weeks after treatment) after single dose brachytherapy, using logistic
and Cox regression.
Results: In total 42/95 (44%) patients were treated for persistent (n=18) and/or
recurrent dysphagia (n=28). Persistent dysphagia (n=18) was caused by persisting
obstructing tumor confirmed at endoscopy, and these patients were treated with
stent placement. Patients needing dilation before treatment had a higher risk of
persistent dysphagia (odds ratio=4.1; 95% CI 1.3-12). There was a trend towards a 
higher risk of persistent dysphagia for patients previously treated with
chemotherapy (odds ratio=3.2; 95% CI 0.81-12). In total, 34 events of recurrent
dysphagia occurred in 28 patients, caused by obstructing tumor regrowth (n=26),
food bolus obstruction (n=5) or other reasons (n=3). None of the investigated patient 
and tumor characteristics had a significant association with the risk of developing
recurrent dysphagia. In the total group of patients needing additional treatment
(42/95), again patients who needed dilation before treatment had a higher risk of 
persistent and/or recurrent dysphagia (hazard ratio=2.1; 95% CI 1.1-4.1).
Conclusions: Patients with stenotic esophageal tumors that cannot be bypassed or 
who previously underwent chemotherapy are poor candidates for single dose 
brachytherapy, and for these patients alternative palliative treatment modalities
should be considered.
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INTRODUCTION
Over 50% of patients with esophageal cancer have inoperable disease at 
presentation due to advanced local tumor progression, metastases or a poor general 
condition (1). The majority of these patients require palliative treatment to relieve 
progressive dysphagia. At present, several treatment modalities are available for the
palliation of dysphagia from esophageal carcinoma. Treatment options most
commonly used include metal stent placement (2-6), laser therapy (7, 8), external
beam radiation in combination with brachytherapy (9, 10), and brachytherapy as a 
single treatment (11-14). A disadvantage of laser therapy is that repeat treatment
sessions are required to achieve and maintain adequate palliation (7, 8). A combined 
treatment of external beam radiation with brachytherapy is often too intensive for
patients with inoperable, metastatic disease and a poor medical condition.
Therefore, in many patients with inoperable disease, placement of a metal stent or 
single dose brachytherapy are used for the palliation of dysphagia (15).
We performed a randomized trial comparing single dose brachytherapy (n=101) 
with metal stent placement (n=108) in patients with inoperable esophageal
carcinoma (16). This study showed that despite a less rapid improvement of 
dysphagia, single dose brachytherapy gave a better long term relief of dysphagia.
Single dose brachytherapy was also associated with fewer complications compared
to stent placement and a benefit in health-related quality of life. A major drawback
of single dose brachytherapy was that almost half of the patients needed additional
treatment for persistent or recurrent dysphagia after single dose brachytherapy (16).
The consensus guideline of the American brachytherapy society has distinguished 
several criteria (based on tumor characteristics) to divide patients in good 
candidates, poor candidates and patients with contraindications for brachytherapy
(in combination with external beam radiation) in the definitive and palliative
treatment of esophageal cancer (13). Based on these recommendations and the 
results of our comparative study between single dose brachytherapy and stent
placement, we aimed to investigate which baseline patient and tumor characteristics
within our study influenced the occurrence of persistent and recurrent dysphagia 
after single dose brachytherapy. In this way, a more individualized palliative
treatment strategy for patients with esophageal cancer may be established.
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PATIENTS AND METHODS
Study population
Between December 1999 and July 2002, 209 patients with inoperable esophageal
cancer due to metastatic disease and/or a poor medical condition with progressive
dysphagia were randomized to single dose brachytherapy (n=101) or metal stent
placement (n=108).
Patients were treated with a single dose of 12 Gy brachytherapy (intraluminal
radiotherapy) or with a covered Ultraflex stent (Boston Scientific, Natick, MA.,
USA). Patients were included and treated in three university and six general
hospitals in the Netherlands. The study was approved by the Central Committee on
Research Involving Human Subjects in The Netherlands.
Inclusion criteria included inoperable cancer of the esophagus or esophagogastric
junction due to metastatic disease (as defined by the TNM-classification) and/or a
poor medical condition (unfit to undergo surgery) with a dysphagia score of 2-4 on
the dysphagia score scale (17), and a written informed consent. Exclusion criteria
were a tumor length of more than 12 cm, tumor growth within 3 cm of the upper 
esophageal sphincter, deep ulceration or a trachea-esophageal fistula, macroscopic
or microscopic tumor growth into the tracheal lumen, the presence of a pacemaker,
and previous radiation therapy or stent placement.
Of the 101 patients randomized to brachytherapy, 95 patients received the allocated
intervention. One patient died before treatment due to progression of the disease, 
three patients experienced problems during endoscopy prior to brachytherapy 
including anxiety of the patient (n=1), cardiac arrhythmia (n=1), and inability to pass 
the tumor (n=1). Two patients did not fulfill the inclusion criteria because of tumor
length >12 cm (n=1), and deep ulceration of the tumor (n=1), which had not been
reported at the previous endoscopy. In the present analysis, we hence consider 95
patients.
Treatment
Prior to the brachytherapy, an endoscopy was performed. Dilation was performed
on indication to a maximum of 11 mm by a Savary-Miller Esophageal Dilator
(Wilson-Cook Medical, Winston-Salem, NC, USA). The proximal and distal tumor
margins were marked by injecting radiographic contrast medium into the 
submucosa of the esophageal wall through a sclerotherapy needle. Then a guide 
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wire was left, over which a flexible applicator (Bonvoisin-Gérard Esophageal 
Applicator, Nucletron, Veenendaal, The Netherlands) with a diameter of 10 mm was 
passed down the esophagus. A single dose of 12 Gy was administered with the
radioactive source 192Iridium at 1 cm from the source axis of the applicator. The 
standard active length of the application was the tumor length plus two centimeters
extra at both ends of the tumor. All patients were consciously sedated with
midazolam during the treatment procedure. Sucralfate was prescribed for a period
of 4 weeks after brachytherapy as a prophylactic measure for odynophagia. A 
lifelong daily dose of 40 mg omeprazole was prescribed to patients of whom the 
active length of application of brachytherapy was below the esophagogastric
junction to prevent gastroesophageal reflux after the procedure. 
Study endpoints
Persistent dysphagia was defined as continuing dysphagia within 4 weeks after
treatment with tumor growth causing obstruction observed at endoscopy 
necessitating a second treatment. Recurrent dysphagia was defined as recurrent 
dysphagia occurring at more than 4 weeks after treatment caused by tumor
regrowth, food bolus obstruction or other reasons necessitating additional 
treatment. The choice of the treatment modality for persistent or recurrent
dysphagia was made by the responsible physician. Dysphagia was scored as 
follows: score 0: ability to eat a normal diet; score 1: ability to eat some solid food; 
score 2: ability to eat some semisolids only; score 3: ability to swallow liquids only; 
score 4: complete obstruction (17).
Patients were prospectively followed by home visits of one of six specially trained 
research nurses at 14 days, 1 month and then monthly until one year after treatment.
After one year of follow-up, patients were visited every 3 months, and/or telephone
calls to the patient and the patients’ practitioner were made. If indicated, patients
were readmitted for clinical evaluation. All participating clinicians filled out
standardized case record forms during control visits, re-treatments and admissions.
Statistics
Improvement in dysphagia score was tested with the Wilcoxon signed-rank test. We 
investigated which patient and tumor characteristics influenced the occurrence of
persistent or recurrent dysphagia. Variables considered in the analyses were age, 
gender, tumor histology, tumor length (divided into <10 cm and ǃ10cm), location of 
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the tumor (esophagus or esophagogastric junction), presence of metastases, poor 
general condition (unfit to undergo curative treatment), dysphagia score and WHO
performance score before treatment, dilation prior to treatment, and previous
chemotherapy treatment. We used logistic regression analysis to estimate
univariable and multivariable odds ratios for the risk of persistent dysphagia. For 
the analysis of recurrent dysphagia and the total group of persistent and/or
recurrent dysphagia, we used Cox regression analysis to estimate univariable and
multivariable hazard ratios to adjust for time of occurrence of the event and 
potential survival differences. In all multivariable models, variables were selected in 
a backward stepwise procedure with p>0.20 for exclusion of variables. Univariable
Kaplan-Meier curves were constructed to investigate the influence of covariables on 
the risk of needing additional treatment for persistent and/or recurrent dysphagia.
The median survival was calculated using the Kaplan-Meier method. A 
multivariable Cox regression model was used to evaluate which variable(s) 
correlated with a shorter survival. We considered a two-sided p-value <0.05 as
statistically significant. Calculations were performed with SPSS 10.1 (SPSS Inc., 
Chicago, IL, USA).
RESULTS
Clinical outcome
Clinical characteristics of the patient group are given in Table 1. At 30 days after
treatment, dysphagia score had improved from a median of 3 to 1 (p<0.001).
Dysphagia score was improved by at least one grade in 62/84 (74%) of the patients.
In total, 12 major complications occurred in 11/95 (12%) patients, of which 3 major
complications occurred within 7 days after treatment. Early major complications
included perforation (n=1), fever (n=1), and aspiration pneumonia (n=1). Late major
complication (>7 days after treatment) included hemorrhage (n=4), fistula formation
(n=3), perforation (n=1) and severe pain (n=1). Minor complications occurred in 8/95
(8%) patients, including mild retrosternal pain (n=5), gastro-esophageal reflux (n=1),
radiation esophagitis (n=1) and candida esophagitis (n=1). 
The median survival was 155 days (95% CI 118-192). Multivariate Cox regression 
analysis showed that a tumor length of more than 10 cm (hazard ratio 1.6; 95% CI
1.02-2.6, p=0.04), metastases (hazard ratio 2.5; 95% CI 1.4-4.3, p=0.002), and a more
advanced WHO-performance score (hazard ratio 1.8; 95% CI 1.4-2.3, p<0.001)
correlated with a shorter survival.
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Table 1: Clinical characteristics of 95 patients with inoperable esophageal carcinoma 
treated with single dose brachytherapy 
Characteristic
Age (years ± SD) 69 ± 13 
Gender M/F 71/24
Tumor histology (N (%)) 
   Squamous cell carcinoma
   Adenocarcinoma
   Other
27 (28) 
65 (68) 
3 (3) 
Tumor length (mean ± SD) 
   < 10 cm (N (%)) 
ǃ 10 cm (N (%)) 
7.4 ± 2.6 
68 (72) 
27 (28) 
Location of tumor (N (%)) 
   Esophagus
   Cardia
82 (86) 
13 (14) 
Indication for palliative treatment (N (%)) 
   Metastases 
   Poor general condition 
   Both
63 (66) 
21 (22) 
11 (12) 
Dysphagia score before treatment (N (%)) 
   2 
   3 
   4 
40 (42) 
36 (38) 
19 (20) 
WHO performance score (scale 0-4) (mean ± SD) 1.0 ± 1.0 
Dilation before treatment (N (%)) 23 (24) 
Previous chemotherapy treatment (N (%)) 12 (13) 
Persistent dysphagia
Eighteen (19%) of 95 patients reported persistent dysphagia within 4 weeks after
treatment. In these patients, endoscopy confirmed persistent tumor growth. These 
patients were treated with a metal stent. Univariable logistic regression analysis
showed that a dysphagia score of 4 (complete obstruction) before treatment, dilation
prior to treatment, and previous chemotherapy treatment increased the risk of
persistent dysphagia (Table 2). In a multivariable analysis, dilation prior to
treatment proved to be the most important factor for the risk of persistent
dysphagia. There was a trend towards a higher risk for persistent dysphagia in 
patients previously treated with chemotherapy (Table 3).
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Table 3: Multivariable logistic and Cox regression model of variables associated with the 
risk of persistent dysphagia (n=18) or persistent and/or recurrent dysphagia (n=42) after 
single dose brachytherapy (n=95). Variables were selected in a backward stepwise procedure
with p<0.20. The separate model for recurrent dysphagia (n=28) did not been show any 
variable to be significant.
Variable Logistic regression persistent
dysphagia
Cox regression total persistent and
recurrent dysphagia
Odds ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Dilation before treatment 4.1 (1.3-12) 0.01 2.1 (1.1-4.1) 0.03
Previous chemotherapy treatment 3.2 (0.81-12) 0.097 - -
Figure 1: Effect of dilation before treatment on the risk of persistent or recurrent dysphagia
in patients with esophageal carcinoma after single dose brachytherapy (n=95).
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Recurrent dysphagia
In total, 34 events of recurrent dysphagia occurred in 28/95 (29%) patients. Recurrent
dysphagia was caused by tumor regrowth (n=26), food bolus obstruction (n=5), stent
migration (n=2), and oblique stent positioning (n=1). Tumor regrowth was treated
by placement of a metal stent (19/26; 73%), a second dose of brachytherapy (3/26;
12%) or another treatment (4/26; 15%). Stent migration and oblique stent positioning
occurred in 3 patients after stent placement for tumor regrowth after initial
brachytherapy. Univariable and multivariable Cox regression analysis showed that
none of the investigated patient and tumor characteristics were associated with an
increased risk of recurrent dysphagia. 
Persistent and/or recurrent dysphagia
In total, 42/95 (44%) patients needed additional treatment due to persistent and/or
recurrent dysphagia after single dose brachytherapy. Both univariable and
multivariable Cox regression analysis showed that dilation prior to treatment
increased the risk of additional treatment for persistent and/or recurrent dysphagia
after single dose brachytherapy (Figure 3). 
DISCUSSION
Single dose brachytherapy is an effective treatment for the palliation of dysphagia
from esophageal cancer, however both persistent and recurrent dysphagia diminish 
its effectiveness both on the short and long term after treatment. This will negatively
influence quality of life in this group of patients with only a limited life expectancy.
We found that dilation prior to treatment was a risk factor for persistent and
recurrent dysphagia after single dose brachytherapy. In addition, there was a trend
towards a higher risk for persistent dysphagia in patients previously treated with
chemotherapy.
Patients which stenotic tumors that needed dilation to pass the applicator down the
esophagus had a higher risk of persistent and recurrent dysphagia. This can 
probably be explained by the larger tumor load in these patients, resulting in only a
partial effect of the radiation on the tumor. The radiation dose of 12 Gy was 
administered at 1 cm from the source axis of the applicator. This means that the dose 
administrated to the surface of the tumor (0.5 cm from the source axis) amounted
200% of the prescribed dose. The dose at 1.25 cm from the source axis (at 0.75 cm
from the surface of the tumor) amounted only 65%. A single dose of 12 Gy 
brachytherapy was probably less or not effective for these patients with a large 
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tumor load (18). Increasing the dose is likely to improve the results of brachytherapy 
for these patients. Moreover, it has recently been shown that it is best to deliver this
higher dose in two or three fractions to prevent serious radiation complications (14,
19).
There was a trend towards patients with previous chemotherapy treatment having a
higher risk of persistent dysphagia after treatment with brachytherapy.
Chemotherapy consisted of a combined treatment of cisplatin and paclitaxel (n=9),
or carboplatin and paclitaxel (n=3) with a median of 6 doses given to each patient. In 
general, it has been reported that the results of chemotherapy before radiotherapy 
are disappointing, whereas concurrent radiation and chemotherapy leads to a better
therapeutic effect (20, 21). The mechanism(s) that decrease the effect of radiation
therapy after chemotherapy are not fully understood. Chemotherapy may lead to 
cell death and fibrosis, which will decrease the blood supply and thereby the
delivery of oxygen to the tumor. Much of the tissue damage from radiation therapy
depends on the formation of free radicals resulting in DNA damage (22). Since this
process requires oxygen, it seems likely that a decreased oxygen supply in tumors 
after chemotherapy is an important factor in determining resistance to radiation
therapy. In addition, there might be a higher probability of selection of drug-
resistant cells that may be cross-resistant to radiation therapy (21).
In the consensus guideline of the American Brachytherapy Society, several tumor
characteristics have been distinguished to divide patients in good and poor
candidates, and patients with contraindications for brachytherapy (13). These 
guidelines were established for brachytherapy in combination with external beam
radiation for the definitive and palliative treatment of esophageal cancer. In the
present study, we focused on single dose brachytherapy as a palliative treatment
modality for esophageal cancer. Contraindications for brachytherapy described by 
the American Brachytherapy Society include an esophageal fistula and a cervical
esophageal location of the tumor. These patients were excluded in our study. A
third contraindication in the guidelines is a stenotic tumor that cannot be bypassed.
In this study, patients with a stenotic tumor underwent dilation on the day of
brachytherapy. Dilation of the tumor did not increase the risk of developing major
complications, such as perforation or hemorrhage (p>0.20). We confirmed however,
that these patients had an increased risk of persistent and recurrent dysphagia. Poor 
candidates described by the American Brachytherapy Society are patients with a 
tumor length of more than 10 cm, tumors involving the gastroesophageal junction or 
cardia, extra-esophageal extension of the tumor, and regional lymphadenopathy 
(13). In the present study, patients were selected with inoperable cancer of the 
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esophagus or esophagogastric junction due to metastatic disease and/or a poor
medical condition. In our experience of 95 patients treated with brachytherapy,
tumor lengths of 10 cm or more, tumors involving the gastroesophageal junction, or 
metastatic disease did not increase the risk of additional treatment for persistent or 
recurrent tumor growth. Multivariable Cox regression analysis showed however 
that a tumor length of 10 cm or more and the presence of metastases correlated with
a shorter survival. Based on our results, it is our opinion that patients with a long
tumor (ǃ 10 cm), a tumor involving the gastroesophageal junction, or metastatic
disease can effectively be palliated for dysphagia with single dose brachytherapy.
Which palliative treatment could be an alternative for patients who are poor
candidates for single dose brachytherapy? Stent placement is presently a commonly
used and effective palliative treatment modality for dysphagia from esophageal 
cancer. For patients with stenotic tumors that cannot be bypassed, stent placement
should be an attractive alternative since stent placement offers a more rapid relief of 
dysphagia (16). We recently demonstrated that metal stent placement is a safe and 
effective palliative treatment for malignant dysphagia in patients who underwent
prior radiation and/or chemotherapy (23). 
Our findings can be used to establish a more individualized palliative treatment
strategy for patients with dysphagia from esophageal cancer. Patients with a tumor 
size of more than 10 cm, a tumor located across the gastroesophageal junction or 
with evidence of metastatic disease can effectively be palliated with single dose
brachytherapy. Patients with stenotic tumors that cannot easily be bypassed or 
previously underwent chemotherapy are poor candidates for single dose 
brachytherapy. For these patients alternative palliative treatment modalities, such as 
stent placement, should be considered.
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The Dutch SIREC study group consisted of: 
Erasmus MC / University Medical Centre Rotterdam: Dept. of Gastroenterology & Hepatology: 
Marjolein Y.V. Homs, Ernst J. Kuipers, Peter D. Siersema; Dept. of Public Health: Ewout W. 
Steyerberg, Suzanne Polinder, Marie-Louise Essink-Bot, Gerard J.J.M. Borsboom; Dept. of 
Radiotherapy: Wilhelmina M.H. Eijkenboom; Dept. of Surgery: Hugo W. Tilanus; Dept. of 
Internal Oncology: Ate van der Gaast. Academic Medical Centre, Amsterdam: Dept. of 
Radiotherapy: Lukas J.A. Stalpers; Dept. of Gastroenterology & Hepatology: Joep F.W.M. 
Bartelsman; Dept. of Surgery: Jan J.B. van Lanschot. University Medical Centre Utrecht: Dept of 
Radiotherapy: Harm K. Wijrdeman, Dept. of Gastroenterology: Hans W. Bogaard. Rijnstate 
Hospital Arnhem / Arnhem Radiotherapeutic Institute: Dept. of Gastroenterology: Chris J.J. 
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Mulder, Peter J. Wahab; Arnhem Radiotherapeutic Institute: Janny G. Reinders. The
Netherlands Cancer Institute, Amsterdam: Dept. of Gastroenterology: Henk Boot; Dept. of 
Radiotherapy Berthe M.P. Aleman. Leyenburg Hospital, The Hague: Dept. of Gastroenterology: 
Jan J. Nicolai; Dept. of Radiotherapy: Frank M. Gescher. Medical Centre Haaglanden, The Hague:
Dept. of Internal Medicine: Maarten A.C. Meijssen; Dept. of Radiotherapy: Ruud G.J. 
Wiggenraad. Gelre Hospital, Apeldoorn: Dept. of Internal Medicine Jitty M. Smit. Reinier de 
Graaf Hospital, Delft: Dept. of Gastroenterology: Clemens J.M. Bolwerk.
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and Netty M. Mouthaan, and to Coleta Verheij from the Trial Office of the Department of 
Oncology, Erasmus MC Rotterdam.
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The effect of prior radiation and/or chemotherapy on stent placement 
ABSTRACT
Objective: It is still unclear whether prior radiation and/or chemotherapy (RTCT)
increases the risk of complications after self-expanding metal stent placement in 
patients with inoperable esophagogastric carcinoma. We evaluated the influence of 
prior RTCT on the outcome of stent placement in a large group of patients. 
Methods: From October 1994 to December 2000, 200 patients underwent self-
expanding metal stent placement for malignant dysphagia, and were followed
prospectively. Forty-nine of these patients had received prior RTCT (chemotherapy
n=35, radiation therapy n=8, or both n=6). 
Results: At 4 weeks after stenting, the dysphagia score had improved similarly in 
patients with or without prior RTCT, from a median of 3 to 0 (p<0.001). The 
occurrence of major complications (bleeding, perforation, fistula formation, fever
and severe pain) was not different between patients with or without prior RTCT
(29% versus 21%; relative risk (RR)=1.15 (95% CI 0.54-2.46; p=0.72)), as was the
occurrence of recurrent dysphagia due to tumor overgrowth, stent migration, or 
food-bolus impaction (35% versus 27%; RR=1.49 (95% CI 0.71-3.13; p=0.29)). Median
survival of both patient groups after stent placement was similar (110 versus 93 
days; RR=0.90 (95% CI 0.60-1.34; p=0.60) for prior RTCT versus no prior treatment).
Only minor complications (mainly mild retrosternal pain) occurred more frequently
in patients with prior RTCT (41% versus 15%; RR=2.12 (95% CI 1.06-4.25; p=0.035)).
Conclusions: Both the incidence of life-threatening complications and survival after
self-expanding metal stent placement for esophagogastric carcinoma are not affected
by prior RTCT, however retrosternal pain occurs more frequently in patients who
had previously undergone RTCT. 
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INTRODUCTION
More than 50% of patients with carcinoma of the esophagus or the gastric cardia
have inoperable disease at presentation and most of them require palliative
treatment to relieve progressive dysphagia. At present, self expanding metal stent 
placement is a commonly used method for the palliation of malignant dysphagia.
Previously reported studies have demonstrated that stent placement is an effective
and safe method for palliation of malignant dysphagia (1-9). An unresolved 
question is whether prior radiation and/or chemotherapy (RTCT) affects the
outcome. Eight studies addressed this question (1, 6, 10-15) (Table 1).
Table 1: Overview of studies on the influence of prior radiation and/or chemotherapy on
the outcome of stent placement for palliation of esophagogastric carcinoma. 
Author / Year 
(ref.)
No. of patients Type of study Type of stent Life-threatening
complications
Increased risk
Bethge et al. 1996 
(14)
Prior RTCT: n=13
Prior surgery: n=4
No controls
Prospective Wall stent 3/17 (18%) 
Kinsman et al.
1996 (10)
Prior RTCT: n=22
No treatment: n=37
Retrospective Z-stent 8/22 (36%)
1/37 (3%)
Siersema et al.
1998 (6)
Prior RTCT: n=28
No treatment: n=47
Prospective Plastic tubes n=38
Z-stent n=37
12/28 (43%)
8/47 (17%)
Muto et al.
2001(15)
Prior RTCT: n=13
No controls
Retrospective Ultraflex n=9
Wall stent n=2
Z-stent n=2
7/13 (54%)
No difference 
Kozarek et al.
1996 (11)
Prior RTCT: n=59
No treatment: n=26
Retrospective Plastic tubes n=47
Z-stent n=26
Wall stent n=10
Esophacoil/Ultraflex
n=2
Tubes: 2/32 (6%)
vs. 1/15 (7%)
SEMS: 1/27 (4%)
vs. 1/11 (9%)
Nelson et al. 1997 
(12)
Prior RTCT: n=6
No/other treatment:
n=15
Retrospective Wall stent 0/6 (0%)
?
Raijman et al.
1997 (13)
Prior RTCT: n=39
No treatment: n=21
Retrospective Wall stent 3/39 (8%) 
2/21 (10%)
Bartelsman et al.
2000 (1)
Prior RTCT: n=54
No treatment: n=99
Retrospective Song stent No relation (not
further
specified)
Present series Prior RTCT: n=49
No treatment: n=151
Prospective Z-stent n=70
Wall stent n=71
Ultraflex stent n=59
14/49 (29%)
31/151 (21%)
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Four studies showed an increased risk of complications after prior RTCT (6, 10, 14, 
15), whereas the other four studies did not find such a relationship (1, 11-13). 
Sample sizes of these studies were rather small, six studies were retrospective (1, 10-
13, 15), and two studies also included conventional prosthesis (6, 11). 
In this study, data of all patients who underwent self-expanding metal stent
placement for palliation of malignant dysphagia performed in our hospital were 
combined, which resulted in 200 prospectively followed patients. We investigated
whether prior RTCT influenced functional outcome, complication rate, the 
occurrence of recurrent dysphagia and survival after stent placement.
METHODS
From October 1994 to December 2000, 200 patients with dysphagia caused by an
inoperable carcinoma of the esophagus or gastric cardia, or recurrent dysphagia 
after prior radiation with curative or palliative intent for esophageal cancer were
palliated with a self-expanding metal stent in the Erasmus MC Rotterdam.
Three types of metal stents were inserted: the covered Gianturco-Z stent (Wilson-
Cook Europe A/S, Bjaeverskov, Denmark), the partially covered Flamingo Wallstent
(Microvasive/Boston Scientific Corp., Watertown, Mass., USA), and the partially 
covered Ultraflex stent (Microvasive/ Boston Scientific Corp., Watertown, Mass.,
USA). If it was impossible to pass the tumor with an endoscope, the stricture was 
dilated to 9-14 mm by a KeyMed Advanced Esophageal Dilator (KeyMed Ltd.,
Southend-on-Sea, U.K.). The proximal and distal tumor margins were marked by
injecting radiographic contrast medium into the submucosa through a sclerotherapy
needle. The stent was introduced and deployed under fluoroscopic monitoring. The
stent was at least 2-4 cm longer than the stricture to allow for a 1-2 cm extension
above and below the proximal and distal tumor margins. Following placement,
deployment of the stent was endoscopically and radiographically assessed. All
patients were consciously sedated with midazolam (DormicumR, Roche Nederland 
BV, Mijdrecht, the Netherlands). Written informed consent was obtained from all
patients.
All patients were evaluated before stent placement and at 4-week intervals until
death. Regular follow-up visits were made by a specially trained nurse and/or by
telephone calls to the patient’s general practitioner. If indicated, patients were
readmitted for clinical evaluation. Dysphagia was scored before treatment and at 4
weeks after stent placement, according to Ogilvie et al. (16) as: grade 0: ability to eat
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a normal diet; grade 1: ability to eat some solid food; grade 2: ability to eat some 
semisolids only; grade 3: ability to swallow liquids only; grade 4: complete
dysphagia. Major complications were defined as life-threatening or severe 
complications, such as perforation, bleeding, fever, fistula formation and severe
pain, whereas minor complications were defined as not life-threatening or
moderately severe complications such as mild retrosternal pain and
gastroesophageal reflux. Pain was defined as mild pain if it was treatable with non-
narcotic analgesics, such as acetaminophen or a non-steroidal anti-inflammatory
drug, or (low-dose) narcotic analgesics for a period of maximal 3 days. Severe pain
was pain for which (high-dose) narcotic analgesics for a longer period and/or
removal of the stent was indicated. Early complications were defined as procedure-
related complications occurring within 7 days after stent placement. Complications
occurring more than 7 days after treatment, for which it was often unsure whether 
these were related to placement of the stent or progression of the disease, were 
defined as late complications.
The results were expressed as means ± standard deviation (SD), dysphagia scores 
were expressed as medians. The improvement of the dysphagia score was analyzed
using Wilcoxon signed-ranks test, and differences in dysphagia score improvement 
between the patient group with prior RTCT and the group without prior treatment
was determined by the Mann-Whitney test. The observed median survival was 
calculated using the Kaplan Meier method. Multivariate Cox regression analysis 
was performed to investigate differences in the occurrence of major and minor 
complications, recurrent dysphagia, and survival between the group with prior 
RTCT and the group without prior treatment. Covariates included in the analysis
were gender, age, histology, length and location of the tumor, type, length and
diameter of stent, and dilation before stent placement. Age and histology were 
always included in the different models because of a skew distribution of age and a 
difference in the incidence of squamous cell carcinoma and adenocarcinoma
between the prior RTCT group and the group without prior treatment. Interactions
between covariates, particularly prior RTCT / no prior RTCT with age and tumor
histology were tested. The assumption of proportional hazards of the Cox
regression was tested for each covariate extending the model with covariate*log 
(follow-up time). The used level of significance was ΅=0.05.
100
The effect of prior radiation and/or chemotherapy on stent placement 
RESULTS
Clinical characteristics
The clinical characteristics of the two patient groups are shown in table 2. Forty-nine
patients had received prior chemotherapy (n=35), prior radiation therapy (n=8) or
both (n=6). Chemotherapy consisted of the combination Cisplatinum and Paclitaxel
(n=31), or the combination Cisplatinum, 5FU and Vepesid (n=10) with a median of 5
(range 1-8) treatments. The median total radiation dose was 30 (range 15-66) Gy,
including five patients receiving external beam radiation with additional
intraluminal radiotherapy (brachytherapy). The median time between the end of the 
radiation and/or chemotherapeutic treatment and stent placement was 64 (range 6-
899) days.
Outcome of stent placement
Successful placement of a self-expanding metal stent was achieved in 198 (99%) of 
the 200 patients (Table 3). For one stent the releasing system failed and another stent
migrated during placement. Both these stents were removed and a second metal 
stent was successfully inserted. 
Table 2: Clinical characteristics of 200 patients with or without prior radiation and/or 
chemotherapy (RTCT) given a self expanding metal stent for palliation of malignant 
dysphagia
Prior RTCT
(n=49)
No prior RTCT
(n=151)
Mean Age (y)* 60r11 72r11
Gender (%) 
Male
Female
37 (75) 
12 (25) 
113 (75) 
38 (25) 
Tumor histology (%)†
Squamous cell carcinoma
Adenocarcinoma
Other
Unknown
22 (45) 
25 (51) 
1 (2) 
1 (2) 
44 (29) 
103 (69) 
2 (1) 
2 (1) 
Mean Tumor length (cm) 7.8r2.5 7.7r2.5
Type of stent (%) 
Ultraflex stent 
Flamingo Wall stent 
Gianturco-Z stent 
12 (24) 
18 (37) 
19 (39) 
47 (31) 
53 (35) 
51 (34) 
Dilation before stent placement 9 (18) 13 (9) 
*p=0.02
†p=0.03
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Table 3: Outcome and survival in 200 patients with or without prior radiation and/or 
chemotherapy (RTCT) given a self-expanding metal stent for palliation of malignant 
dysphagia
Prior RTCT
(n=49)
No prior RTCT 
(n=151)
Technical success (%) 48 (98) 150 (99) 
Median dysphagia score before stent 
placement*
(10e – 90e percentile) 
3 (3-4) 3 (3-4) 
Median dysphagia score at 4 weeks after 
stent placement* (10e – 90e percentile) 
0 (0-2) 0 (0-2) 
30-day mortality (%) 7 (14) 24 (16) 
Median survival in days (95% CI) 110 (62-158) 93 (77-109) 
* on a scale from 0 (normal) to 4 (complete dysphagia) 
Figure 1: Dysphagia scores (on a scale from 0 (normal) to 4 (complete dysphagia)) in 
patients with (n=43) or without (n=128) prior radiation and/or chemotherapy (RTCT) before 
and 4 weeks after stent placement for palliation of malignant dysphagia.
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At 4 weeks after stenting, the dysphagia score had improved from a median of 3 to 0
(p<0.001) in both groups (Figure 1). There was no difference in the degree of
improvement between both groups. The dysphagia score at 4 weeks had improved
in 161/171 (94%) of the patients by at least one grade, allowing an equal number of 
patients to eat solids or semi-solids, 27 patients died before the 4 weeks follow-up,
and for 2 patients data were missing.
Major complications
Multivariate Cox regression analysis showed that the occurrence of major (both 
early and late) complications did not differ between both groups (Table 4). The
relative risk (RR) for a major complication was RR=1.15 (95% confidence interval
(CI) 0.54-2.46; p=0.72) for patients with prior RTCT versus no prior treatment.
Early major (procedure-related) complications occurred in 3 (6%) patients who
underwent prior RTCT and in 13 (9%) patients without prior treatment (Table 5).
The relative risk for a major complication within 7 days after stent placement was
RR=0.70 (95% CI 0.19-2.60; p=0.58) for patients with prior RTCT versus no prior
treatment. One patient who had previously received chemotherapy experienced 
severe pain during placement of a metal stent. The stent was removed and a feeding 
tube was placed. Two patients, both treated with chemotherapy, developed fever
within 24 hours after placement of a metal stent. These patients were not 
neutropenic and a chest X-ray showed no evidence of perforation or aspiration 
pneumonia. Both patients recovered after treatment with antibiotics and feeding
through a naso-duodenal tube. In the group with no prior treatment, nine
perforations occurred, two of these were fatal (see below), while seven patients
improved with conservative treatment, later dying of causes unrelated to the 
perforation. One patient developed hematemesis within 24 hours after placement
and required a transfusion. One patient developed fever without evidence of a
perforation or aspiration, and this was treated with antibiotics. Two patients
experienced severe pain in the first week following stent placement. In one of these 
patients, removal of the stent resulted in diminution of the pain. Subsequently, this
patient was treated by radiation therapy. An endoscopy in the other patient
revealed an ulcer at the proximal end of the stent, which was treated by retraction of
the stent.
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Table 4: Relative Risk (RR) for a major complication, minor complication, recurrent
dysphagia and survival for patients with prior RTCT versus no prior RTCT according to a 
multivariate Cox regression analysis 
RR (Prior RTCT versus
No Prior RTCT) (95% CI) 
p-value
Major complications
ǂ 7 days 
   > 7 days 
1.15 (0.54-2.46) 
0.70 (0.19-2.60) 
1.46 (0.61-3.53) 
p=ns
p=ns
p=ns
Minor complications 2.12 (1.06-4.25) p=0.035*
Recurrent dysphagia 1.49 (0.71-3.13) p=ns
Survival 0.90 (0.60-1.34) p=ns
Table 5: Complications and recurrent dysphagia in 200 patients with or without prior 
radiation and/or chemotherapy (RTCT) after placement of a self-expanding metal stent for 
palliation of esophagogastric cancer 
Prior RTCT
(n=49)
No prior RTCT 
(n=151)
Major complications
d 7 days 
Perforation
Bleeding
Fever
Severe pain 
> 7 days 
Bleeding
Fistula
Severe pain 
15 in 14 patients (29%) 
2
1
11
1
33 in 31 patients (21%) 
9
1
1
2
17
2
1
Minor complications*
Retrosternal pain 
Gastroesophageal reflux 
Atrial Fibrillation
24 in 20 patients (41%) 
15
8
1
24 in 22 patients (15%) 
14
10
Recurrent dysphagia
Tumor overgrowth 
Migration of device 
Food-bolus impaction 
Fracture of device 
21 in 17 patients (35%) 
12
5
4
46 in 40 patients (27%) 
15
19
11
1
*p=0.035
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Late major complications, including hematemesis, fistula formation and severe pain, 
occurred in 12 (24%) patients with prior RTCT and in 20 (13%) patients without
prior treatment (Table 5). The relative risk for a major complication occurring more 
than 7 days after treatment was RR=1.46 (95% CI 0.61-3.53; p=0.40) (Table 4) for
patients with prior RTCT versus no prior treatment. Eleven patients who were
treated with prior RTCT developed hematemesis after a median of 59 days (range 8-
260 days). One patient who received prior chemotherapy complained of severe pain
2 months after stent placement and insisted on removal of the stent. Endoscopy 
showed tumor progression after stent removal. This patient was then treated with
brachytherapy without improvement of dysphagia and finally received a PEG-
catheter. In the group of patients without prior RTCT, 17 patients developed
hematemesis after a median of 41 days (range 8-510 days). Two patients developed
an esophagorespiratory fistula at 2 months and 6.5 months, respectively. In both
patients this was treated with a second covered metal stent. One patient experienced
severe pain at 10 days after stent placement due to pressure necrosis at the proximal
end of the stent. The stent was retracted over 2 cm, resulting in disappearance of the
pain.
Dilation before stent placement, particularly in the group with prior treatment (9/49
(18%) vs. 13/151 (9%) in patients without prior treatment; p=0.06), significantly
increased the risk of major complications compared to patients without prior
dilation (p=0.03). Five of the nine perforations occurred in patients, in whom the
stricture was dilated before stent placement. Interactions with prior RTCT / no prior
RTCT were not significant.
Minor complications
Minor complications occurred more frequently in patients who underwent prior 
RTCT (prior RTCT: 41% versus no prior RTCT: 15%, Table 5). The relative risk for a 
minor complication was RR=2.12 (95% CI 1.06-4.25; p=0.035) for patients with prior
RTCT versus no prior treatment (Table 4). Minor retrosternal pain was observed in
15 (31%) patients with prior RTCT compared to 14 (7%) patients without prior
treatment. Eight patients with prior RTCT and 10 patients without prior treatment
experienced symptoms of gastroesophageal reflux, which was treated with a proton-
pump inhibitor. 
105
Chapter 5A 
Recurrent dysphagia
Sixty-seven incidents of recurrent dysphagia occurred in 57 patients, at a similar rate
in both groups, and this was caused by tumor overgrowth (n=27), stent migration
(n=24), food bolus-impaction (n=15) and fracture of the stent (n=1) (Table 5). Eight
patients had two episodes of recurrent dysphagia with a different cause and one 
patient had three episodes of dysphagia with a different cause. The relative risk for 
recurrent dysphagia was RR=1.49 (95% CI 0.71-3.13; p=0.29) for patients with prior
RTCT versus no prior treatment, after correction for stent length (Table 4). Length of
stent was also included in the analysis because there was a trend (p=0.07) that a
longer stent length was associated with an increased risk of developing recurrent
dysphagia.
Recurrent dysphagia due to tumor overgrowth at the proximal or distal end of the
stent occurred in 12 patients who were previously treated with RTCT after a median
of 116 days (range 33-290), and in 15 patients without prior treatment after a median
of 125 days (range 26-364 days). Stent migration occurred in 5 patients with prior
RTCT after a median of 18 days (range 5-147 days), and in 19 patients without prior
treatment after a median of 57 days (range 0-399 days). One patient had two
incidents of food-bolus impaction within one week, occurring almost 6 months after 
placement of the stent, and it was found to be caused by a fracture of the stent.
Survival
Median survival of all patients was 99 days, with no statistically significantly
difference between both groups (Table 3, Figure 2). The relative risk was 0.90 (95%
CI 0.60-1.34; p=0.60) for patients with prior RTCT versus no prior treatment (Table 
4). Stent-related mortality was 2% (1 patient) in the group with prior RTCT and 1%
(2 patients) in the group without prior treatment. One patient, previously treated 
with chemotherapy, developed fatal hematemesis 18 days after stent placement. At 
autopsy, one of the edges of the proximal end of the stent had perforated the
esophageal wall, leading to a fistula between the esophagus and aorta (17). In the
group with no prior treatment, 2 patients died from septic complications following
perforation after stent placement. The majority (74%) of the other patients died from
tumor progression, whereas 12% of patients died from causes unrelated to the 
tumor. Eleven patients died from hematemesis for which it was uncertain whether 
this was due to tumor progression, stent placement or another etiology, because no 
endoscopy or autopsy were performed in these patients. In 9 patients the cause of 
death was unknown, 2 patients were lost to follow-up, and 4 patients are still alive. 
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Figure 2: Kaplan-Meier plots showing no significant difference in survival between
patients with and without prior radiation and/or chemotherapy (RTCT) (0 months 
indicates the day of stent placement). 
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DISCUSSION
The influence of prior RTCT on the outcome of self-expanding metal stent
placement is as yet still unresolved. In this study, the occurrence of major
complications and survival after stent placement were similar for patients with or
without prior RTCT. This is in contrast with our previous published conclusion that
prior RTCT indeed increases the risk of device-related complications (6) (Table 1). It
was drawn from a study comparing placement of conventional prosthesis with self-
expanding metal stents. The majority of complications occurred in patients with
conventional prostheses. The present study involved only patients, who were 
treated with a self-expanding metal stent.
The most optimal method to investigate the effect of prior RTCT on the occurrence 
of complications after stent placement would be to perform a randomized trial.
Randomized studies comparing palliative radiation and/or chemotherapy with no 
treatment are however rare (18, 19), and for an ideal study all patients from both
groups (RTCT and no treatment) should undergo stent placement after a defined
period. This is practically not feasible, as patients will only be treated with a stent if 
they develop dysphagia at some stage. In addition, if patients with inoperable
esophagogastric carcinoma are offered the option of radiation and/or chemotherapy, 
they are often not willing to be randomized. Therefore, in our opinion, this study
with a large number of patients (n=200) and prospectively collected data offers the
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best possibility to study the influence of prior RTCT on the outcome of metal stent
placement.
A retrospective study by Kinsman et al. (10) in 59 patients with obstructive
esophagogastric carcinoma also showed an increased risk of life-threatening
complications, including hematemesis, perforation or fistula formation, after
placement of a Gianturco-Z stent in patients treated with prior RTCT compared to 
patients without prior treatment (8/22 (36%) versus 1/37 (3%); p=0.012). Bethge et al. 
(14) prospectively followed 17 patients with prior curative RTCT (n=13) or surgery 
(n=4) treated with a Wallstent for recurrent dysphagia. During follow-up, there were
3 fatal complications (aortoesophageal fistula in 1 patient after 137 days, and septic
complications in 2 patients at 39 and 52 days after stenting). Muto et al. (15)
retrospectively analyzed the results of stent placement in 13 patients after failure of
primary chemoradiotherapy. Perforation occurred in 3 (23%) patients, stent-related
mediastinitis and pneumonia developed in 6 (46%) and 3 (23%) patients,
respectively. Seven (54%) patients died from pulmonary complications. In the last
two cited studies, no patients without prior RTCT were included (14, 15).
Four retrospective studies support the results of the present study in demonstrating
no difference in life-threatening or device-related complications after self-expanding
metal stent placement between patients with prior RTCT and patients without prior
treatment. Raijman et al. (13) analyzed the data of 60 patients, treated with a
Wallstent for malignant dysphagia or an esophagorespiratory fistula. Life-
threatening complications, defined as bleeding requiring blood transfusion,
perforation, fistula formation, or aspiration pneumonia, occurred in 3 (8%) of 39 
patients with prior RTCT and in 2 (10%) of 21 patients without prior treatment.
Nelson et al. (12) studying 23 patients treated with a Wallstent for inoperable
malignant esophagogastric carcinoma, found that none of the 6 patients with prior
radiotherapy and chemotherapy experienced life-threatening complications, such as 
perforation or bleeding within the first week after stent placement. Bartelsman et al. 
(1) evaluated the outcome of Gianturco-Z stents in 153 patients with
esophagogastric malignancies. They also failed to identify any relationship between
previously RTCT (35% of the patients) and the occurrence of device-related
complication (not further specified). Finally, Kozarek et al. (11), comparing
placement of conventional prosthesis and self-expanding metal stents for inoperable 
esophageal carcinoma, found no association between prior RTCT and the
development of stent-related complications, such as stent erosion with consequent 
tracheoesophageal fistulas or bleeding in the esophagus. In patients treated with a
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self-expanding metal stent, 1 of 27 (4%) patients previously treated with RTCT had
such a complication, against 1 of 11 (9%) patients without prior treatment.
In some respects the two groups in our study were not wholly comparable. The 
median age of the patients with prior RTCT was significantly lower compared to the
group without prior treatment. This reflects the fact that younger patients are more
often considered suitable candidates for radiation and/or chemotherapy. A
histological diagnosis of squamous cell carcinoma was observed more often in the 
group with prior RTCT, which was due to the fact that some of these patients
participated in a trial, studying the effect of chemotherapy on squamous cell
carcinoma. For this reason a multivariate analysis was performed, to correct for 
these differences between the groups. We want to emphasize that in none of the 
studied endpoints (major and minor complications, recurrent dysphagia, and 
survival) age and histology had a significant influence.
Dilation prior to stent placement was a risk factor for perforation, independent from
the fact whether prior radiation and/or chemotherapy had been administered. Some 
authors advocate a gradual dilation of the stricture over several sessions before stent
placement (3, 20). It is, however, questionable whether the increased risk of 
perforation is due to the dilation itself and it may well be inherent to the tightness of
the malignant stricture. Recently, a method was described for the placement of 
metal stents under fluoroscopic control, making dilation unnecessary, and allowing 
the small caliber delivery system of self-expanding metal stents to be negotiated
through malignant esophageal strictures (21). Although this method seems 
promising, further studies are needed to establish whether the occurrence of major 
complications such as perforation can be reduced by this method.
Minor complications were more common in patients with prior RTCT, particularly
retrosternal pain (31% versus 7%). This is possibly due to therapy effects of radiation
and chemotherapy such as necrosis and fibrosis, resulting in the esophageal wall 
being more prone to develop pain (22). Chest pain after placement of a self-
expanding metal stent is in itself a common problem. In a study by Golder et al. (23), 
26/52 (50%) patients required narcotic analgesics for chest pain within 48 h after
stent placement compared to 11/52 (21%) before stenting. Adequate pain control
after stenting is therefore indicated, especially for patients with prior RTCT.
The incidence of recurrent dysphagia was not significantly different between 
patients with or without prior RTCT. The observed trend of more recurrent
dysphagia for a longer stent length needs to be verified in further studies. However, 
as yet, there is no plausible reason that could explain this observation.
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In conclusion, our results indicate that prior RTCT does not increase the risk of 
major complications after stent placement, compared to patients without prior
treatment. Stent placement was effective in relieving dysphagia, at a similar rate in 
both groups. Only minor complications, particularly minor chest pain, occurred
more often in the group with prior RTCT. The occurrence of recurrent dysphagia 
and survival rates were similar in both groups. Therefore, placement of a self-
expanding metal stent is as safe and effective in patients with prior RTCT as in those 
without such treatment.
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Re-intervention after stent placement for esophageal carcinoma 
ABSTRACT
Background: Recurrent dysphagia frequently complicates the palliation of 
esophageal cancer with self-expanding metal stents. Neither the strategies nor the
outcomes of re-interventions have been adequately reported.
Methods: Two-hundred sixteen patients underwent placement of a self-expanding 
metal stent (Ultraflex, n=75; Flamingo Wallstent, n=71; Z-stent, n=70) for malignant
dysphagia, and were followed prospectively. The causes of stent-related recurrent
dysphagia, the intervals after first stent placement, the procedures used for re-
intervention and their outcomes were evaluated.
Results: Seventy-four episodes of stent-related recurrent dysphagia occurred in 63 
(29%) patients, mainly due to tumor overgrowth (n=30; median: 129 days), stent
migration (n=26; median: 92 days) and food bolus obstruction (n=16; median: 80
days). Stent migration occurred more frequently (p=0.05), whereas tumor
overgrowth occurred less frequently (p=0.05) with Ultraflex stents compared to
Flamingo Wallstents and Z-stents. Tumor overgrowth was treated in 25 patients
mainly by a second stent (n=19) and was effective in 23/25 (92%) patients. Five
patients received no further treatment. Stent migration was treated by placement of 
a second stent (n=14), repositioning of the migrated stent (n=7), other treatments
(n=3), or no further treatment (n=2) and treatment was effective in 20/24 (83%) 
patients. Food bolus obstruction was treated by endoscopic stent clearance in all 
patients. Re-intervention for stent-related recurrent dysphagia improved the 
dysphagia score from a median of 3 to 1 (p< 0.001). Median survival after re-
treatment was 68 days.
Conclusions: Recurrent dysphagia occurs in almost one-third of patients after stent 
placement. Re-intervention for stent-related recurrent dysphagia is effective in over
90% of patients. New innovations in stent design are needed to reduce the risk of 
stent-related recurrent dysphagia. 
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INTRODUCTION
The incidence of adenocarcinomas of the esophagus and esophagogastric junction is
increasing at a faster rate than that of any other cancer (1-3). Self-expanding metal
stents are now in common use for the palliation of cancer of the esophagus and 
gastro-esophageal junction. A number of studies have shown that self-expanding 
metal stent placement are both effective and safe for that purpose (4-10), however, 
the occurrence of recurrent dysphagia after stent placement remains the
predominant problem during follow-up. The most frequently reported causes are
stent-related problems, such as tumor overgrowth at the proximal or distal ends,
stent migration and food bolus obstruction. Surprisingly little is known about the
strategy and the outcome of re-intervention for stent-related recurrent dysphagia 
(11-13).
In the present study, involving a cohort of 216 prospectively followed patients after
self-expanding metal stent placement, we investigated the incidence and the causes 
of stent-related recurrent dysphagia and, in addition, the procedures used for re-
intervention, and their outcomes. 
METHODS AND MATERIALS 
Between October 1997 and July 2002, 216 consecutive patients with carcinomas of
the esophagus or esophagogastric junction, which were non-resectable because of 
metastatic disease and/or a poor medical condition, were treated for dysphagia 
grade 2-4 on the dysphagia score (14) with a self-expanding metal stent and
followed prospectively. Exclusion criteria were tumor growth within 3 cm of the
upper esophageal sphincter, a fistula, previous self-expanding metal stent
placement, WHO performance score of more than 3, or unfit to undergo conscious
sedation. Clinical characteristics of the patient population are shown in Table 1.
Written informed consent for prospective follow-up was obtained from all patients.
Three types of metal stents were used: 1) the partially covered Ultraflex stent 
(Microvasive/ Boston Scientific Corp., Watertown, Mass., USA) which is available in 
lengths of 10, 12 en 15 cm, and diameters of 18 mm or 22 mm at its midpoint; 2) the
partially covered Flamingo Wallstent (Microvasive/Boston Scientific Corp., 
Watertown, Mass., USA), which is available in lengths of 12 cm (proximal diameter:
24 mm and distal diameter: 16 mm) and 14 cm (proximal diameter: 30 mm and 
distal diameter: 20 mm); and 3) the covered Z-stent (Wilson-Cook Europe A/S,
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Bjaeverskov, Denmark), which is available in lengths of 10, 12 and 14 cm, and 
diameters of 18 mm or 22 mm at its midpoint (Table 1). Stent placement was
performed according to a standardized procedure described previously (9). 
Table 1: Clinical characteristics of 216 patients treated with a self expanding metal stent for 
the palliation of malignant dysphagia. 
Ultraflex
N=75
Flamingo Wall 
N= 71 
Z stent 
N=70
Mean age (years r SD) 69 r 12 69 r 13 70 r 11 
Gender (M / F) 64 / 11 53 / 18 49 / 21 
Tumor histology (N (%)) 
Squamous cell carcinoma
Adenocarcinoma
Other / Unknown 
27 (36) 
48 (64) 
-
25 (35) 
43 (61) 
3 (4) 
19 (27) 
50 (71) 
1 (1) 
Mean tumor length (cm r SD) 8.0 r 2.4 7.6 r 2.4 7.8 r 2.5 
Location of tumor (N (%)) 
Mid esophagus 
Distal esophagus
Cardia
15 (20) 
46 (61) 
14 (19) 
14 (20) 
38 (54) 
19 (27) 
12 (17) 
38 (54) 
20 (29) 
Indications for palliative therapy (N (%)) 
Metastases
Local tumor progression
Poor medical condition 
48 (64) 
4 (5) 
23 (31) 
39 (55) 
9 (13) 
23 (32) 
46 (66) 
6 (9) 
18 (26) 
Length of stent (N (%)) 
10
12
14
15
14 (19) 
35 (47) 
-
26 (35) 
-
40 (56)†
31 (44) 
-
22 (31) 
22 (31) 
-
26 (37) 
Diameter of stent (N (%)) 
Small (midpoint 18-20 mm) 
Wide (midpoint 22-25 mm) 
66 (88) 
9 (12) 
40 (56) †
31 (44) 
61 (87) 
9 (13) 
Dilation before initial stent placement (N (%)) 7 (9) 10 (14) 6 (9) 
Initial dysphagia score (mean r SD) 3.0 r 0.7 3.2 r 0.5 3.2 r 0.5 
Radiation and/or chemotherapy (N (%)) 
Prior chemotherapy 
Prior radiation 
Additional chemotherapy 
16 (21) 
1 (1) 
6 (8) 
16 (23) 
7 (10) 
4 (6) 
14 (20) 
7 (10) 
5 (7) 
†The Flamingo Wall stent is available in 12 cm with a small diameter or 14 cm with a large diameter
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Stent-related recurrent dysphagia was considered present in cases of obstructive
tumor growth at the proximal or distal end of the stent, stent migration, food bolus
obstruction, or fracture of the stent causing dysphagia during follow-up after stent 
placement. The most frequently used treatments for stent-related recurrent 
dysphagia were placement of a second stent, single dose brachytherapy, retrieval or 
repositioning of migrated stents and endoscopic clearance of stents obstructed by a 
food bolus. Where a second stent was inserted, this was placed across the area of 
tumor overgrowth with about 40% of the stent overlapping the lumen of the original
stent. For brachytherapy, a guide wire was endoscopicaly inserted into the 
duodenum. Subsequently, a flexible applicator was passed down the esophagus 
through which a 192Iridium radio-active source administered a dose of 10-15 Gray at
1 cm from the axis of the applicator.
Endoscopic retrieval of a migrated stent was performed by collapsing the stent
through traction on the purse string (lasso) attached to the proximal flange
(Ultraflex stent), or by constricting it with a polypectomy snare (Flamingo Wallstent,
Z-stent). In some patients with a distally migrated Ultraflex stent or Flamingo
Wallstent, it was possible to reposition the stent. This was done by traction with an
endoscopic forceps on the upper rim of the Flamingo Wallstent or on the purse 
string of the Ultraflex stent.
Complete follow-up was obtained for all patients. Patients were evaluated before
initial stent placement and at 4-week intervals until death by regular home visits 
made by a specially trained nurse and/or telephone calls to the patient and the 
general practitioner. When indicated, patients were readmitted for clinical
evaluation, the majority to our hospital but if elsewhere, relevant clinical 
information was obtained from the admitting hospital.
Statistics
The results were expressed as means ± standard deviation (SD). Dysphagia scores 
and survival were expressed as medians. Dysphagia was scored as follows: score 0: 
ability to eat a normal diet; score 1: ability to eat some solid food; score 2: ability to
eat some semisolids only; score 3: ability to swallow liquids only; score 4: complete
dysphagia (14). Dysphagia scores before and after re-intervention were compared
by the Wilcoxon signed-rank test. Survival after re-intervention was analyzed using
the Kaplan-Meier method. We compared the incidence of stent-related recurrent 
dysphagia between the 3 types of stents with the Kaplan Meier method, taking time
between initial stent placement and recurrent dysphagia into account. If multiple
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incidents of stent-related recurrent dysphagia from the same origin occurred, only
the first incident was considered for statistical analysis. Separate multivariate Cox 
regression analyses were performed to determine predictors of tumor overgrowth,
stent migration, and food bolus obstruction. Variables included in the model were 
age, gender, presence of metastases, histology, length and location of the tumor, 
type, length and diameter of the stent and dilation before stent placement. We 
considered a p-value <0.05 as statistically significant.
RESULTS
Seventy-four episodes of stent-related recurrent dysphagia occurred in 63 patients 
(29%), caused by tumor overgrowth (n=30) (Figure 1A), stent migration (n=26) 
(Figure 1B), food-bolus obstruction (n=16) (Figure 1C), or fracture of the stent (n=2) 
(Figure 2). There was no significant difference in the overall incidence of stent-
related recurrent dysphagia between the 3 stent types: 28/75 (37%) for the Ultraflex
stent, 19/71 (27%) for the Flamingo Wallstent and 16/70 (23%) for the Z-stent (p=0.13)
(Table 2). There was a difference in survival after initial stent placement between 
patients with stent-related recurrent dysphagia compared to patient with no stent-
related recurrent dysphagia (median survival with recurrent dysphagia: 189 (95% CI
168-210) days versus with no recurrent dysphagia: 69 (95% CI 49-89) days; p<0.001).
Of the patients surviving more than 120 days, 48/98 (49%) developed stent-related
recurrent dysphagia. 
Tumor overgrowth 
The median interval between stent placement and stent-related recurrent dysphagia 
due to tumor overgrowth was 129 days (Table 3). Tumor overgrowth was observed
at the proximal end of the stent (n=15), the distal end (n=13), or at both ends (n=2).
Tumor overgrowth occurred less frequently with an Ultraflex stent compared to a
Flamingo Wallstent and a Z-stent (p=0.05) (Table 2). None of the other variables
included in the model influenced the occurrence of tumor overgrowth.
The predominant strategy for treating tumor overgrowth involved the placement of 
a second stent. This was performed in 18/30 patients (60%) and in one patient, with
tumor overgrowth at both ends of the stents, two stents were placed. Dysphagia
scores after placement of a second stent for tumor overgrowth improved from a
median of 3 to 1 (n=18; p=0.001). One patient with tumor overgrowth at the proximal
end of the stent and treated by a second stent, developed 4 weeks later tumor 
overgrowth at the distal end, which was treated by a third stent which only
119
Chapter 5B 
Table 2: Causes of stent-related recurrent dysphagia after placement of an Ultraflex stent 
(n=75), a Flamingo Wallstent (n=71), or a Z-stent (n=70).
Ultraflex stent 
(N=75)
Flamingo Wallstent 
(N=71)
Z-stent
(N=70)
Total 36 in 28 patients 
(37%)
22 in 19 patients
(27%)
16 in 16 patients 
(23%)
Tumor overgrowth* 7 12 11
Stent migration* 17 5 4
Food bolus obstruction* 10 5 1
Stent fracture 2
*p-values adjusted for age, gender, presence of metastases, histology, length and location of the tumor,
length and diameter of the stent and dilation before stent placement were respectively: tumor
overgrowth: p=0.05, stent migration: p=0.05, food bolus obstruction p=0.06.
Table 3: Outcome of re-intervention after self-expanding metal stent placement for 
malignant dysphagia in 216 patients. 
Tumor overgrowth 
(n=30)
Stent migration 
(n=26)
Food bolus
obstruction
(n=16)
Median time after initial stent 
placement (days) 
129 (range 26-364) 92 (range 6-399) 80 (range 8-165) 
Effective treatment for recurrent 
dysphagia
23/25 (92%) 20/24 (83%) 16/16 (100%) 
Median dysphagia score before 
and after reintervention 
3o 2 
(p=0.001)
3o 1.5 
(p=0.001)
4o 1 
(p<0.001)
Median survival after re-
intervention (days) 
55 (range 4-644) 74 (range 11-410) 68 (range 19-616) 
*5 patients with tumor overgrowth and 2 patients with stent migration did not receive treatment for
recurrent dysphagia
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Figure 1: Endoscopic view of tumor overgrowth (A), migration of an Ultraflex stent (B), and 
food bolus obstruction (C) after placement of a metal stent for palliation of dysphagia due 
to inoperable esophageal carcinoma. 
Figure 2: Fractured Ultraflex stent removed from a patient, subsequently followed by
placement of a new stent.
Figure 3: Three stents removed from a patient with inoperable esophageal carcinoma.
This patient first developed recurrent tumor growth at the proximal end of the stent, which 
was treated by placement of a second stent, followed by tumor overgrowth at the distal end
of the first stent, which was treated by placement of a third stent. In an attempt to remove the 
partially deployed third stent, all three stents were removed.
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deployed partially. In an attempt to remove this stent, all three stents were 
withdrawn (Figure 3) after which the patient was able to eat a fluid diet. Five weeks 
later a new (fourth) stent was placed. This patient survived for another 5 months
after placement of the fourth stent, eventually dying from tumor progression.
Another patient had a second episode of recurrent dysphagia due to tumor 
overgrowth, 182 days after the second stent placement, which was successfully 
treated by a third stent.
Other treatment modalities for recurrent dysphagia due to tumor overgrowth were 
dilation (n=1), laser treatment (n=1), external beam radiation therapy (which failed 
to improve dysphagia) (n=1), and argon plasma coagulation (this patient died 10
days later from tumor progression) (n=1). Two patients received a naso-gastric
feeding tube, later replaced by a PEG catheter, and one patient had a subclavian
catheter inserted for intravenous feeding. Reasons for the use of other treatment
modalities depended on individual patient and tumor characteristics. Five patients
received no further treatment, because of progressive disease and a short life 
expectancy. The median survival after re-intervention for tumor overgrowth was 55 
days (Table 3). 
Stent migration
The median interval between stent placement and recurrent dysphagia due to stent
migration was 92 days (Table 3). Stent migration occurred more frequently with an
Ultraflex stent (17/75 (23%)) compared to a Flamingo Wallstent (5/71 (7%)) and a Z-
stent (4/70 (6%)) (p=0.05) (Table 2). In particular, long (15 cm) Ultraflex stents were 
more prone to migrate (10 of the 26 long Ultraflex stents had migrated). There was a 
trend towards more migrations with the small diameter stents compared to large 
diameter stents (p=0.07). Location of the stent did not influenced the occurrence of 
stent migration (mid-esophagus: 4/41 (15%), distal esophagus: 19/122 (16%) and 
gastric cardia: 3/53 (6%); p>0.20). None of the other variables included in the model
influenced the occurrence of stent migration. 
Stent migration occurred in 8 (31%) of 26 migrating stents proximally and in 18 
(69%) distally, 11 of which into the stomach. Two of these 11 stents were retrieved
from the stomach because the patients experienced pain, two stents could be 
repositioned, and one stent passed the gastrointestinal tract uneventfully. The other 
6 stents were left in the stomach without causing symptoms. Proximal stent
migration occurred after a median of 46 (range 10-363) days compared to distal
migration which occurred after a median of 107 (range 6-399) (p=0.18).
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Four patients with stent migration had received chemotherapy 
(Cisplatinum/Paclitaxel) after placement of the first stent. In total, 15/216 (7%) 
patients received chemotherapy after stent placement (Table 1). The stents migrated 
proximally (n=2) or into the stomach (n=2). Both patients with distally migrated
stents had a symptomatic complete response following chemotherapy and were able
to eat solids again. Nevertheless, due to recurrent tumor growth, a second stent was 
placed 2.5 and 8 months after migration of the initial stent. Both patients with
proximally migrated stents complained of dysphagia, necessitating the placement of
a second stent. 
For stent migration the predominant strategy was placement of a second stent in
14/26 patients (54%), which was effective in 13/14 patients (93%). One patient
returned with recurrent dysphagia one week after placement of a second stent. 
Endoscopy showed that this stent had migrated as well. A third stent was inserted,
however, dysphagia persisted for unknown reasons, and a naso-gastric feeding tube
was placed. Another strategy was repositioning of the stent, performed in another 7 
of these 26 patients (27%). Repositioning was effective in 5/7 patients (71%). All 
these stents had migrated distally (2 of which into the stomach). In 2/7, the
repositioning procedure failed because the stent migrated again. After stent 
migration, two patients received brachytherapy (which failed to improve the
dysphagia score in one patient), one patient received a naso-gastric feeding tube and 
two patients remained free of dysphagia in spite of stent migration, both having 
undergone chemotherapy with a complete clinical response after stent placement 
(see above).
The median dysphagia scores after re-intervention for stent migration improved 
from 3 to 1.5 (n=26; p=0.001), and median survival after re-intervention was 74 days
(Table 3).
Food-bolus obstruction
The median interval between stent placement and recurrent dysphagia due to food 
bolus obstruction was 80 days (Table 3). There was a trend that food bolus
obstruction occurred more frequently with an Ultraflex stent than with a Flamingo
Wallstent and a Z-stent (p=0.06; Table 2). None of the other variables included in the
model influenced the occurrence of food bolus obstruction. 
In all cases, the strategy was endoscopic stent clearance. Four patients had repeated 
episodes of food bolus obstruction. In one patient this was caused by a small
fracture in the cover of the stent. One other patient experienced fracture of the metal
mesh of an Ultraflex stent (Figure 2). Both these stents were removed and new stents 
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were successfully placed. The median dysphagia score after re-intervention for food 
bolus obstruction improved from a median of 4 to 1 (n=16, p<0.001), and the median
survival after re-intervention was 68 days (Table 3).
DISCUSSION
Stent-related recurrent dysphagia after metal stent placement for non-resectable 
carcinomas of the esophagus or the esophagogastric junction occurred in almost one
third of our patients. This was mainly caused by tumor overgrowth at the proximal
and/or distal end of the stent, stent migration, and food bolus obstruction. The 
incidence of stent-related recurrent dysphagia in our study population was in 
accordance with findings in other series, where an incidence of stent-related 
recurrent dysphagia has been reported varying between 22% and 50% (4-7, 10). Re-
intervention for stent-related recurrent dysphagia was effective in over 90% of our
patients and improved dysphagia in most of these patients. Survival after re-
intervention was longer than 2 months. 
In the majority of patients with tumor overgrowth (60%), the successful treatment
strategy was placement of a second stent. Incidentally other treatments were used 
with variable results. Tumor overgrowth affected both ends of the stent at a similar
rate. As tumor overgrowth occurred after a median of 129 days (range 26-364), it
was likely to have been the result of tumor growth rather than an incorrect stent 
positioning. Tumor overgrowth was histologically confirmed in the majority of 
patients. We did not observe recurrent dysphagia due to nonmalignant obstructive 
tissue, such as granulation tissue, reactive hyperplasia and fibrosis at the proximal
or distal end of the stent. Mayoral et al. (15) reported this cause of recurrent 
dysphagia in more than 30% of their patients at a mean interval of 22 weeks after
stent placement. We observed the development of this nonmalignant tissue in a
number of patients undergoing endoscopy for reasons other than recurrent 
dysphagia. It was predominantly found at the proximal end of the stent but did not
cause dysphagia. In theory, tumor overgrowth could be delayed by using stents 
which, after expansion, are approximately 2-4 cm longer than the stricture to allow
for a 1-2 cm tumor growth above the proximal and below the distal end of the stent.
In our opinion, prevention of tumor overgrowth should be an important issue in the
design of new stent types. Possibly this could be achieved by impregnating metal
stents with chemotherapeutic agents or the incorporation of beta-radiation emitting
agents (16, 17). Further randomized trials would be needed to establish whether 
such modifications could, in practice, result in longer stent patency without
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increasing stent-related complications, such as fistula formation or stricture
formation at either end of these modified stents. 
Stent migration, which occurred in 12% of our patients, involved distal migration in
over two-thirds, eleven stents (5.5%) ending up in the stomach. In two patients, this
led to upper abdominal pain, particularly after eating and/or drinking, necessitating
retrieval of these two stents. Since endoscopy revealed no clear explanation, we 
hypothesized that the pain was caused by an irritating effect of the stent on the
gastric wall. We endorse the recommendation made by others that stent retrieval
from the stomach is probably only indicated in a minority of patients in whom a
migrated stent causes pain or obstruction of the pylorus, or if it hampers successful
placement of a second stent. Perforation or obstruction of the digestive tract are 
uncommon complications of stent migration (11, 18).
Our predominant strategy in stent migration was placing a second stent (14/26),
which was effective in 13/14. A more cost-effective strategy to stent migration might
be the repositioning of the migrated stent. Thanks to their mechanical properties, the 
Ultraflex stent and the Flamingo Wallstent were easier to reposition or remove 
endoscopically than the Z-stent. This is done by traction at the upper rim of the 
Flamingo Wallstent or at the purse string (lasso) attached to the inside of the 
proximal flange of the Ultraflex stent, a procedure which was successful in 5 of 7 
patients. Others have described a different technique of repositioning a stent by 
placing the endoscope in a retroflexed position and using it a as a ‘hook’. This
method can be applied successfully with the Ultraflex stent (19)], however it cannot
be used for the Z-stents, because it can result in a ‘kink’ in the stent, damaging the
esophageal mucosa and preventing it from being removed (20). 
Four patients in whom the stent migrated had received chemotherapy after stent 
placement. The effect of chemotherapy on the tumor itself was likely the cause of 
stent migration, particularly in the two patients with distally migrated stents, as
these patients had a complete (temporary) response on chemotherapy treatment. 
Presently, whenever a patient is scheduled to undergo treatment with
chemotherapy, we only place a stent if the patient has received at least 2 courses of
chemotherapy and is still complaining of persistent dysphagia with evidence of 
stable or progressive malignant disease at endoscopy. If a patient is not able to drink
enteral feeding in the initial period, we prefer to place a naso-gastric tube for 
feeding. In the future, these group of patients may be candidates for the placement 
of a bio-absorbable stent. These stents have the advantage that disintegration of the 
stent occurs over time, and therefore stent retrieval is probably no longer necessary 
(21).
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Stent design may play a role in stent migration. In our study, stent migration 
occurred frequently with Ultraflex stents. This can, at least partly, be explained by 
the lower expansion force of the Ultraflex stent compared to the other two stent 
types (22). In addition, migration of the Flamingo Wallstent is prevented by the 
proximal increase in diameter inherent to the conical shape. Moreover, the change in 
the braiding angle between the proximal and distal parts of the Flamingo Wallstent
mesh allows the distal part of this stent to stretch in response to peristaltic traction.
The European Z-stent has metal barbs on the outside of the stent to anchor it into the 
tumor (22, 23). There was a trend towards fewer stent migrations after placement of
a large diameter stent. We previously reported however, that in a non-randomized 
study comparing 19 large diameter Flamingo Wallstents with 21 small diameter
Flamingo Wallstents five of seven complications (mainly perforation and bleeding)
occurred with large diameter stents (p=0.07) (23). Therefore, widespread use of
larger diameter stents should wait until comparative studies have proven their
greater efficacy without compromising safety. Since stent migration has been 
reported to occur less frequently with uncovered stent types , new stent types, 
particularly a design with a double layer consisting of a covered inner layer and an 
uncovered outer layer, are currently under investigation. 
For food bolus obstruction, the successful strategy was endoscopic stent clearance.
As a stent lumen has a fixed diameter and lack peristalsis, food bolus obstruction is 
usually caused by a discrepancy between the size of the bolus and the lumen of the
stent. Smaller food particles of a fibrous nature may sometimes adhere together to 
form an obstruction and food particles can also be snagged on defects in the stent 
cover as occurred in one of our patients. Therefore, it is important not to damage the
stent cover during placement or re-intervention and in cases of recurrent 
obstruction. Careful endoscopic inspection can detect such defects, which 
necessitate the replacement of the damaged stent. 
Prevention consists of providing clear eating instructions, specifically, very 
thorough chewing of food, especially meat, and drinking effervescent drinks 
between bites and after meals in order to flush the stent. Although our patients
received instructions in a brochure, food bolus obstruction still occurred in 16/216
(7%) patients.
In conclusion, although self-expanding metal stent placement is a safe and effective 
treatment for malignant dysphagia, stent-related recurrent dysphagia occurred in 
almost one-third of our patients. Re-intervention for stent-related recurrent 
dysphagia was generally effective and improved dysphagia scores. The most
effective treatment strategy for both tumor overgrowth and stent migration was
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placement of a second stent, or, in cases of migration, stent repositioning. 
Innovations in stent design could potentially reduce the risk of these two causes of
stent-related recurrent dysphagia and thereby increase the effectiveness of metal
stents. For food bolus obstruction, endoscopic stent clearance was a universally
effective treatment strategy. Our findings confirm the importance of referring 
patients with recurrent dysphagia after stent placement for endoscopic investigation
as this problem is almost always amenable to treatment.
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Brachytherapy versus stent placement for palliation of esophageal cancer 
ABSTRACT
Background: Both single dose brachytherapy and self-expanding metal stent
placement are commonly used for the palliation of esophageal obstruction due to
inoperable cancer, but their relative merits are unknown.
Methods: Between December 1999 and June 2002, 209 patients with dysphagia from
inoperable carcinoma of the esophagus or gastro-esophageal junction were 
randomized to placement of an Ultraflex stent (n=108) or single dose (12 Gy)
brachytherapy (n=101). Patients were followed by monthly home visits from a
specialized nurse who collected outcome data using standardized questionnaires on 
relief of dysphagia, health-related quality of life, and costs. In addition,
complications and treatments for persistent or recurrent dysphagia were recorded.
Results: Dysphagia improved more rapidly after stent placement than after
brachytherapy, but long term relief of dysphagia was better after brachytherapy.
Complications occurred more often after stent placement (stent: 36/108 (33%) vs.
brachytherapy: 21/101 (21%); p=0.02), which was mainly due to a higher incidence of 
late hemorrhage (14/108 (13%) vs. 5/101 (5%); p=0.05). The number of patients
treated for persistent or recurrent dysphagia was similar for both treatment groups 
(stent: 43/108 (40%) vs. brachytherapy: 43/101 (43%)), as was median survival (stent:
145 (95% CI: 103-187) vs. brachytherapy: 155 (95% CI: 127-183) days). There was a
benefit in general and disease-specific quality of life scores in favor of brachytherapy 
compared to stent placement. Total medical costs, including hospital stay, re-
treatment and extramural health care, were similar at € 8,215 for stent placement
and € 8,135 for brachytherapy.
Conclusions: Despite a less rapid improvement, single dose brachytherapy gave a 
better long term relief of dysphagia. Since brachytherapy was also associated with
fewer complications than stent placement, it is recommended as the initial treatment
for the palliation of dysphagia from esophageal cancer. 
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INTRODUCTION
Annually, approximately 400,000 patients are diagnosed with esophageal cancer 
world-wide, and more than 350,000 die of this malignancy, which makes esophageal
cancer the eighth most common cancer, and sixth on the list of cancer mortality
causes (1). The incidence of esophageal carcinoma has risen markedly over the past 
two decades in the Western world, due to a marked increase in the incidence of 
adenocarcinoma (2, 3). The prognosis of esophageal cancer is poor with a 5-year 
survival of 10-15% (4, 5). Moreover, more than 50% of patients with esophageal
cancer have already inoperable disease at presentation. The majority of these 
patients require palliative treatment to relieve progressive dysphagia or fistula
formation. Presently, endoscopic placement of a covered self-expanding metal stent 
is the treatment of choice for an esophago-respiratory fistula. Treatment options
most commonly used for palliation of dysphagia include self-expanding metal stent
placement (6-10), laser therapy (11, 12), external beam radiation in combination with
brachytherapy (13, 14), and brachytherapy as a single treatment (15-18). A 
disadvantage of laser therapy is that repeated treatment sessions are required to
achieve and maintain adequate palliation (11, 12). A combined treatment of external
beam radiation with brachytherapy is often too intensive for patients with
inoperable, metastatic disease and a poor medical condition. Therefore, in many 
patients with inoperable disease, placement of a self-expanding metal stent or single 
dose brachytherapy are used for the palliation of dysphagia (19). Both these
treatment modalities have been proven to be effective in relieving dysphagia with a
low complication rate (7-10, 15-18), however, their relative effectiveness is unknown.
In the present study, patients presenting with inoperable cancer of the esophagus or 
gastro-esophageal junction were randomized to stent placement or single dose
brachytherapy. We compared the two treatments with respect to relief of dysphagia,
complications, treatment for persistent or recurrent dysphagia, health-related 
quality of life, and costs (20).
METHODS
Study population
Between December 1999 and July 2002, 253 consecutive patients with progressive
symptoms from esophageal obstruction due to inoperable cancer were eligible to
enter the trial. Since 44 patients refused to participate, 209 patients were randomized
to self-expanding metal stent placement or single dose brachytherapy (Figure 1).
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Figure 1: Flow chart of the study comparing brachytherapy with stent placement for 
inoperable carcinoma of the esophagus or gastro-esophageal junction.
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Refused to participate (n=44)
Randomized (n=209)
Lost to follow-up (n=0) 
Received stent (n=45) 
Received 2nd brachytherapy (n=3)
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Excluded from analysis (n=0)
Lost to follow-up (n=0) 
Received brachytherapy (n=2) 
Received 2nd stent (n=24)
Allocated to stent placement (n=108) 
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Inclusion criteria included inoperable cancer of the esophagus or gastro-esophageal 
junction due to metastatic disease (as defined by the TNM-classification) and/or a
poor medical condition (unfit to undergo surgery) with a dysphagia score of 2-4 on
the dysphagia score scale (21), and a written informed consent. Exclusion criteria
were a tumor length of more than 12 cm, tumor growth within 3 cm of the upper 
esophageal sphincter, deep ulceration or a trachea-esophageal fistula, macroscopic
or microscopic tumor growth into the tracheal lumen, the presence of a pacemaker,
and previous radiation therapy or stent placement. 
The study was approved by the Central Committee on Research Involving Human
Subjects in The Netherlands. Participating centers included 3 university and 6
general hospitals as listed in the Appendix.
For randomization, patients were stratified for location of the tumor (esophagus or
gastro-esophageal junction) and for administration of chemotherapy prior to
treatment. Randomization was centrally performed by telephone at the Trial Office 
of the Department of Oncology, Erasmus MC Rotterdam. 
Interventions
Prior to both interventions, an endoscopy was performed. Dilation was performed
on indication to a maximum of 11 mm by a Savary-Miller Esophageal Dilator
(Wilson-Cook Medical, Winston-Salem, NC, USA). The proximal and distal tumor
margins were marked by injecting radiographic contrast medium into the 
submucosa of the esophageal wall through a sclerotherapy needle. Then a guide 
wire was left.
For patients randomized to stent placement, the partially covered Ultraflex stent 
(Boston Scientific, Natick, MA, USA) was used, which is available in lengths of 10, 
12 and 15 cm with a proximal diameter of 23 mm and a distal diameter of 18 mm.
The stent was introduced and deployed under fluoroscopic monitoring. The stent 
length was at least 3 cm longer than the stricture to allow for at least a 1.5 cm
extension above and below the proximal and distal tumor margins. Following 
placement, deployment of the stent was assessed endoscopically and
radiographically.
For brachytherapy, a flexible applicator (Bonvoisin-Gérard Esophageal Applicator,
Nucletron, Veenendaal, The Netherlands) with a diameter of 10 mm was passed
down the esophagus. A single dose of 12 Gy was administered with the radioactive 
source 192Iridium at 1 cm from the source axis of the applicator. The standard active
length of the application was the tumor length plus two centimeters extra at both
ends of the tumor.
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All patients were consciously sedated with midazolam during either treatment
procedure. Sucralfate was prescribed for a period of 4 weeks after brachytherapy as
a prophylactic measure for odynophagia. A lifelong daily dose of 40 mg omeprazole
was prescribed to all patients of whom the distal end of the stent or the active length
of application of brachytherapy was below the gastro-esophageal junction to
prevent gastro-esophageal reflux after the procedure.
Study endpoints
The primary outcome of the study was dysphagia score (21) during follow-up;
secondary outcomes included complications, treatment for persistent or recurrent 
dysphagia, health-related quality of life, and costs.
Dysphagia was scored as follows: score 0: ability to eat a normal diet; score 1: ability
to eat some solid food; score 2: ability to eat some semisolids only; score 3: ability to
swallow liquids only; score 4: complete obstruction (21). Major complications were 
defined as life-threatening or severe complications, such as perforation, hemorrhage
(hematemesis, melena, or a significant drop in hemoglobin level), fever, fistula
formation and severe pain, whereas minor complications were defined as not life-
threatening or moderately severe complications, such as mild pain and gastro-
esophageal reflux. Early complications were defined as complications occurring 
within seven days after treatment. Complications occurring more than seven days
after treatment were defined as late complications, although it was often not known
whether these were related to the treatment or to progression of the disease.
Persistent dysphagia was defined as continuing dysphagia 2-4 weeks after treatment
with tumor growth observed at endoscopy, necessitating a second treatment.
Recurrent dysphagia was defined as occurrence of tumor regrowth more than four 
weeks after treatment, stent migration, food bolus obstruction or fracture of the stent 
causing dysphagia. If more incidents of recurrent dysphagia of the same origin 
occurred, only the first incident was considered for analysis. The choice of the 
treatment modality for complications, and persistent or recurrent dysphagia was
made by the responsible physician.
Health-related quality of life was assessed using the oncology-specific European
Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 measure
(22), the esophageal cancer specific EORTC OES-23 measure (23), the EuroQol-5D 
measure (24) including a self-classifier with 5 questions and a visual analogue scale 
(EQ-VAS) for the measurement of overall self-rated health, and a visual analogue
pain scale. Total medical costs included initial costs of treatment, hospital stay, re-
treatment costs, medical services, and extramural health care (25). We estimated full
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cost prices on the basis of real resource use from a societal perspective. Volumes of 
care were recorded for all patients and unit prices were determined with a
microcosting method (25). All costs are reported in Euros for the year 2002.
Follow-up
Patients were prospectively followed by home visits of one of six specially trained 
research nurses at 14 days, 1 month and then monthly until one year after treatment.
After one year of follow-up, patients were visited every 3 months, and/or telephone
calls to the patient and the patients’ practitioner were made. Patients received a
diary in which they scored dysphagia daily until 1 month and thereafter weekly. 
Questionnaires for assessing quality of life were filled out on the day of treatment
and during each home visit. Diary and questionnaires were completed, if necessary, 
by the research nurse. The response was more than 90% during the entire follow-up
period (in total 681/724 (94%) questionnaires were collected in the brachytherapy
group and 717/752 (95%) in the stent group). The use of medical services and
extramural health care was assessed during home visits by a standardized checklist.
If indicated, patients were readmitted for clinical evaluation. All participating
clinicians filled out standardized case record forms during control visits, re-
treatments and admissions.
Statistics
Analyses were performed on an intention-to-treat basis with follow-up data until
February 2003. The improvement in dysphagia score by at least one grade at 30 days 
after treatment was compared between treatment groups with a ̙2-test. This 
comparison was calculated to have a 90% power with a sample size of 104 patients
in each group (΅=0·05) if the improvement in dysphagia was 89% after stent
placement  and 70% after brachytherapy (15, 16, 26, 27). The dysphagia score at
different time points between treatment groups was compared with a linear
regression model that included the baseline dysphagia score to adjust for any pre-
treatment differences between the groups. Time was included as a restricted cubic 
spline function, which was chosen because of its flexibility and smoothness (28). The 
interaction between time and treatment group was also included to allow for the 
presence of different time courses in the two groups. Survival of the two groups was 
calculated and compared using Kaplan-Meier curves and the log rank test. Survival
was combined with dysphagia score to calculate dysphagia-adjusted survival. The 
area under the curve represented the number of days alive without or with mild 
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dysphagia (dysphagia score 0 or 1). We tested the difference between areas with a 
non-parametric bootstrap procedure. We drew 2000 samples with replacement and
determined the empirical 95% confidence interval and p-value (29). Complications
and treatment for persistent or recurrent dysphagia between the two groups were 
compared using Kaplan-Meier and log rank tests to adjust for time of occurrence of
the event and survival differences. We analysed quality of life scores with analysis 
of repeated measurements (30). For each scale a model was fitted that included day 
and treatment group as fixed factors, and the baseline measure and interaction
between day and treatment group as covariates. A simple compound symmetric
covariance structure was assumed to hold for all scales. For easier interpretation of 
differences between randomised groups, we also estimated the average differences
over time for scales where no clear interaction was noted (p>0.10). Since cost data
per patient are typically highly skewed, we used non-parametric bootstrap
techniques to derive a p-value for the differences in distribution of the direct 
medical costs (31). We considered a p-value <0·05 statistically significant.
Calculations were performed with SPSS 9·0 (SPSS Inc., Chicago, IL, USA), SAS 8·2
(SAS Institute Inc., Cary, NC, USA), and S-plus 2000 (Insightful Inc., Seattle, WA, 
USA).
RESULTS
Patient demographics
The two patient groups were comparable with respect to clinical characteristics
(Table 1). Three patients died before treatment due to progression of the disease, one 
patient was considered to be unfit to undergo metal stent placement at the day of
treatment, and five patients did not receive the allocated intervention (Figure 1).
Functional outcome and survival 
The dysphagia score improved more rapidly after stent placement than after
brachytherapy (Figure 2). At 30 days after treatment, however, dysphagia score 
improvement was not significantly different between stent placement and 
brachytherapy any longer. At this time, dysphagia score had improved by at least
one grade in 64/88 (73%) patients after brachytherapy and in 70/92 (76%) patients
after stent placement (p=0.61). In the long term, the dysphagia score was better after
brachytherapy than after stent placement, although the difference became smaller
with overlapping confidence intervals after about 350 days (Figure 2).
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Table 1: Clinical characteristics of 209 patients randomized to brachytherapy or stent 
placement for palliation of dysphagia due to inoperable carcinoma of the esophagus or 
gastro-esophageal junction.
Brachytherapy
N=101
Stent placement 
N=108
Age (years (SD)) 69 (13) 69 (11) 
Gender (M/F) 76/25 86/22
Dysphagia score before treatment (mean (SD)) 2.8 (0.9) 2.8 (0.7) 
Tumor length (cm) (mean (SD)) 7.5 (2.6) 7.5 (2.8) 
Indications for palliative therapy
Metastases
Poor medical condition 
Both
66 (65%) 
23 (23%) 
12 (12%) 
68 (63%) 
28 (26%) 
12 (11%) 
Location of tumor 
Esophagus
Gastro-esophageal junction
86 (85%) 
15 (15%) 
93 (86%) 
15 (14%) 
Tumor histology
Squamous cell carcinoma
Adenocarcinoma
Other
29 (29%) 
69 (68%) 
3 (3%) 
29 (27%) 
75 (69%) 
4 (4%) 
Prior chemotherapy 13 (13%) 17 (16%) 
Taking survival into account, patients randomized to brachytherapy had more days
with almost no dysphagia (grade 0 or 1) during follow-up than patients randomized
to stent placement (115 days versus 82 days, difference 33 days, 95% CI 1-64 days, 
p=0.015) (Figure 3). Median survival was 155 (95% CI: 127-183) days after
brachytherapy and 145 (95% CI: 103-187) days after stent placement (p=0.23) (Figure 
3).
By February 2003, 158 patients had died from tumor progression, 7 patients from
hemorrhage, of which it was unclear whether this was due to tumor progression, to 
the treatment or another unrelated cause, and 3 patients had died from the 
complications of perforation. Twenty-five patients had died from a cause unrelated 
to the tumor or treatment, and the remaining 16 patients were still alive with a 
follow-up of at least 6 months (range 6.4-31.8 months).
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Figure 2: Dysphagia scores (scored on a scale from 0 (normal) to 4 (complete dysphagia)) in 
patients randomized to brachytherapy (n=101) or stent placement (n=108) for dysphagia 
due to inoperable carcinoma of the esophagus or gastro-esophageal junction. The symbols
̇ and 2 represent mean dysphagia scores, the lines are spline functions with 95% confidence 
intervals.
Time (days)
0 50 100 150 200 250 300 350 400
D
ys
ph
ag
ia
 s
co
re
0,5
1,0
1,5
2,0
2,5
3,0
Stent
Brachy
Figure 3: (Dysphagia-adjusted) survival after treatment with brachytherapy (n=101) or stent 
placement (n=108) for dysphagia due to inoperable carcinoma of the esophagus or gastro-
esophageal junction. The upper 2 survival curves represent the percentage of all patients 
alive after brachytherapy or stent placement. The lower 2 dysphagia-adjusted survival curves 
represent the percentage of patients alive without or with mild dysphagia (dysphagia score 0 
or 1).
0 30 60 90 120 150 180 210 240 270 300 330 360 390
Days
0%
20%
40%
60%
80%
100%
(D
ys
ph
ag
ia
 a
dj
us
te
d)
su
rv
iv
al
Alive with dysphagia
score 0 or 1
Brachytherapy
Stent
Alive
143
Chapter 6A 
Table 2: Complications and persistent/recurrent dysphagia in 209 patients randomized to 
brachytherapy or stent placement for palliation of dysphagia due to inoperable carcinoma 
of the esophagus or gastro-esophageal junction.
Brachytherapy
N=101
Stent placement 
N=108
p-value*
Total complications
Major complications
ǂ 7 days 
     Perforation
     Fever
     Severe pain
     (Aspiration) pneumonia
  > 7 days 
     Perforation
     Fever
     Hemorrhage
     Fistula formation
     Severe pain
     Pressure necrosis
     Pre-stenotic dilation
Minor complications
  Mild retrosternal pain 
  Gastro-esophageal reflux
  Radiation esophagitis 
  Candida infestation 
23 in 21 patients (21%) 
14 in 13 patients (13%) 
1
1
1
1
1
5
3
1
8 in 8 patients (8%) 
5
1
1
1
45 in 36 patients (33%) 
28 in 27 patients (25%) 
2
1
2
1
14
3
1
3
1
16 in 16 patients (15%) 
9
5
2
p=0.02
p=0.02
p=0.08
Persistent/recurrent dysphagia
  Tumor persistence 
  Tumor regrowth 
  Stent migration
  Food bolus obstruction
  Fracture of stent
  Oblique position stent 
53 in 43 patients (43%) 
18
26
3#
5
1#
52 in 43 patients (40%) 
0
16
18
16
2
p=0.81
* Log rank test for time to first complication
# Some patients randomized to brachytherapy later received a stent for various reasons.
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Complications and treatment for persistent and recurrent dysphagia 
Complications occurred more frequently after stent placement than after
brachytherapy (p=0.02) (Table 2). Major complications included 4 perforations, 2 in
each treatment group, resulting in the death of three patients. Late major
complications consisted predominantly of hemorrhage (n=19) at a median of 123 
days (range 12-280) after treatment. Hemorrhage occurred more frequently after
stent placement (n=14) than after brachytherapy (n=5) (p=0.05). Thirteen (9 in the
stent group) of these patients underwent an endoscopy. In 8 patients (6 in the stent 
group), the hemorrhage was clearly caused by bleeding from the tumor, whereas in
the other 5 patients the cause was unclear. In 7 patients, one or more blood
transfusions were given, and 6 patients were treated with external beam radiation.
Seven patients died from this complication (1 patient randomized to brachytherapy
and 6 to stent placement). Fistula formation (n=6) occurred at a similar rate in both
groups after a median of 209 (range 13-448) days.
There was a trend towards more minor complications, in particular mild 
retrosternal pain and gastro-esophageal reflux, after stent placement (p=0.08) (Table
2). Retrosternal pain was effectively treated with analgesics, gastro-esophageal
reflux with omeprazole. 
The number of patients treated for persistent or recurrent dysphagia was not 
different between the two treatment groups (Table 2). Eighteen of 101 (18%) patients
randomized to brachytherapy had persistent dysphagia 2-4 weeks after treatment.
Endoscopy confirmed persistent tumor growth and a stent was placed. Tumor
regrowth occurred in 26 patients after brachytherapy, which was treated by
placement of a stent (19/26; 73%), a second dose of brachytherapy (3/26; 12%), or
another treatment (4/26; 15%). Recurrent dysphagia after stent placement was 
predominantly caused by tumor overgrowth, stent migration or food bolus 
obstruction (Table 2). Tumor overgrowth was treated by placement of a second stent 
(11/16; 69%), or a variety of other treatments; stent migration by placement of a 
second stent (9/18; 50%), repositioning of the stent (7/18; 39%), or another treatment; 
food obstruction by endoscopic cleaning of the stent.
Health related quality of life
There was a benefit over time for brachytherapy on the majority of the health related
quality of life scales (Figure 4A-H). For the oncology specific EORTC QLQ-C30 
measure, there were overall differences between brachytherapy and stent placement
on several functional scales including role functioning (p=0.05), emotional
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Figure 4: Quality of life scores after treatment with brachytherapy (n=101) or stent 
placement (n=108) for dysphagia due to inoperable carcinoma of the esophagus or gastro-
esophageal junction, including the role functioning (4A), emotional functioning (4B), 
cognitive functioning (4C), social functioning (4D), and global health status (4E) scales 
from the EORTC QLQ-C30 measure, the dysphagia scale from the EORTC OES-23 measure 
(4F), the EuroQol visual analogue scale for self-rated health status (4G), and the visual 
analogue pain scale (4H). Graphs show the mean scores with 95% confidence intervals of the 
different quality of life scales during follow-up. Higher scores represent a better functioning
or quality of life, except for the dysphagia scale (4F) and pain scale (4H) were higher scores 
represent more dysphagia or pain.
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4E EORTC QLQ-C30 Global health status / Quality of life
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functioning (p=0.04), cognitive functioning (p=0.006) and social functioning (p=0.03)
(Figure 4A-D). The differences between treatments on these scales were small at the 
beginning of follow-up and more pronounced at later time points. For emotional,
cognitive, and social functioning (Figure 4B-D), the differences in effect over time
were statistically significant (interactions between time and treatment group p<0.05).
The average difference over time was 6.5 points in favour brachytherapy for role 
functioning (Figure 4A), and 2.7 points for global health status (Figure 4E). For the
disease specific EORTC OES-23 measure, there was an overall significant difference
on the dysphagia scale (p=0.009, Figure 4F). The interaction between time and 
treatment group was significant which is in agreement with the observation that
stent placement was better at the beginning of follow-up and became worse at later
time points. There was no significant difference on the EuroQol visual analogue 
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scale for overall self-rated health (Figure 4G, average difference 1.5 points). There 
was a trend towards less pain in the brachytherapy group (average difference 3.8,
Figure 4H). 
Medical costs
The initial costs of stent placement (€ 1,500) were higher than the costs of 
brachytherapy (€ 570). The total medical costs were however similar (stent € 8,215 
vs. brachytherapy € 8,135, p=0·87, Table 3). Hospital re-admission during follow-up
occurred frequently in both groups. Total hospital stay during follow-up was 11·5 
days after stent placement versus 12·4 days after brachytherapy, causing high 
intramural costs (€ 5,675 vs. € 6,085, p=0·85). Costs for the use of medical procedures
during follow-up were higher after stent placement (€ 250 vs. € 170, p=0·01).
Table 3: Average medical costs (in €) per patient of brachytherapy or stent placement for 
dysphagia due to inoperable carcinoma of the esophagus and gastro-esophageal junction.
Cost category Brachytherapy
N=101
Stent placement
N=108
p-value5
Total treatment1 1415 1945 p=0.001
Total intramural care2 6085 5675 p=0.85
Medical procedures3 170 250 p=0.01
Extramural care4 465 345 p=0.81
Total 8135 8215 p=0.87
1Costs include initial treatment costs and additional placement of a stent after brachytherapy or 
placement of a second stent.
2Costs include hospital stay and visits to outpatient clinic.
3Costs include medical procedures related to the treatment, for example endoscopy, X-ray. 
4Costs include for example visits to the general practitioner and tube feeding.
5Derived from 2000 bootstrap samples drawn with replacement
DISCUSSION
This is the first randomized study that compares the two most widely used methods 
for the palliation of dysphagia due to inoperable cancer of the esophagus or gastro-
esophageal junction, i.e. single dose brachytherapy and stent placement. 
Brachytherapy resulted in a better relief of dysphagia at longer follow-up and was 
associated with fewer complications. In addition, there was a slight benefit in
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quality of life after brachytherapy. The number of repeated procedures for persistent
or recurrent dysphagia and costs of both treatment modalities were similar.
In this study, we obtained detailed longitudinal data on the course of dysphagia. In
this way, we were able to investigate the expected delay in treatment effect after
brachytherapy during the first few weeks (Figure 2). In the long term, dysphagia
scores were better in the group of patients randomized to brachytherapy. The long-
term benefit in the brachytherapy group could not be ascribed to the fact that
patients who had persistent dysphagia after brachytherapy were treated with a stent
(n=18). This group had worse dysphagia scores than the stent group or the
brachytherapy group without persistent dysphagia until 3 months of follow-up. 
After 3 months, the dysphagia scores were not different from the dysphagia scores
in the stent group (results not shown). This confirms that brachytherapy as the
initial treatment was more effective in the relief of dysphagia at longer follow-up.
Complications occurred more often after stent placement than after brachytherapy.
A common late complication was the occurrence of hemorrhage, in particular in 
patients treated with a stent. It is possible that in some patients, especially in those
who died, this was caused by the stent exerting pressure on the tumor and/or the 
normal mucosa of the esophagus. A few case reports have been published on 
massive hemorrhage after stent placement caused by perforation of the stent 
through the esophageal wall into the aorta (32, 33). In the literature, reported
incidence rates of hemorrhage after brachytherapy vary between 0% and 5% (15, 16, 
18, 26). In contrast, incidences varying between 5% and 16% have been reported
after stent placement (7-10). Whether the radiation effect of brachytherapy has a 
protective effect on bleeding from the tumor through tumor reduction or injury to 
the tumor vasculature (34), or that the expanding force of a stent increases this risk
remains to be elucidated.
Many patients in both treatment groups needed treatment for persistent or recurrent 
dysphagia (Table 2). After brachytherapy, a second treatment was most commonly
the placement of a stent, because of persistent or recurrent tumor growth. It can be 
debated whether a single treatment of 12 Gy brachytherapy was the optimal dose, or 
that the biological effects of brachytherapy might be improved by increasing and/or
fractionating the delivered dose. Different doses of brachytherapy were compared
previously in 172 patients with advanced esophageal (mainly squamous cell) 
carcinoma (27). Patients were randomized to receive 12 Gy in 2 sessions, 16 Gy in 2
sessions or 18 Gy in 3 sessions. Patients who received 16 or 18 Gy did significantly
better than patients who received 12 Gy in 2 sessions in terms of dysphagia-free
survival and persistent tumor growth in the oesophagus after treatment. The 
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treatment regimes with 16 Gy in 2 sessions and 18 Gy in 3 sessions were again
compared in a randomized trial with 232 patients, with similar results for the two
treatment regimes (18). Therefore, additional studies are needed to investigate 
whether a higher and/or fractionated dose of brachytherapy will increase the
efficacy of dysphagia relief in patients with metastatic disease and/or a poor general
condition.
The need for a second treatment in the stent group was mostly caused by tumor
overgrowth and migration of the Ultraflex stent. This stent, which is presently the 
most commonly used worldwide (35), was previously compared with the Flamingo 
Wallstent and Z stent in randomized trials. No clear differences were found in
functional outcome, complication rate and incidence of recurrent dysphagia 
between these stent types (7, 36). Stent migration is still a frequently occurring
problem, particularly for distally located tumors. The migration rate in our study
was 18/108 (17%), which is in line with other studies (37, 38). The Ultraflex stent has 
an uncovered proximal and distal segment that allows the normal mucosa to project 
into the stent lumen. In the present study, the small diameter Ultraflex stent was 
used, however, larger diameter stents have been demonstrated to reduce migration, 
particularly if placed across the ogastro-esophageal junction (35).
The measurement of health related quality of life after palliative treatment for 
dysphagia is important for patients diagnosed with an incurable disease (20, 39). To 
obtain complete data on quality of life, all patients were regularly visited by a
specialized nurse, since such patients are often not capable to fill out questionnaires
due to the severity of the disease. The scores found in our study were in agreement 
with results from a study, in which quality of life was measured in patients
undergoing various palliative treatments, using the same measures (39). On some
scales, differences in health related quality of life became obvious more than 6
months after treatment with a benefit for brachytherapy. Our results highlight the
importance of longitudinal data on quality of life using standardized measures in 
trials comparing curative or palliative treatment modalities for esophageal
carcinoma.
We performed a detailed cost analysis (Table 3). We found that stent placement was 
initially more expensive than brachytherapy, due to the high purchase costs of the
stent, but at the long term costs were comparable. Since this patient group often
needs additional medical care due to the occurrence of complications and 
progressive disease, these initial costs were only a small part of the total medical 
costs. Therefore, costs considerations should not play an important role in the
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decision on which of these two palliative treatments to use in patients with
malignant dysphagia.
In conclusion, single dose brachytherapy is preferable to stent placement as the 
initial treatment for patients with progressive dysphagia due to inoperable
carcinoma of the esophagus or gastro-esophageal junction. Stent placement may be 
reserved for patients with severe dysphagia in combination with a short life
expectancy that need a more rapid relief of dysphagia or for persistent or recurrent 
tumor growth after brachytherapy. It remains to be studied, whether results of
brachytherapy or stent placement can be improved by higher and/or fractionated 
radiation doses or by improved stent designs without jeopardizing safety.
APPENDIX
The Dutch SIREC study group consisted of: 
Erasmus MC / University Medical Center Rotterdam (n=124): Dept. of Gastroenterology &
Hepatology: Marjolein Y.V. Homs, Ernst J. Kuipers, Peter D. Siersema; Dept. of Public Health:
Ewout W. Steyerberg, Suzanne Polinder, Marie-Louise Essink-Bot, Gerard J.J.M. Borsboom; 
Dept. of Radiotherapy: Wilhelmina M.H. Eijkenboom; Dept. of Surgery: Hugo W. Tilanus;
Dept. of Internal Oncology: Ate van der Gaast. Academic Medical Center, Amsterdam (n=33):
Dept. of Radiotherapy: Lukas J.A. Stalpers; Dept. of Gastroenterology & Hepatology: Joep
F.W.M. Bartelsman; Dept. of Surgery: Jan J.B. van Lanschot. University Medical Center Utrecht 
(n=18): Dept of Radiotherapy: Harm K. Wijrdeman, Dept. of Gastroenterology: Hans W.
Bogaard. Rijnstate Hospital Arnhem / Arnhem Radiotherapeutic Institute (n=15): Dept. of 
Gastroenterology: Chris J.J. Mulder, Peter J. Wahab; Arnhem Radiotherapeutic Institute:
Janny G. Reinders. The Netherlands Cancer Institute, Amsterdam (n=11): Dept. of
Gastroenterology: Henk Boot; Dept. of Radiotherapy Berthe M.P. Aleman. Leyenburg Hospital,
The Hague (n=3): Dept. of Gastroenterology: Jan J. Nicolai; Dept. of Radiotherapy: Frank M. 
Gescher. Medical Center Haaglanden, The Hague (n=2): Dept. of Internal Medicine: Maarten A.C.
Meijssen; Dept. of Radiotherapy: Ruud G.J. Wiggenraad. Gelre Hospital, Apeldoorn (n=2): Dept.
of Internal Medicine Jitty M. Smit. Reinier de Graaf Hospital, Delft (n=1): Dept. of 
Gastroenterology: Clemens J.M. Bolwerk.
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and Netty M. Mouthaan, and to Coleta Verheij from the Trial Office of the Department of 
Oncology, Erasmus MC Rotterdam.
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ABSTRACT
Background: Metal stent placement and single dose brachytherapy are commonly
used treatment modalities for the palliation of inoperable esophageal carcinoma. We 
investigated generic and disease specific health-related quality of life (HRQoL) after
these palliative treatments.
Methods: Patients with dysphagia from inoperable esophageal carcinoma were 
randomized to placement of a covered Ultraflex stent (n=108) or single dose (12 Gy)
brachytherapy (n=101). We obtained longitudinal data on disease specific
(dysphagia score, EORTC OES-23, visual analogue pain scale) and generic (EORTC
QLQ-C30, EQ-5D) HRQoL at monthly home visits by a specially-trained research 
nurse. We compared HRQoL between the two treatments and analyzed changes in
HRQoL during follow-up. 
Results: Dysphagia improved more rapidly after stent placement than after
brachytherapy, but long term relief of dysphagia was better after brachytherapy. For
generic HRQoL, there was an overall significant difference in favor of
brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, 
emotional, cognitive and social) (p<0.05). Generic HRQoL deteriorated over time on
all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and 
role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of 
follow-up). This decline was more pronounced in the stent group. Major
improvements were seen on the dysphagia and eating scales of the EORTC OES-23, 
in contrast to other scales of this disease specific measure, which remained almost
stable during follow-up. Reported levels of chest or abdominal pain remained stable
during follow-up in both treatment groups, general pain levels increased to a minor 
extent.
Conclusions: The effects of single dose brachytherapy on HRQoL compared 
favorably to those of stent placement for the palliation of esophageal cancer. Future
studies on palliative care for esophageal cancer should at least include generic
HRQoL scales, since these were more responsive in measuring patients’ functioning
and well-being during follow-up than disease specific HRQoL scales. 
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INTRODUCTION
Esophageal cancer is associated with a poor prognosis with a 5-year survival rate of 
around 10%(1, 2). More than 50% of patients with esophageal cancer have
inoperable disease at presentation and the majority of these patients develop
progressive dysphagia (3). Palliative treatments aim to relief dysphagia with
minimal morbidity and mortality. Two widely used treatment modalities for 
palliation of malignant dysphagia include self-expanding metal stent placement (4-
7) and single dose brachytherapy (8-11).
The preservation of health-related quality of life (HRQoL) is an important goal of 
palliative treatment, and therefore HRQoL should be an outcome measure in trials
comparing palliative treatment modalities (12). In the majority of studies, relieve of 
dysphagia is the only aspect of HRQoL being measured although physical, mental,
and social functioning and other esophageal cancer specific aspects of HRQoL are 
additional important outcome measures. HRQoL is commonly assessed by
combining generic and disease specific measures. Various validated measures are
available to assess generic HRQoL after cancer treatment (13, 14). In addition,
measures for the assessment of disease specific HRQoL have been developed, and
these have been suggested to be more specific for measuring differences in outcome
between various treatment modalities for esophageal cancer (15).
We conducted a randomized trial comparing metal stent placement with single dose
brachytherapy for the palliation of esophageal cancer. Longitudinal data on HRQoL
before treatment and during follow-up were obtained. We compared these two 
treatment modalities with respect to generic and disease specific HRQoL. In 
addition, we determined the changes of HRQoL in patients with esophageal
carcinoma during follow-up.
METHODS
Study population
Between December 1999 and July 2002, 209 patients with inoperable cancer of the
esophagus or esophagogastric junction due to metastatic disease and/or a poor
medical condition with progressive dysphagia were randomized to metal stent
placement (n=108) or single dose brachytherapy (n=101).
Patients were treated with a covered Ultraflex stent (Boston Scientific, Natick, MA,
USA) or a single dose of 12 Gy brachytherapy (intraluminal radiotherapy). Patients
were included and treated in three university hospitals and six general hospitals in
the Netherlands. The study was approved by the Central Committee on Research 
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Involving Human Subjects in The Netherlands. The results of this study in terms of 
clinical outcome (16) and costs (17) were reported previously.
Health related quality of life assessment
Disease specific quality of life was assessed with the dysphagia score (18), the 
esophageal cancer specific European Organization for Research and Treatment of
Cancer (EORTC) OES-23 measure (15) and a visual analogue pain scale. Dysphagia
was scored as follows: score 0: ability to eat a normal diet; score 1: ability to eat some 
solid food; score 2: ability to eat some semisolids only; score 3: ability to swallow
liquids only; score 4: complete obstruction (18). The EORTC OES-23 measure
determines disease specific HRQoL which is relevant to patients with esophageal
carcinoma. It incorporates six multi-item scales (dysphagia, deglutition, eating,
indigestion, chest/abdominal pain and emotional) and four single symptoms
(having a dry mouth, troublesome taste, troublesome coughing and troublesome 
talking). The original measure has one extra symptom (hair loss). This item was 
removed because it was not applicable to the treatments under investigation. Before 
the start of the study, a Dutch translation was validated according to EORTC
guidelines. Answer categories of the questions rang from ‘not at all’ (scored as 1) to
‘very much’ (scored as 4). We used a visual analogue pain scale consisting of a 
horizontal line of 10 cm in length on which patients were asked to score the severity
of pain that they experienced, from ‘no pain’ to ‘the most severe pain they could 
imagine’.
Generic HRQoL was assessed using the oncology-specific EORTC QLQ-C30
measure (14), and the EQ-5D (13) including an index score and a visual analogue 
scale (EQ-VAS) for self-rated health. The EORTC QLQ-C30 covers aspects of generic 
quality of life specific for cancer patients. The EORTC QLQ-C30 incorporates nine 
multi-item scales: five functional scales (physical, role, cognitive, emotional, and 
social), three symptom scales (fatigue, pain, and nausea and vomiting), and a global
health/quality of life scale. Various single symptoms are included as well. The
scoring system is equivalent to the scoring system of the EORTC OES-23; answer
categories on the questions rang from ‘not at all’ (scored as 1) to ‘very much’ (scored 
as 4). Scores on the items for the global health/quality of life scale rang from 1 (‘very 
poor’) to 7 (‘excellent’). The EQ-5D assesses 5 dimensions including mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression. For each dimension, 
patients mark one of three levels of severity (level 1=no problems, level 
2=some/moderate problems, level 3=severe/extreme problems), which subsequently 
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can be classified into one of 243 (35) possible health status profiles. Each profile can
be linked to an index score based on empirical preferences for health status from an 
English general population sample (19). The EQ-VAS is a 20 cm vertical visual
analogue scale on which patients are asked to rate their overall health between 0
(‘worse imaginable health state’) and 100 (‘best imaginable health state’).
Patients were prospectively followed by home visits of specially trained research 
nurses at 14 days, 1 month and then monthly until one year after treatment. After
one year of follow-up, patients were visited every 3 months, and/or telephonic calls
to the patient and the patients’ practitioner were made until death. The EORTC
OES-23, EQ-VAS, and visual analogue pain scale were filled out before treatment
and during each home visit; the EORTC QLQ-C30 and EQ-5D were filled out before 
treatment, and 1, 3, 6, 9 and 12 months after treatment. The baseline HRQoL 
questionnaires were completed with help from one of the physicians or the principal
investigator (MYVH), whereas questionnaires during follow-up were completed
with help from the research nurses. Clinical baseline and follow-up data were 
obtained from all patients. The response of the quality of life measures was almost 
95% during the entire follow-up period (in total 681/724 (94%) questionnaires were 
collected in the brachytherapy group and 717/752 (95%) in the stent group).
Statistics
Analyses were performed on an intention-to-treat basis. The occurrence of clinical 
endpoints was analyzed with Kaplan-Meier curves and log rank tests (16). The 
dysphagia scores at different time points between treatment groups were compared
with a linear regression model that included the baseline dysphagia score to adjust 
for any pre-treatment differences between the groups. Time was included as a 
restricted cubic spline function, which was chosen because of its flexibility and 
smoothness (20). The interaction between time and treatment group was also
included to allow for the presence of different time courses in the two groups.
The HRQoL measures were scored according to standard scoring algorithms to 
obtain scores for the various multi-item scales for the EORTC OES-23 (15) and 
EORTC QLQ-C30 (14) and the index and VAS scores for the EQ-5D (19). For the 
EORTC OES-23 and EORTC QLQ-C30 the crude scores for the individual items
within a scale were first summed, and then divided by the number of items within 
the scale. Then, these scores were linearly transformed such that all scales ranged
from 0 to 100 with a higher scale score representing a higher level of functioning.
For the symptom scales and single symptoms of both measures, higher scores are
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equivalent to a higher level of symptoms. For the EQ-5D index score and the EQ-
VAS, higher scores represent a better health status. We compared quality of life 
scores of both treatments with analysis of repeated measurements(21). For each 
scale a model was fitted that included day and treatment group as fixed factors, and 
the baseline measure and interaction between day and treatment group as 
covariates. A simple compound symmetric covariance structure was assumed to
hold for all scales.
For the analysis of the changes of HRQoL during follow-up, a model was fitted for
each scale with time as linear factor. In case of interaction between both treatment
modalities (with a p-value of <0.10), this model was fitted separately for each 
treatment, otherwise one model was fitted for the whole group. For the dysphagia 
and eating scale of the EORTC OES-23, two phases were described: an acute phase
(< 30 days after randomization) and a chronic phase (> 30 days after treatment), as 
these scores did not follow a reasonable linear pattern in time. For each phase, a
separate line was fitted. Calculations were performed with SPSS 10.1 (SPSS Inc., 
Chicago, IL, USA) and SAS 8.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Clinical outcomes
The two patient groups were comparable with respect to their clinical characteristics
(Table 1). Major complications during follow-up occurred more frequently after
stent placement than after brachytherapy (28 in 27 patients (25%) vs. 14 in 13
patients (13%); p=0.02). Complications mainly consisted of bleeding (stent: 14 vs.
brachytherapy: 5), perforation (2 vs. 2), fistula formation (6 vs. 3) and severe pain (3 
vs. 1). Patients often needed additional treatment during follow-up for persistent or 
recurrent dysphagia, however, the number of patients needing re-treatment was not 
different between both groups (stent: 52 in 43 patients (40%) vs. brachytherapy: 53 in
43 patients (43%); p>0.20). Reasons for re-treatment after stent placement were
mainly tumor recurrence (n=16), stent migration (n=18) and food bolus obstruction
(n=16), and after brachytherapy tumor persistence (n=18) or tumor recurrence
(n=26). Median survival was 155 (95% CI: 127-183) days after brachytherapy and 145 
(95% CI: 103-187) days after stent placement (p>0.20).
Disease specific health related quality of life
The dysphagia score (18) improved more rapidly after stent placement than after
brachytherapy. At 30 days after treatment, however, the dysphagia score was not 
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significantly different between stent placement and brachytherapy, and in the long 
term, the dysphagia score was better after brachytherapy (Figure 1).
The disease specific EORTC OES-23 scale scores showed overall significant 
differences in favor of brachytherapy on the dysphagia scale (p=0.009) and eating
scale (p=0.003) both with a similar pattern (Figure 2). The other scales (deglutition,
indigestion, retrosternal pain and emotional) did not show major differences 
between stent placement and brachytherapy, nor did the single symptoms of the 
EORTC OES-23. The visual analogue pain scale showed a trend towards less pain in 
the brachytherapy group (overall score: p=0.07) (Figure 3).
Scores on the dysphagia and eating scale of the EORTC OES-23 improved after both 
treatments during the first month of follow-up. After 1 month, scores on both scales
deteriorated slowly during follow-up (Table 2, Figure 2). The scores on the
deglutition scale, indigestion scale and pain scale of the EORTC OES-23 remained 
stable during follow-up in both treatment groups. Scores on the emotional scale (10 
points on a 100 points scale during 0.5 years of follow-up in both treatment groups)
and the different single symptoms (on average 8 points during 0.5 years of follow-
up in the brachytherapy group vs. 13 points in the stent group) deteriorated to a
moderate degree during follow-up. Experienced pain on the visual analogue pain
scales increased only slightly during follow-up (+6 points during 0.5 years of follow-
up in both groups; Table 2, Figure 3).
Table 1: Clinical characteristics of 209 patients randomized to brachytherapy or stent 
placement for palliation of dysphagia due to inoperable carcinoma of the esophagus or 
esophagogastric junction.
Brachytherapy
N=101
Stent placement 
N=108
Age (mean r SD) 69 r 13 69 r 11 
Male / Female 76/25 86/22
Tumor Histology
Squamous cell carcinoma
Adenocarcinoma
Other
29 (29%) 
69 (68%) 
3 (3%) 
29 (27%) 
75 (69%) 
4 (4%) 
Dysphagia score before treatment 2.8 r 0.9 2.8 r 0.7 
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Table 2: Average changes in health related quality of life (HRQoL) during follow-up after 
brachytherapy (B) or stent placement (S) for palliation of dysphagia due to inoperable 
carcinoma of the esophagus or esophagogastric junction.
Scale General
population
scores*
Mean
baseline
value
Changes in HRQoL during follow-up 
(per 0.5 year of follow-up) (95% CI)#
Total group of patients Brachytherapy group (B) 
Stent group (S) 
EORTC OES-23
Dysphagia scale (0=best)
< 30 days
> 30 days
58 -27 (-31 to -23)†
B: 12 (8 to 16)
S: 21 (16 to 25)
Deglutition scale (0=best) 12 2 (0.2 to 4)
Eating scale (0=best)
< 30 days
> 30 days
49 -13 (-17 to -9)†
B: 11 (7 to 16)
S: 21 (16 to 26)
Indigestion scale (0=best) 18 0.8 (-1 to 3)
Pain scale (0=best) 21 2 (0.02 to 4)
Emotional scale (100=best) 44 -10 (-12 to -8)
EORTC QLQ-C30 
Physical functioning
(100=best)
87 64 B: -18 (-23 to -12)
S: -28 (-34 to -23)
Role functioning (100=best) 85 62 B: -19 (-25 to -12)
S: -30 (-37 to -23)
Emotional functioning
(100=best)
81 74 -6 (-9 to -2)
Cognitive functioning
(100=best)
88 83 B: -6 (-11 to -2)
S: -16 (-20 to -11)
Social functioning (100=best) 87 76 -14 (-18 to -10)
Global health/quality of life 
(100=best)
66 59 B: -7 (-12 to -3)
S: -13 (-18 to -9)
Pain (0=best) 20 25 12 (9 to 16)
Euroqol
EQ-5D (100=best) 76 63 -21 (-27 to -16)
Euroqol visual analogue scale
(100=best)
59 B: -12 (-15 to -10)
S: -16 (-19 to -14)
Visual analogue pain scale
Visual analogue pain scale
(0=best)
18 6 (4 to 8)
* For the EORTC QLQ-C30 scores of a general German population (n=390) of men between 60-69 years
are given (22). For the EQ-5D, scores of a general Swedish population (n=1321) of men and women
between 60-69 years are given (23). Norm scores were not available for the EORTC OES-23 and visual
analogue pain scale.
# In case of interaction between treatment and time (p<0.10), we fitted a model for each treatment, in case 
of no interaction, the model was fitted for the total group of patients. A change of -10 means that HRQoL
deteriorates with 10 points on a 100 point-scale during 0.5 years of follow-up.
† Change in HRQoL for 30 days of follow-up.
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Figure 1: Dysphagia scores (scored on a scale from 0 (normal) to 4 (complete dysphagia)) in 
patients randomised to brachytherapy (n=101) or stent placement (n=108) for dysphagia due 
to inoperable carcinoma of the esophagus or esophagogastric junction. The symbols ̇ and 
2 represent mean dysphagia scores, the lines are spline functions with 95% confidence 
intervals.
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Figure 2: Dysphagia scale and eating scale of the disease specific EORTC OES-23 measure 
after treatment with brachytherapy (n=101) or stent placement (n=108) for dysphagia due to 
inoperable carcinoma of the esophagus or esophagogastric junction. Graphs show the mean 
scores with 95% confidence intervals of the scales during follow-up. Higher scores represent 
more dysphagia or problems with eating.
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Figure 3: Self-reported pain level on the visual analogue pain scale after treatment with 
brachytherapy (n=101) or stent placement (n=108) for dysphagia due to inoperable 
carcinoma of the esophagus or esophagogastric junction. Graphs show the mean scores with 
95% confidence intervals of the scales during follow-up. Higher scores represent a higher 
level of pain.
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Generic health related quality of life
There was an overall benefit for brachytherapy on the generic HRQoL measures
over time. The EORTC QLQ-C30 scale scores showed an overall significant
difference in favor of brachytherapy on four out of five functional scales including 
role functioning (p=0.05), emotional functioning (p=0.04), cognitive functioning
(p=0.006), and social functioning (p=0.03) (Figure 4). This difference was most
predominant at 6 months or later after randomization. Patients randomized to
brachytherapy scored overall better on the single item dyspnea (p=0.003), and there
was a trend towards fewer symptoms of fatigue and pain after brachytherapy (both
p=0.07). The scores on the EQ-5D index and visual analogue scale for overall self-
rated health were not significantly different for both treatments (Figure 5).
The generic HRQoL of our patient group with inoperable esophageal cancer was 
already lower before treatment compared to the general population (Table 2). Their
generic HRQoL deteriorated further during follow-up on all functional scales of the
EORTC QLQ-C30, in particular physical and role functioning (Table 2). This decline 
was more pronounced in the stent group than in the brachytherapy group 
(brachytherapy: -18 and -19 on a 100 points scale during 0.5 years of follow-up vs
stent: -28 and -30 points for physical and role functioning, respectively). In addition,
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Figure 4: Functional scales of the EORTC QLQ-C30 measure after treatment with 
brachytherapy (n=101) or stent placement (n=108) for dysphagia due to inoperable 
carcinoma of the esophagus or esophagogastric junction. Graphs show the mean scores with 
95% confidence intervals of the scales during follow-up. Higher scores represent a higher 
level of functioning.
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Figure 5: Euroqol visual analogue scale (EQ-VAS) for self-rated health after treatment with 
brachytherapy (n=101) or stent placement (n=108) for dysphagia due to inoperable 
carcinoma of the esophagus or esophagogastric junction. Graphs show the mean scores with 
95% confidence intervals of the scales during follow-up. Higher scores represent a better self-
rated health status.
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the scores on the symptom scales and most single symptoms increased during 
follow-up (indicating a higher level of symptoms), in particular fatigue, dyspnea
and appetite loss. Pain level on the EORTC QLQ-C30 increased during follow-up
(+12 points during 0.5 years of follow-up in both groups; Table 2). We found no
change in the symptom constipation/diarrhea and in financial difficulties during
follow-up. Scores on the EQ-5D index and Euroqol visual analogue scale also 
declined during follow-up (Table 2). 
DISCUSSION
This study provides a longitudinal prospective comparison of generic and disease 
specific HRQoL between two commonly used palliative treatments for esophageal
cancer, i.e. single dose brachytherapy and stent placement. Although both 
treatments were effective in relieving dysphagia, treatment with single dose
brachytherapy gave better overall scores on HRQoL scales compared to stent
placement for the palliation of esophageal cancer. Most aspects of HRQoL
deteriorated during follow-up in both treatment groups, however, the decline was
more pronounced in the stent group.
Only a few studies have been published on HRQoL after palliative treatment for
esophageal carcinoma (24-28). Palliative therapy in these studies included
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placement of a plastic (25, 27, 28) or a metal stent (25, 26), laser therapy (24, 26, 27), 
external beam radiation (28) and chemoradiation (25). No studies have been 
published assessing HRQol after single dose brachytherapy for the palliation of
malignant dysphagia. An overview of the results of these studies is shown in Table 
3. From these studies, it can be concluded that although dysphagia scores improved
after most of these palliative treatments, other aspects of HRQoL remained stable or 
deteriorated during follow-up. None of these studies however, made a comparison
between two palliative treatments with respect to HRQoL, and patient numbers 
were small. Moreover, our study provides detailed longitudinal data with monthly
assessments of HRQoL.
A variety of measures has been used in the reported studies to assess HRQoL after 
palliative treatment for esophageal carcinoma (24-28) (Table 3). In our study, we
assessed disease specific HRQoL as well as generic HRQoL after brachytherapy and 
stent placement. We expected that the disease specific HRQoL measure (the EORTC
OES-23) would have been the one that was most responsive to differences between 
the two treatments and changes in HRQoL during follow-up. The separately scored 
dysphagia scores (18) and the dysphagia scale of the EORTC OES-23 followed a
similar pattern over time, consisting of a rapid improvement after treatment and a
slow deterioration of dysphagia scores during follow-up. In line with this, the eating
scale showed a similar pattern. However, all other scales of the EORTC OES-23 did 
not reveal differences between the two treatments. In addition, most of these scales
remained stable during follow-up. In contrast, several aspects of generic HRQoL 
differed between the two treatments, becoming even more evident after 6 months of
follow-up. Generic HRQoL deteriorated during follow-up, and this decline was
more pronounced after stent placement. Therefore, we consider the generic HRQoL 
measures (in particular the EORTC QLQ-C30) more responsive in measuring
patients’ functioning and well-being during follow-up than the disease specific 
EORTC OES-23.
Recently, the EORTC OES-23 has been revised to a measure with 18 questions. This 
revised EORTC OES-23 was recently validated in a large cohort of patients (29). In
this revised measure, the emotional scale and the single item ‘hair loss’ were 
removed, whereas the indigestion scale now consists of 2 instead of 3 items. The 
authors recommended the new EORTC OES-18 as a valuable addition to the EORTC
QLQ-C30 for patients with esophageal cancer. However, since only the dysphagia
and eating scales showed differences in the EORTC OES-23 and these items can 
effectively be measured with the separate dysphagia score, we consider it sufficient 
to use the EORTC QLQ-C30 in combination with the separate dysphagia score to
obtain complete HRQoL data in patients with inoperable esophageal carcinoma.
In our study we also used the EQ-5D for generic HRQoL. This measure provides a
single index value, which is easy to use for cost-effectiveness calculations, and is 
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therefore advisable in case a cost-effectiveness analysis will be performed. A
detailed cost calculation of our study was reported previously (17). 
For the interpretation of the HRQoL in our patient group and the differences during
follow-up, it is interesting to compare HRQoL in our patient group with inoperable
esophageal cancer to HRQoL in the general population. Norm scores of the general 
population were available for the EORTC QLQ-C30 (22) and the EQ-5D (23). We are
not aware of norm scores of the EORTC OES-23 and the visual analogue pain scale. 
As expected, the scores on all scales of our study population at baseline were lower
compared to the available scores of the general population (22, 23) (Table 2). In 
particular, substantial differences were noted for physical and role functioning, as
well as for the EQ-5D. This stresses the importance of preservation of the already 
diminished HRQoL in patients with esophageal cancer needing palliative treatment.
Pain is an important issue of HRQoL after palliation. In our study, pain was 
assessed using various pain scales, i.e., the pain scale of the EORTC OES-23, which 
measures pain while eating, chest pain and abdominal pain, the pain scale of the
EORTC QLQ-C30, which measures pain in general, and a visual analogue pain scale 
on which patients could rate their experienced level of general pain. Pain level on 
the EORTC OES-23 (both chest pain and abdominal pain) remained stable during 
follow-up in contrast to general pain, which increased moderately on both the
EORTC QLQ-C30 and the visual analogue pain scale (Table 2). The three pain scales 
had similar baseline scores of, on average, 20 points on a 100-points scale, which
was reported previously as well (25). Chest or abdominal pain might well be the
result of the palliative treatment itself. In our experience, this pain usually 
diminishes or disappears a few days to one week after the procedure. Although the 
pain scale of the EORTC OES-23 is not a measure for acute post-treatment pain (the
first follow-up visit was at 14 days after treatment), the scores indicate that chest or
abdominal pain was not a problem during follow-up. During follow-up more than
50% of our patients needed narcotic analgesics. In most patients, this is probable due 
to progression the disease rather than a result of the palliative treatment. The 
reported pain levels on the EORTC QLQ-C30 and the visual analogue pain scale
only moderately increased during follow-up. This indicates that pain management
was adequate during follow-up.
In conclusion, treatment with single dose brachytherapy gave better overall scores
on HRQoL scales compared to stent placement for the palliation of esophageal 
cancer. Major improvements were seen on the dysphagia and eating scales of the 
disease specific EORTC OES-23, in contrast to other scales of this disease specific 
measure, which remained almost stable during follow-up. In addition, pain levels 
remained stable or increased to a minor extent during follow-up, indicating that
adequate pain management during follow-up is important. Future studies on 
palliative care for esophageal cancer should at least include generic HRQoL scales, 
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since these were more responsive in measuring patients’ functioning and well-being 
during follow-up than disease specific HRQoL scales.
APPENDIX
The Dutch SIREC study group consisted of: 
Erasmus MC / University Medical Centre Rotterdam (n=124): Dept. of Gastroenterology &
Hepatology: Marjolein Y.V. Homs, Ernst J. Kuipers, Peter D. Siersema; Dept. of Public Health:
Ewout W. Steyerberg, Suzanne Polinder, Marie-Louise Essink-Bot, Gerard J.J.M. Borsboom; 
Dept. of Radiotherapy: Wilhelmina M.H. Eijkenboom; Dept. of Surgery: Hugo W. Tilanus;
Dept. of Internal Oncology: Ate van der Gaast. Academic Medical Centre, Amsterdam (n=33):
Dept. of Radiotherapy: Lukas J.A. Stalpers; Dept. of Gastroenterology & Hepatology: Joep
F.W.M. Bartelsman; Dept. of Surgery: Jan J.B. van Lanschot. University Medical Centre Utrecht 
(n=18): Dept of Radiotherapy: Harm K. Wijrdeman, Dept. of Gastroenterology: Hans W.
Bogaard. Rijnstate Hospital Arnhem / Arnhem Radiotherapeutic Institute (n=15): Dept. of 
Gastroenterology: Chris J.J. Mulder, Peter J. Wahab; Arnhem Radiotherapeutic Institute:
Janny G. Reinders. The Netherlands Cancer Institute, Amsterdam (n=11): Dept. of
Gastroenterology: Henk Boot; Dept. of Radiotherapy Berthe M.P. Aleman. Leyenburg Hospital,
The Hague (n=3): Dept. of Gastroenterology: Jan J. Nicolai; Dept. of Radiotherapy: Frank M. 
Gescher. Medical Centre Haaglanden, The Hague (n=2): Dept. of Internal Medicine: Maarten A.C.
Meijssen; Dept. of Radiotherapy: Ruud G.J. Wiggenraad. Gelre Hospital, Apeldoorn (n=2): Dept.
of Internal Medicine Jitty M. Smit. Reinier de Graaf Hospital, Delft (n=1): Dept. of 
Gastroenterology: Clemens J.M. Bolwerk.
Special thanks to the dedicated work of the research nurses: Joke Moerman, Alice M. 
Froeling, Hannie van Ginkel-Welmers, Corine A. van Poortvliet-de Ruiter, Liesbeth E. Boon 
and Netty M. Mouthaan, and to Coleta Verheij from the Trial Office of the Department of 
Oncology, Erasmus MC Rotterdam.
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Cost study of stent placement versus brachytherapy 
ABSTRACT
Self-expanding metal stent placement and single dose brachytherapy are commonly
used for the palliation of esophageal obstruction due to inoperable esophagogastric
cancer. We randomized 209 patients to placement of an Ultraflex stent (n=108) or 
single dose brachytherapy (12 Gy, n=101). Costs comparisons included 
comprehensive data of hospital costs, diagnostic interventions and extramural care.
We acquired detailed information on health care consumption from a case record
form and from monthly home visits by a specialized nurse. 
Initial costs of stent placement were higher than the costs of brachytherapy (€1,500 
vs. €570; p<0.001). Total medical costs were however similar (stent €11,195 vs.
brachytherapy €10,078, p>0.20). Total hospital stay during follow-up was 11.5 days
after stent placement versus 12.4 days after brachytherapy, which was responsible
for the high intramural costs in both treatment groups (stent: €6,512 vs.
brachytherapy: €7,982, p>0.20). Costs for medical procedures during follow-up were 
higher after stent placement (stent: €249 vs. brachytherapy: €168, p=0.002), while the
costs of extramural care were similar (€1,278 vs. €1,046, p>0.20).
In conclusion, there are only small differences between the total medical costs of
both palliative treatment modalities, despite the fact that the initial costs of stent
placement are much higher than those of brachytherapy. Therefore, cost 
considerations should not play an important role in decision making on the
appropriate palliative treatment strategy for patients with malignant dysphagia. 
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INTRODUCTION
The incidence of esophageal cancer has risen rapidly, due to a marked increase in 
the incidence of adenocarcinoma (1, 2). Esophageal cancer is a disease with a high 
mortality, as reflected by a 5-year survival of 10-15% (3). Moreover, more than 50% 
of patients with esophageal cancer have already inoperable disease at presentation.
Most of these patients require palliative treatment to relieve progressive dysphagia 
(4). Treatment options presently available for palliation of dysphagia include self-
expanding metal stent placement (5-7), laser therapy (8), photodynamic therapy
(PDT) (9, 10), external beam radiation in combination with brachytherapy (11, 12),
brachytherapy as a sole treatment (13-15), and dilatation (16). A disadvantage of 
laser therapy is that repeated treatment sessions are required to achieve and
maintain adequate palliation (8, 17). A combined treatment of external beam
radiation with brachytherapy is often too intensive for patients with inoperable
disease due to metastases or a poor medical condition. PDT involves the local 
destruction of tumor tissue by light of a specific wavelength activating a previously 
administered photosensitizer which is retained in malignant tissue. Due to the high 
costs of the treatment, the side effects and the necessity of repeated treatments every 
6-8 weeks, PDT is not considered to be the most optimal treatment for palliation of
malignant dysphagia (18). Dilatation can relieve dysphagia temporarily, but it often
provides relief palliation for a short period. In many patients with inoperable 
disease, a stent is placed for the palliation of dysphagia. In addition, brachytherapy
as a sole treatment is frequently used in Western Europe, South Africa, Japan and to 
a lesser extent in the USA. Both stent placement and brachytherapy have been 
proven to be effective in relieving dysphagia with a low complication rate, but
recurrent dysphagia due to various causes is seen in 30-40% of patients (13, 15, 19). 
In order to comprehensively assess the relative merits of the different palliative
treatments of malignant dysphagia, health economic aspects should be 
incorporated. Remarkably, the economic implications of both stent placement and
brachytherapy have been evaluated only in a few studies(8, 20-23). If costs were 
considered, these were only 'roughly' calculated (8), using charges/fees and with
little information about the differentiation of the costs. In addition, the number of
patients incorporated in the studies was low (8, 21, 23). In studies on costs this may
result in a high degree of distortion, because peaks in volumes of some expensive
cost items can highly influence the average outcomes.
We aimed to study the total direct and indirect costs of brachytherapy and stent
placement in the palliation of malignant dysphagia within the framework of a 
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randomized trial. We present estimates of the full cost price, based on real resource
use, in substantial patient groups. 
MATERIALS AND METHODS
Study population
We performed a prospective study in 3 university hospitals and 6 general hospitals 
in the Netherlands. Between December 1999 and July 2002, 209 consecutive patients
with dysphagia from inoperable carcinoma of the esophagus or gastric cardia due to 
metastases and/or a poor medical condition were randomized to placement of a 
covered Ultraflex stent (n=108) or single dose (12 Gy) brachytherapy (n=101). For 
brachytherapy, a flexible applicator (Bonvoisin-Gérard Esophageal Applicator,
Nucletron, Veenendaal, The Netherlands) with a diameter of 10 mm was passed
down the esophagus. A single dose of 12 Gy was administered with the radioactive 
source 192Iridium at 1 cm from the source axis of the applicator. The study was
approved by the Central Committee on Research Involving Human Subjects in the
Netherlands.
Study endpoints
Clinical outcomes were functional outcome, complications, persisting or recurrent
dysphagia needing re-intervention, survival and quality of life, as measured by 
standardized questionnaires. The clinical outcomes have been presented in detail 
elsewhere (24, 25). Here, we will focus on the real medical costs of the two treatment
strategies. Costs were studied from a societal perspective and were estimated for the 
period after randomization until death for 95% of the patients or follow-up of at
least 9 months for the remaining 5% of patients.
Follow-up
Patients were prospectively followed by home visits of specially trained research 
nurses at 14 days, 1 month and then monthly until one year after treatment. After
one year, patients were visited every 3 months, and/or telephone calls to the patient
and/or the patients' general practitioner were made. For each patient, we registered 
the number of inpatient days, the time needed for nursing care and therapy as well
as the visits to physicians and other health practitioners by a checklist filled in by 
the research nurse. The response was more than 90% during the entire follow-up
period. The participating clinicians filled out standardized case record forms (CRFs) 
during control visits, re-treatments and admissions.
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Cost calculations
Real medical costs were calculated by multiplying the volumes of health care use 
with the corresponding unit prices. We made a distinction between the full cost
price of the interventions brachytherapy and stent placement by itself and the total
medical costs per patient during follow up.
The calculation of the full cost price of brachytherapy and stent placement consisted
of detailed measurement of investments in manpower, equipment, materials, 
housing and overhead. The salary schemes of hospitals and other health care 
suppliers were used to estimate costs per hour for each caregiver. Taxes, social
securities and vacations were included, as well as the costs of the time that could not
be assigned to other patients. The costs of equipment included those of depreciation,
interest and maintenance.
For the calculation of the total medical costs per patient, we distinguished
intramural medical costs (inpatient days, health practitioner activities, the full cost 
price of the medical treatment and other medical procedures) and extramural
medical costs (home care, general practitioner). Costs caused by loss of production 
due to absence from work were not taken into account, because the majority of
patients were retired from work.
For the most important cost items, unit prices were determined by following the
micro-costing method (26), which is based on a detailed inventory and 
measurement of all resources used. For instance, we registered time investments of 
health practitioners per patient (during the intervention). Costs for inpatient days in
hospital were estimated as real, basic costs per day using detailed information from 
the financial department of the hospital. We made a distinction between the costs of
general and university hospitals. These estimates included overhead and indirect 
costs. From a differential point of view, i.e. comparison of the two treatment
strategies, some diagnostic interventions were decided to be less relevant. We chose
not to invest much time and effort in exploring costs that were unlikely to make any
difference to the study result (27), for example because they were low in price or 
volume. For these items we used charges as a proxy of real costs. In the Netherlands 
a detailed ‘fee for service’ system is used for the remuneration of medical 
interventions and diagnostic procedures. In order to calculate for the costs for 
medication, we used average charges for analgesics, antibiotics, and additional
medications.
Table A (appendix) gives an overview of the cost categories and data used in the
cost calculations. We reported costs in Euro for the year 2002, when 1 Euro
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equalized approximately 1 US dollar. Discounting was not relevant because of the 
limited time horizon (median survival 4-5 months).
Statistical analysis
All analyses were performed on an intention-to-treat basis. The cost differences
between brachytherapy and stent placement were analyzed using the Mann-
Whitney U test. Since cost data per patient (but not per day care) are typically highly
skewed, we used non-parametric bootstrap techniques to derive a 95% confidence 
interval for the differences in distributions of the direct medical costs. 
In a sensitivity analysis the effect of excluding 'palliative related costs' was assessed 
by leaving these costs out of consideration. We performed calculations assuming
that nursing home admissions and nursing care at home were not directly related to 
both treatments, but could be attributed to the advanced stage of the disease.
RESULTS
Patient characteristics and clinical outcomes
The two patient groups were comparable with respect to patient and tumor 
characteristics. Both treatment groups consisted predominantly of males, with a
mean age of 69 year (Table 1).
Dysphagia improved more rapidly after stent placement than after brachytherapy.
However, overall improvement of dysphagia was better after brachytherapy. More
complications occurred after stent placement (33% total complications versus 21%
after brachytherapy; p=0.02). Major complications within 7 days after treatment
included perforation (n=3), fever (n=2), severe pain (n=2) and aspiration pneumonia
(n=2). Late major complications consisted predominantly of hemorrhage (n=19)
occurring more frequently after stent placement (14 versus 5 after brachytherapy).
The need for re-intervention for persistent or recurrent dysphagia was not 
significantly different for both groups (40% vs. 43%, respectively). Recurrent
dysphagia after stent placement was predominantly caused by tumor overgrowth 
(n=16), stent migration (n=18) or food bolus obstruction (n=16), and was treated by
placement of a second stent, endoscopic stent clearance or a variety of other 
treatments. The majority of re-interventions after brachytherapy were caused by
tumor persistence (n=18) or tumor recurrence (n=26), both most frequently treated
with placement of a stent.
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Median survival was similar for both treatment groups (stent: 145 vs.
brachytherapy: 155 days). There was an overall longterm benefit in general (EORTC
QLQ C-30 and EuroQol-5D) and disease-specific quality of life scores (EORTC OES-
23) in the brachytherapy group during follow-up.
Table 1: Characteristics of 209 patients randomized to brachytherapy or stent placement for 
palliation of malignant dysphagia 
Brachytherapy
N=101
Stent placement 
N=108
Age 69+/-13 69+/-11
Gender (male/female) 76/25 86/22
WHO performance score before treatment 
(mean +/- SD) 
1.0+/-0.4 0.9+/-0.5
Indications for treatment 
Metastases
Poor medical condition 
Both
66 (65%) 
23 (23%) 
12 (12%) 
68 (63%) 
28 (26%) 
12 (11%) 
Tumor length (cm) (mean +/- SD) 7.5 +/- 2.6 7.5 +/- 2.8 
Received assigned intervention 96 (brachytherapy) 105 (stent) 
Re-intervention 45 (stent)
3 (2nd brachytherapy)
2 (brachytherapy) 
24 (2nd stent)
Median survival (days) 155 (95% CI: 128-182) 145 (95% CI: 104-186) 
Total complications 23 in 21 patients (21%) 45 in 36 patients (33%) 
Major complications 14 in 13 patients (13%) 28 in 27 patients (25%) 
Minor complications 8 in 8 patients (8%) 16 in 16 patients (15%) 
Persistent/recurrent dysphagia 53 in 43 patients (43%) 52 in 43 patients (40%) 
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Costs
The initial cost price of treatment, based on real resource use, was much higher for 
stent placement (€1,500) than for brachytherapy (€570). The main cause for this
difference was the high purchase costs of the Ultraflex stent (€1,100) (Table 2).
Table 3 gives an overview of the average health care use and costs per patient for
stent placement and brachytherapy. Patients randomized to brachytherapy were 
admitted on average 7.1 days longer in a health care institution than patients
randomized to stent placement (23.4 versus 16.3 days). The main reason for this was
the longer period patients randomized to brachytherapy were admitted to nursing
homes (11.0 versus 4.6 days). The average time spent in hospital was similar for both
treatments (12.4 for brachytherapy and 11.5 for stent placement). The costs for
intramural care were by far the highest cost category for both treatments, but 
differences were not statistically significant (stent placement €6,512 vs.
brachytherapy €7,982, p>0.20). Costs of medical procedures during follow up were 
significantly higher for stent placement (€249) than for brachytherapy (€168) 
(p=0.002), since major complications and re-interventions occurred more often after
stent placement than brachytherapy. The average costs for extramural care were 
€1,278 for brachytherapy and €1,046 for stent placement. For both treatments, this
could largely be attributed to home visits by the general practitioner and specialized
nursing care at home. The costs for medications were similar for brachytherapy and 
stent placement (€350 and €325).
The total average costs per patient for both treatments were similar at €11,195 for 
brachytherapy and €10,078 for stent placement (p>0.20). If the 'palliation related'
health care was not taken into consideration, then the costs of intramural and
extramural care for brachytherapy and stent placement decreased. This resulted in 
total medical costs for brachytherapy of €8,490 and for stent placement of €8,538 
(p>0.20).
Table 2: Full cost price (€, 2002) of brachytherapy and stent placement
Cost category Brachytherapy Stent placement
Personnel 152 74
Equipment 75 40
Materials 14 1307
housing/overhead 70 40
Diagnostics 259 37
Total costs 570 1500
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Table 3: Average health care use and costs (€, 2002) per patient for stent placement and 
brachytherapy
Cost category Brachytherapy
(n=101)
Stent placement
(n=108)
p-value1
Cost price Volume Costs Volume Costs
Treatment
Brachytherapy 570 0.96 547 0.019 11
Stent placement 1500 0.58 870 1.29 1935
1417 1946 p<0.001
Intramural care 
inpatient days
hospital (academic) 520 7.7 4006 6.9 3587
hospital (general) 381 4.7 1788 4.6 1760
ICU 1450 0.02 31 0.06 72
nursing home 173 11 1898 4.8 838
health practitioner (inpatient)
physician (academic) 135 1.41 190 1.30 176
physician (general) 98 0.70 69 0.82 79
7982 6512 p>0.20
Medical procedures
Endoscopy 125 0.74 93 1.17 146
PEG 100 0.04 4 0.04 4
X-ray thorax 37 0.78 29 1.41 52
X-ray abdomen 37 0.07 3 0.21 5
Ultra-sound abdomen 42 0.05 3 0.04 2
X-ray esophagus 37 0.13 5 0.19 7
ERT 39 0.81 32 0.57 22
Adjustment ERT 98 0.15 15 0.09 9
168 249 p=0.002
Extramural care 
general practitioner (inpatient) 19 0.9 18 1.06 20
general practitioner (home visit) 37 9 333 8.1 298
nursing care at home
(specialized)
55.6 13.4 750 11.4 638
nursing care at home 32.4 1.9 61 2 64
drip-feed 8.5 13.7 116 3.05 26
1278 1046 p>0.20
Medication 350 325
Total costs per patient 11195 10078 p>0.20
1 derived from 2000 bootstrap samples drawn with replacement.
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DISCUSSION
We found only small differences between the total medical costs of single dose 
brachytherapy as compared to metal stent placement for the palliation of dysphagia 
from inoperable esophageal carcinoma. Stent placement was initially more
expensive than brachytherapy, due to the high purchase costs of the stent, but at the
long term costs were comparable. 
Many patients in both treatment groups needed re-intervention for persistent or 
recurrent dysphagia. Of the patients randomized to brachytherapy, 45/101 (45%) 
subsequently received a stent, while 24/108 (22%) of the patients randomized to
stent placement received a second stent during follow-up. Since our analysis was 
based on the intention-to-treat principle, costs of non-assigned treatment were
accounted to the randomized treatment group. Total treatment costs, which
included the average costs of additional treatment plus re-intervention, were higher 
for stent placement. However, if the intramural and extramural health care costs
were also taken into account, then these high initial costs were only a small part of
the total medical costs, which resulted in similar total medical costs.
Cost comparisons between medical treatments are often based only on the initial
costs. This would imply that stent placement, with the high purchase costs of the 
device, would be less attractive than brachytherapy. In this study, we clearly
demonstrated that total medical costs of stent placement and brachytherapy were
similar when the full follow-up period was considered. This illustrates that cost
comparisons between interventions may vary substantially depending on which, 
and how many, components are included in a total cost equation (28).
Few studies have been published on costs of brachytherapy or stent placement in 
the palliative treatment of esophageal cancer. Three studies compared stent
placement with plastic endoprostheses (23), conventional therapy (22) or thermal
ablative therapy (8). These three studies reported corresponding initial costs for 
stent placement, but found lower total medical costs, compared to our study. Dallal
et al. (8) included only the costs of the intervention and hospital stay in the total
costs for stent placement (€4,920), which can explain the difference in total costs
compared to our study. They found a median hospital stay of 12 days after stent
placement, similar to findings in our study (Table 3). Farndon et al. (21) compared
the placement of a plastic endoprosthesis with single dose brachytherapy and
showed that the total costs of brachytherapy (€2,603) were lower compared to
stenting (€3,564). Presently, plastic endoprostheses are no longer considered 
adequate for palliation of malignant dysphagia due to a high procedure-related
complication rate with plastic endoprostheses (29). Since there is no detailed
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information available on the costs in the above-mentioned articles (8, 21-23), it is not
possible to explain the differences in total costs between these studies and ours. It 
could well be that both intramural and extramural health care use was 
underreported. Finally, the number of patients included and receiving stent 
placement or brachytherapy was relatively low (n<35) in all these studies (8, 21-23).
A common problem when using clinical trials for any kind of cost assessment arises 
from the fact that the clinical protocol mandates more visits, consultations, and
examinations than otherwise used in clinical practice (30). For a treatment in a
research setting there will be more costs, compared to daily practice. Therefore, we
excluded protocol driven medical care such as visits of the nurses from our cost
calculation. The main goal of these visits was, apart from giving advice to patients,
registration of health care consumption and outcomes, which is, of course, not
common practice in normal daily care of patients.
Despite the high costs involved, detailed cost studies in the treatment of malignant
disease and palliative therapy have received little attention. This may be due to the
inherent difficulties in performing such studies. Follow up of patients with
malignant disease is sometimes difficult since the mortality rate is high, particularly
among patients receiving palliative therapy (31). In a palliative setting it is 
sometimes difficult to differentiate between health care consumption which can be 
attributed to the palliative stage of the disease or only to the treatment modality. If 
palliation related costs were excluded, we found a decrease of total costs of both
treatments but this did not affect the final conclusion that the total costs for
brachytherapy and stent placement were similar.
This study focused on costs and not on efficiency. The primary aim of both 
treatments is to palliate symptoms rather than to improve survival of esophageal 
cancer. Both treatments resulted in an improvement of an important symptom of
inoperable esophageal cancer, i.e. dysphagia. As survival of the two treatment
groups was comparable, we did not perform a formal cost-effectiveness analysis.
Despite a less rapid relief of dysphagia and a higher initial failure rate,
brachytherapy was found to be an attractive alternative to stent placement in the
palliation of malignant dysphagia, as brachytherapy was safer with fewer
procedures needed for recurrent dysphagia (24). 
In conclusion, our study provides detailed insight in the total medical costs of two
frequently used palliative treatments of dysphagia due to esophageal cancer, i.e., 
stent placement and brachytherapy. In spite of the higher initial costs for stent
placement than for brachytherapy, total medical costs were similar. Therefore, cost 
186
Cost study of stent placement versus brachytherapy 
considerations should not play an important role in decision making on the
appropriate treatment strategy.
APPENDIX
The Dutch SIREC study group consisted of: 
Erasmus MC / University Medical Center Rotterdam: Dept. of Gastroenterology & Hepatology:
Marjolein Y.V. Homs, Peter D. Siersema, Ernst J. Kuipers; Dept. of Public Health: Ewout W. 
Steyerberg, Suzanne Polinder, Marie-Louise Essink-Bot; Dept. of Radiotherapy: Wilhelmina 
M.H. Eijkenboom; Dept. of Surgery: Hugo W. Tilanus. Academic Medical Center, Amsterdam:
Dept. of Radiotherapy: Lucas J.A. Stalpers; Dept. of Gastroenterology & Hepatology: Joep 
F.W.M. Bartelsman; Dept. of Surgery: Jan J.B. van Lanschot. University Medical Center Utrecht:
Dept of Radiotherapy: Harm K. Wijrdeman. Rijnstate Hospital Arnhem: Dept of 
Gastroenterology: Chris J.J. Mulder, Peter J. Wahab. Arnhem Radiotherapeutic Institute: Janny 
G. Reinders. Antoni v Leeuwenhoek Hospital, Amsterdam: Dept. of Gastroenterology: Henk Boot; 
Dept. of Radiotherapy Berthe M.P. Aleman. Leyenburg Hospital, The Hague: Dept. of 
Gastroenterology: Jan J. Nicolai; Dept. of Radiotherapy: F M. Gescher. Medical Center 
Haaglanden, The Hague: Dept. of Internal Medicine: Maarten A.C. Meijssen; Dept. of 
Radiotherapy: R G.J. Wiggenraad. Gelre Hospital, Apeldoorn: Dept. of Internal Medicine Jitty M. 
Smit. Reinier de Graaf Hospital, Delft: Dept. of Gastroenterology: C.J.M. Bolwerk.
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APPENDIX
Table A: cost categories and data used in cost calculations 
cost category Parameter Data collection volume of care Cost estimate 
CRF
(physician)
Questionnaire
(nurse)
(unit price) 
Treatment
Brachytherapy Number * Real costs
Stent placement Number * Real costs 
Inpatient days
Hospital (academic) Days * * Real costs 
Hospital (general) Days * * Real costs 
ICU Days * * Real costs 
Nursing home Days * Charges
Health practitioner (inpatient)
Physician (academic) Visits * * Real costs 
Physician (general) Visits * * Real costs 
Medical procedures 
Endoscopy Number * Real costs
PEG Number * Charges
X-ray thorax Number * Charges
X-ray stomach Number * Charges
Ultra-sound scan stomach Number * Charges
X-ray esophagus Number * Charges
ERT Number * Charges
other therapy Number * Charges
Extramural care 
General practitioner (inpatient) Visits * Fees
General practitioner (home 
visit)
Visits * Fees
Nursing care at home Number * Charges
Nursing care at home
(specialized)
Number * Charges
Drip-feed Days * Charges
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Esophageal stents with anti-reflux valve for tumors 
involving the distal esophagus and gastric cardia: a 
randomized trial
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Anti-reflux stents for tumors involving the gastroesophageal junction
ABSTRACT
Background: Self-expanding metal stents deployed across the gastroesophageal 
junction predispose to gastroesophageal reflux. We assessed the efficacy of the FerX-
Ella stent with an anti-reflux mechanism in preventing gastroesophageal reflux.
Methods: Between April 2002 and May 2003, 30 patients with carcinoma of the
distal esophagus or gastric cardia were randomized to receive either a FerX-Ella 
stent with a windsock-type anti-reflux valve (n=15) or a standard open FerX-Ella
stent (n=15). Gastroesophageal reflux was assessed by standardized questionnaires
and 24-hr pH monitoring 14 days after treatment.
Results: Technical problems during placement occurred in 3 patients caused by 
stent migration (n=2) and a problem with the introducing system (n=1). Dysphagia
improved from a median score of 3 (liquids only) to 1 (eat some solid food) in the
anti-reflux group and from 3 to 0 (solid foods) in the open stent group (p>0.20).
Reflux symptoms were reported by 3/12 (25%) patients with an anti-reflux stent and
by 2/14 (14%) patients with an open stent. The 24-hr pH monitoring succeeded in 11 
patients, with increased esophageal acid exposure for both types of stents (median
24-hr reflux time: anti-reflux stent (n=9): 23% vs. open stent (n=2): 10% (normal:
<4%); p=NS). Major complications were the same in patients with anti-reflux stents 
or open stents, 3 (20%) in each group, consisting of bleeding (n=3), severe pain (n=2), 
and aspiration pneumonia (n=1). The main cause of recurrent dysphagia was stent
migration in 7/30 (23%) patients.
Conclusions: The FerX-Ella stent provides symptomatic relief against malignant
dysphagia, however its anti-reflux valve failed to prevent gastroesophageal reflux. 
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INTRODUCTION
Annually approximately 400,000 patients are diagnosed worldwide with esophageal
cancer and over 350,000 die of this malignancy. This makes esophageal cancer the
eighth most common cancer, and sixth on the list of cancer mortality causes (1). The 
incidence of esophageal carcinoma has risen noticeably over the past two decades in
both the USA and Western Europe, due to a marked increase in the incidence of
adenocarcinoma (2, 3). The prognosis of esophageal cancer is poor with a 5-year 
survival of 10-15% (4, 5). In practice, over 50% of patients with esophageal cancer
already have inoperable disease at presentation with the majority requiring
palliative treatment to relieve progressive dysphagia (6). Covered self-expanding
metal stents have become popular for this indication (7-10). 
Currently, there are several main types of self-expanding stents available: 1) the
Ultraflex stent (Microvasive/Boston Scientific Corp., Watertown, MA), 2) the
Wallstent (Microvasive/Boston Scientific Corp.) with a recently introduced new
design, the Flamingo Wallstent, 3) the Z stent (Wilson-Cook Europe A/S, 
Bjaeverskov, Denmark) with a Korean modification, the Choo stent (M.I. Tech,
Seoul, Korea), and 4) the plastic Polyflex stent (Rüsch GmbH, Kernen, Germany) (7-
10). We recently demonstrated that the Ultraflex stent, the Flamingo Wallstent and
the Z stent afforded a similar degree of relief of dysphagia from inoperable cancer of
the esophagus or gastric cardia. Moreover, the occurrence of complications and 
recurrent dysphagia was similar between these three stent types (11).
As the incidence of adenocarcinoma of the distal esophagus is rising rapidly (2, 3), 
there is likely to be an increasing deployment of metal stents across the 
gastroesophageal junction. In this situation, the benefits of using metal stents can be 
limited by their predisposition to cause gastroesophageal reflux. 
Recently, stents have become available that incorporate an anti-reflux mechanism.
Studies have reported efficacy of these types of stents in vitro, in an animal model, as 
well as in patients (12-16). These studies showed that patients treated with an anti-
reflux stent had fewer symptoms of gastroesophageal reflux than patients with a
standard open stent. However, no clinical trial has yet been performed comparing
anti-reflux stents with open stents of the same design. In addition, the efficacy of the 
anti-reflux design was only assessed by patient interviews and not objectively
studied by 24-hour pH monitoring.
The aim of the present study was to evaluate the effectiveness of a new type of self-
expanding metal stent for palliating malignant dysphagia from carcinoma of the
distal esophagus or gastric cardia, the FerX-Ella stent with an anti-reflux mechanism 
(Ella-CS, Hradec Kralove, Czech Republic), in preventing gastroesophageal reflux 
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by comparing it with the same type of metal stent without anti-reflux mechanism.
The degree of reflux in both stents was assessed by patient interviews at several 
time points and by 24-hour pH monitoring at 14 days after stent placement.
PATIENTS AND METHODS
From April 2002 until May 2003, 30 consecutive patients with dysphagia caused by
inoperable carcinoma of the distal esophagus or gastric cardia were randomized to 
placement of a FerX-Ella stent with anti-reflux valve (n=15) or a standard open FerX-
Ella stent (n=15). Patients were blinded for the type of stent they received. Exclusion
criteria were a tumor length of more than 12 cm, an esophagorespiratory fistula, or
previous stent placement.
Before randomization, patients were stratified for location of the tumor, either the
distal esophagus or gastric cardia, and for prior radiation and/or chemotherapy.
Computer-generated block randomization lists were prepared with block sizes of 4 
and 6 in random order. Randomization by telephone was centrally performed at the
Trial Office of the Department of Oncology, Erasmus MC Rotterdam. A written
informed consent was obtained from all patients prior to enrollment. The study was
approved by the Central Committee on Research Involving Human Subjects in The 
Netherlands.
Intervention
Stent placement was performed in two hospitals: the Erasmus MC Rotterdam (25
patients) and the Rijnstate Hospital Arnhem (5 patients). All stents were placed by 
endoscopists who were well acquainted with the characteristics of the stent used in 
this study, which was the FerX-Ella stent with or without anti-reflux valve (Figure
1). The FerX-Ella stent is supplied in a compressed form inside the introducer with
an outer diameter of 20 Fr. The stent is composed of individual segments made of 
zigzag formed stainless steel wire. Both the zig- and the zag-ends of the wire form
small loops. These loops fit into small stainless steel tubes connecting the individual 
segments. The stents are supplied in lengths of 90 mm, 120 mm or 150 mm,
depending on the numbers of segments. The proximal segment has a purse string 
made of para-aramid thread. The ends of this thread are connected to each other by
a golden tube that serves as a radiopaque marker. Traction on this thread reduces
the diameter of the
stent cone. The stent inside the introducing sheath can be directed to a particular 
position in the esophagus or cardia and withdrawn from the sheath. The body of the 
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stent has a diameter of 20 mm, whereas the proximal cone has a diameter of 36 mm.
The stent is covered with a polyethylene foil, which is applied to both the outside
and inside of the stent. The outer foil layer is sealed to the inner layer, thus fixing
the foil firmly to the wire skeleton. At the distal end of the stent, the polyethylene 
foil extends 47 mm beyond the lower metal cage to form a “windsock”-type valve 
(foil thickness 0.015 mm). The stent is supplied sterile and is designed for single use
only. The material composition as well as the design of the FerX-Ella stent without
anti-reflux valve is identical to the anti-reflux stent, however without the windsock-
type valve. 
Study endpoints and follow-up 
The primary endpoint of the study was gastroesophageal reflux. Secondary 
endpoints were dysphagia score during follow-up, technical success of placement, 
complications, treatment for recurrent dysphagia, and survival.
Gastroesophageal reflux was assessed both by interviews and 24-hr pH monitoring. 
At 2 weeks after stent placement, all patients were asked to undergo 24-hour
esophageal pH monitoring. After an overnight fast, a pH probe was inserted. The 
pH probe was connected to a digital portable recorder (Digitrapper MK III and pH 
probes, Synectics Medical, Stockholm, Sweden) and positioned 5 cm proximal to the
gastroesophageal junction within the stent lumen. The position of the probe was
verified by a chest X-ray (Figure 2). A reference electrode was attached to the upper
chest. Patients were instructed to keep a diary recording meal times and the timing
and type of reflux-like symptoms. Patients were encouraged to pursue their
everyday activities and usual diets. At the beginning of the 24-h pH monitoring, the 
electrode and the system were calibrated for pH 4 and pH 7. Reflux was defined as
pH of <4, and reflux time was defined as the interval until pH is >4. Analysis of the
recorded data was performed using standard, commercially available computer
software (Medical Measure Systems, Enschede, the Netherlands).
Experienced gastroesophageal reflux was assessed by the European Organization 
for Research and Treatment of Cancer (EORTC) OES-23(17), before treatment and at
14 days after treatment, and also by specific asking for reflux symptoms on regular 
follow-up interviews every 2 months until death. The EORTC OES-23 measure
determines disease specific HRQoL which is relevant to patients with esophageal
carcinoma. The indigestion scale of this measure is composed of 3 questions on
heartburn. The total score was linearly transformed such that the scales ranged from 
0 to 100 with a higher scale score representing a higher level of symptoms.
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Dysphagia scores were graded as 0 = ability to eat a normal diet, 1 = ability to eat
some solid food, 2 = ability to eat some semisolids only, 3 = ability to swallow 
liquids only, and 4 = complete dysphagia (18). Major complications were defined as
life-threatening or causing severe distress, such as perforation, hemorrhage 
(hematemesis, melena, or a significant drop in hemoglobin level), fistula formation
and severe pain, whereas minor complications were defined as not life-threatening 
or causing mild to moderate discomfort, such as mild pain and gastroesophageal
reflux. Early complications were defined as complications occurring within 7 days 
after treatment. Complications occurring more than 7 days after stent placement
were defined as late complications, although it was often unknown whether these 
were related to the stent or disease progression. Recurrent dysphagia was defined as 
the occurrence of tumor overgrowth, stent migration, or food bolus obstruction, all 
causing dysphagia.
All patients were evaluated before stent placement, 2 weeks after stent placement, 2 
months after placement and then at a 2 months intervals until death. Regular follow-
up was performed through telephone calls to the patient and/or the patient’s
primary care physician. If indicated, patients were readmitted for clinical
evaluation. For patients who were still alive at the end of the study (October 30, 
2003), follow-up was at least 6 months.
Statistics
Power calculations had shown that a sample size of 20 patients (10 in each group)
was necessary to find a significant difference (΅=0.05) in esophageal acid exposure
time if this was 20% of the time in patients with a FerX-Ella stent with anti-reflux
valve and 40% of the time in patients with an open FerX-Ella stent. Because a
number of patients, for various reasons, did not undergo 24-hour esophageal pH 
monitoring, we continued the study until ten more patients were included (30 in
total), but even then the statistical power was not achieved because of failure to 
perform 24-hr pH monitoring in all patients. 
Results were expressed as means ± standard deviation (SD) or median scores with
the 25th and 75th percentile. Differences in esophageal acid exposure time and 
dysphagia score improvement between the two types of stents were determined by 
the non-parametric Kruskall-Wallis test. Dysphagia scores and scores on the
indigestion scale of the EORTC OES-23 (17) for each stent type on the day of stent 
placement and 14 days after treatment were compared with Wilcoxon’s signed rank 
test. Complications and treatment for recurrent dysphagia for each of the two 
groups were compared using Kaplan-Meier and log rank tests to adjust for time of
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occurrence and survival differences. Survival of the two groups was calculated and 
compared using Kaplan-Meier curves and log rank testing. A p value of <0.05 was 
considered as statistically significant.
RESULTS
Clinical characteristics 
The two patient groups were similar in their clinical characteristics (Table 1). Prior 
to stent placement, 8 patients had been treated with chemotherapy, whereas none 
had received radiation therapy. Chemotherapy consisted of carboplatin and 
paclitaxel (n=5), cisplatin and paclitaxel (n=2), or 5-fluorouracil, cisplatin and 
leucovorin (n=1).
Table 1: Clinical characteristics of 30 patients given a FerX-Ella stent with or without 
anti-reflux valve for palliation of dysphagia due to carcinoma of the distal esophagus or 
gastroesophageal junction.
FerX Ella stent with 
anti-reflux valve
(N=15)
FerX Ella stent without 
anti-reflux valve
(N=15)
Age (yr) 68 r 8 69 r 11 
Gender (M/F) 12/3 12/3
Mean tumor length (cm) 8.3 r 3.1 7.1 r 2.5 
Tumor histology (no. of patients) 
Squamous cell carcinoma
Adenocarcinoma
3 (20%) 
12 (80%) 
3 (20%) 
12 (80%) 
Reason for palliative treatment
Metastases
Poor medical condition 
Combination
12 (80%) 
3 (20%) 
-
11 (73%) 
2 (13%) 
2 (13%) 
Location of tumor (no. of patients) 
Distal esophagus
Cardia
12 (80%) 
3 (20%) 
12 (80%) 
3 (20%) 
Prior chemotherapy (no. of patients) 5 (33%) 3 (20%) 
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Outcome and survival 
Successful placement of a FerX-Ella stent was achieved in 27 out of 30 patients
(Table 2). In two patients (one in each treatment group), the stent migrated directly
after placement. In another patient, the distal tip of the introduction set could not be
removed due to the angled position of the stent at the gastroesophageal junction. 
The introduction system with the stent still mounted was removed and an Ultraflex
stent was placed. In one patient, a second stent was needed because the initial stent
partially migrated during the procedure leading to insufficient bridging of the
stricture. Dilation to 9 mm prior to stenting was necessary in 4 patients (two in each
treatment group).
Table 2: Outcome and survival in 30 patients given a FerX-Ella stent with or without anti-
reflux valve for palliation of dysphagia due to carcinoma of the distal esophagus or 
gastroesophageal junction.
Fer-X Ella stent with
anti-reflux valve
(N=15)
Fer-X Ella stent without 
anti-reflux valve
(N=15)
Technical success (no. of patients)
Single stent 
Two stents
Total
13
-
13 (87%) 
13
1
14 (93%) 
Median dysphagia score
(25-75 percentile) 
Day 0 o day 14* 
3 (3-3) o 1 (0-2) 3 (3-4) o 0 (0-2.5) 
Indigestion scale score EORTC OES-23 
(median (25-75 percentile) on a 100 point 
scale, 0=best)
Day 0 o day 14†
22 (11-33) o 22 (11-44) 11 (0-33) o 11 (11-28) 
Median survival (days) (95% CI) 107 (11-203) 87 (58-116) 
Cause of death (no. of patients) 
Tumor progression 
Not related to tumor 
Alive
11
1
3
11
3
1
* p=NS; improvement within each treatment group: anti-reflux: p=0.002, open stent: p=0.005
†p=NS
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Median dysphagia score improved from 3 before treatment to 1 two weeks after
treatment in patients with an anti-reflux stent and from 3 to 0 in patients with an
open stent. Both the degree of improvement of dysphagia and median survival were 
not different between the two patient groups. The majority of patients (22/30) died
from tumor progression and 4 patients died from causes unrelated to either the
tumor or stent placement. There were no stent-related deaths. After a follow-up of at
least 6 months, 4 patients were still alive. 
24-hour pH monitoring and reflux symptoms 
Twenty-four hour pH monitoring was performed in 12 of the 30 patients (9 patients
with an anti-reflux valve and 3 patients with an open stent). One measurement in a 
patient with an open stent was excluded because the patient had used a proton-
pump inhibitor. Reasons for not undergoing pH monitoring in the other 18 patients
were: placement of another stent type (n=4), a poor medical condition (n=4), patient
deceased (n=3), patient refusal (n=5), stent migration (n=1), and technical problems
in positioning the pH probe (n=1).
Increased esophageal reflux exposure (normal < 4%) was found in 6/9 patients with
an anti-reflux stent and in 1/2 patients with an open stent. The median total reflux
times were 23% in the anti-reflux stent group (range: 0-65%, n=9) and 10% in the
open stent group (values: 0.1% and 19%, Figure 3, p=NS). The median number of
reflux episodes longer than 5 minutes was 14 (25-75 percentile: 2-19) in the anti-
reflux stent group and 5 (values: 0 and 10) in the open stent group (normal: <1)
(p=NS).
Reflux symptoms were reported by 3/12 (25%) patients with an anti-reflux stent and
by 2/14 (14%) patients with an open stent (Table 3). Of the 7 patients with abnormal
esophageal acid exposure time as measured by 24-hour pH monitoring, 2 patients
(one in each treatment group) reported reflux symptoms. Median scores of the 
indigestion scale of the EORTC OES-23 were not different between both groups on
the day of treatment and at 14 days after stent placement (Table 2). One 
symptomatic patient with an anti-reflux stent underwent an endoscopy, which
showed reflux-esophagitis grade C according to the Los Angeles classification. All
symptomatic and asymptomatic patients with abnormal pH recordings were treated
with a proton-pump inhibitor. 
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Figure 1: The FerX-Ella stent with and without anti-reflux valve.
Figure 2: Chest X-ray of the FerX-Ella stent with anti-reflux valve after positioning of the 
pH probe for the 24 h pH monitoring. The arrow shows the end of the pH-probe in the 
lumen of the stent (positioned 5 cm proximal to the gastroesophageal junction).
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Figure 3: Total reflux time after 24 h pH-monitoring in patients with a FerX-Ella stent with 
anti-reflux valve (n=9) or an open FerX-Ella stent (n=2) for palliation of dysphagia due to 
carcinoma of the distal esophagus or gastroesophageal junction.
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Figure 4: Endoscopic view from inside the stent showing the inverted membrane of the 
anti-reflux valve, causing complete obstruction of the stent. 
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Table 3: Complications and persistent/recurrent dysphagia in 30 patients given a FerX-Ella 
stent with or without anti-reflux valve for palliation of dysphagia due to carcinoma of the 
distal esophagus or gastroesophageal junction
Fer-X Ella stent with
anti-reflux valve
(N=15)
Fer-X Ella stent without 
anti-reflux valve
(N=15)
Total complications
Major complications
ǂ 7 days 
Severe pain 
> 7 days 
Hemorrhage
(Aspiration) pneumonia
Minor complications
Mild retrosternal pain 
Gastroesophageal reflux 
7 (47%) 
3 (20%) 
1
2
-
4 (27%) 
1
3
5 (33%) 
3 (20%) 
1
1
1
2 (13%)
-
2
Recurrent dysphagia
Stent migration
Inwards folded anti-reflux valve 
6 (40%) 
5
1
2 (13%) 
2
-
Complications and recurrent dysphagia 
There were no differences in the occurrence of major complications between patients 
with or without an anti-reflux stent (3/15 (20%) vs. 3/15 (20%) (Table 3). Two 
patients (one in each treatment group) experienced severe pain after stent placement 
and needed high doses of narcotic analgesics. Late major complications consisted
predominantly of hemorrhage (n=3), for which one patient underwent endoscopy
showing that the hemorrhage was caused by bleeding from the tumor. None of 
these 3 patients died from bleeding. One patient with an open stent developed
(aspiration) pneumonia 3 weeks after stent placement. This patient had not 
undergone 24-hour pH monitoring. 
There was no difference in the number of patients treated for recurrent dysphagia
between the two treatment groups (Table 3). Recurrent dysphagia after stent
placement was predominantly caused by stent migration in 7 (23%) patients, 5 of 
which occurred in the anti-reflux stent group (p=NS). Migration occurred in the anti-
reflux group on the day of treatment in one patient and at 7, 21, 120 and 288 days
after treatment, in the open stent group at 11 and 77 days after treatment, and was
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treated by placement of a second stent (n=5), or repositioning of the stent (n=2). In
one patient, the foil of the anti-reflux valve had inverted into the distal part of the 
stent, causing complete obstruction (Figure 4). During endoscopy, the foil was
pushed back into the stomach, effectively relieving the obstruction.
DISCUSSION
This is the first randomized study evaluating the ability of a stent with an anti-reflux
mechanism, i.e., the FerX-Ella stent, to prevent gastroesophageal reflux in patients
with inoperable cancer of the distal esophagus and gastric cardia and comparing it 
with a control group that was treated with a standard open stent of the same design.
The function of the anti-reflux valve was not only assessed by patient interviews,
but also by 24-hour pH monitoring in 11/30 (37%) patients. There were no
significant differences in improvement of dysphagia, the occurrence of
complications and recurrent dysphagia, or survival between both stent types,
however the anti-reflux valve of the FerX-Ella stent failed to prevent the occurrence
of gastroesophageal reflux.
Dua et al. (15) reported placing a Z-stent with a similar windsock-type anti-reflux
mechanism, or an open Z-stent, in the distal esophagus of 5 dogs and performed
ambulatory pH monitoring. They demonstrated that the mean esophageal acid 
exposure time decreased from 49% with an open stent to 1% with an anti-reflux
stent. Subsequently, they found that 11 patients treated with this anti-reflux stent 
had daytime heartburn and regurgitation scores less than 1 (score 10 = severe) and 
no nocturnal reflux symptoms. In another study, Laasch et al.(16) reported that only
3/25 (12%) patients treated with an anti-reflux Z-stent had symptoms of
gastroesophageal reflux against 24/25 (96%) patients treated with a Flamingo
Wallstent, a different stent design without anti-reflux valve. Both studies concluded
that the anti-reflux Z-stent was effective in reducing symptoms of gastroesophageal
reflux (15, 16). Finally, Köcher et al. (12) placed a FerX-Ella stent with anti-reflux
valve in 18 patients with cancer at the gastroesophageal junction and reported only 
minor heartburn in two patients and no significant gastroesophageal reflux on 
barium swallow studies. 
How can the different outcomes of the present study and those of the other studies
be explained? In the first place, our study highlights the importance of assessing the 
function of anti-reflux stents not only by patient interviews, but specifically by
performing 24-hour pH recordings within the stent lumen (Figure 2). Although only 
3/12 (25%) patients with an anti-reflux FerX-Ella stent reported symptoms of
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gastroesophageal reflux (Table 3), 6/9 (66%) patients with the anti-reflux stent were 
found to have gastroesophageal reflux as measured by pH monitoring (Figure 3).
Symptoms of gastroesophageal reflux with standard open stents have been reported 
in 5-15% of patients in other studies (11, 19, 20). In the present study and in spite of 
repeated interviews, again only 2/14 (14%) patients with an open FerX-Ella stent 
reported symptoms of gastroesophageal reflux. Therefore, it is likely that in the 
majority of these patients with a short life expectancy, gastroesophageal reflux is 
asymptomatic. This low prevalence of symptomatic reflux may partly be explained
by the fact that patients with Barrett’s esophagus, who form the majority of the 
patients with distal (adeno)carcinomas, have a decreased esophageal chemoreceptor 
sensibility (21-23). In addition, tumor infiltration of the vagus nerve may reduce acid 
production. As there have only been very rare reports of severe esophagitis after 
stent placement (24), which responds well to treatment with a proton-pump
inhibitor, the question arises whether the considerable technical and financial efforts
directed towards developing anti-reflux stents are justified. 
Another important explanation for the discrepancies in outcome between our study 
and that of the other studies could be the different valve design of the anti-reflux
FerX-Ella stent and the anti-reflux Z-stent. The general principle of this anti-reflux
valve is that the membrane cover of the stent extends beyond the lower metal cage
to form a “windsock”-type valve (Figure 1). While allowing food to pass into the
stomach, this mechanism should prevent the occurrence of gastroesophageal reflux 
by the empty windsock being compressed by the intra-abdominal pressure and thus
closing off its lumen. Since it is important that patients retain their ability to belch or 
vomit and to prevent gas bloating after meals, the anti-reflux valve of the Z-stent
can invert itself into the stent lumen under an intra-abdominal and an intra-thoracic
pressure gradient of around 35 mm Hg (15). An inversion pressure at this level
would seem to be adequate in preventing reflux during normal activities and sleep.
The valve membrane of the FerX-Ella stent differs from the Z-stent by the material
used for the membrane (FerX-Ella stent: polyethylene vs. Z-stent: polyurethane), the 
length (FerX-Ella stent: 47 mm vs. Z-stent: 80 mm) and thickness of the membrane
(FerX-Ella stent: 0.015 mm vs. Z-stent: 0.017 mm). Dua et al. (15) have shown that
reducing the thickness of the membrane of the Z-stent from 0.017 mm to 0.015 mm
decreases the pressure necessary to invert the valve membrane into the stent by one-
third. Moreover, polyethylene is a less rigid material than polyurethane. We
therefore suspect that these different stent characteristics of the FerX-Ella stent may 
well explain its failure to prevent gastroesophageal reflux.
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Although the diameter of the valve lumen is the same as the shaft lumen of the Fer-
X Ella stent, we found no evidence of the valve interfering with the passage of food 
(median improvement in dysphagia score from 3 to 1 in both the anti-reflux and
open stent group). When the valve membrane inverts during belching or vomiting, 
it should be possible to revert it to its anti-reflux position by drinking some water.
We instructed all patients to do so after events which could potentially raise the
intra-abdominal pressure or in case of symptoms of gastroesophageal reflux. The 
membrane of the anti-reflux valve inverted into the distal part of the stent in one 
patient, which caused complete obstruction of the stent (Figure 4). Drinking of water
failed to revert the valve into its anti-reflux position. At endoscopy, the membrane
was carefully pushed back into the stomach, relieving the obstruction.
It is known that stent migration is more likely to occur when stents are placed across 
the gastroesophageal junction, because in this position the distal part of the stent 
projects freely into the fundus of the stomach and this part cannot fix itself to the
wall (9). The Fer-X Ella stent was no exception, in fact with 7/30 episodes of
migration its performance was rather poor. The trend towards more episodes of
stent migration with the anti-reflux stents than with the open stents (5 (33%) vs. 2
(13%); p=NS) was not anticipated because the anti-reflux valve is predominantly
positioned in the upper part of the stomach away from strong peristaltic
contractions in the gastric antrum. In addition, the FerX-Ella stent has a proximal
diameter of 36 mm to prevent migration. However, our results would suggest that
the FerX-Ella stent needs additional measures to prevent the stent from migrating, 
for example an uncovered proximal segment to allow the normal mucosa above the 
tumor to project into the stent lumen or metal barbs on the outside of the stent to
anchor it into the tumor. 
In conclusion, the FerX-Ella stent provides symptomatic relief of malignant
dysphagia, however its anti-reflux valve fails to prevent gastroesophageal reflux. In 
addition, stent migration, particularly with anti-reflux stents, was seen in almost
one-quarter of patients. Changes in the design of the stent and its anti-reflux valve
are needed to improve its clinical usefulness. In addition, we believe that the
efficacy of all anti-reflux stents should be evaluated by 24-hour pH monitoring,
although our study illustrates the practical difficulties in achieving such
measurements. Finally, companies planning to introduce new stent designs with
anti-reflux mechanism on the market would do well to wait with marketing until
randomized trials have provided solid data for both their efficacy and their
necessity.
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In this thesis the first randomized study between the two most widely used
methods for the palliation of dysphagia from esophageal cancer, i.e., single dose 
brachytherapy and metal stent placement, is reported. Apart from relief of 
dysphagia and complications as outcome measures an extended quality of life study
and a cost study were performed. In addition, specific brachytherapy- and stent-
related problems were investigated. Using this data, a more evidence-based 
treatment advice can probably be given to patients needing palliation of dysphagia 
from esophageal cancer.
Main conclusions from this thesis: 
 Dysphagia improved more rapidly after stent placement than after
brachytherapy, but brachytherapy resulted in a better relief of dysphagia in the
long term.
 Stent placement was associated with more complications compared to
brachytherapy which was mainly due to a higher incidence of hematemesis
after stent placement.
 More than 40% of the patients needed additional treatment for persistent or 
recurrent dysphagia after stent placement or brachytherapy with no difference 
between both treatments.
 Brachytherapy gave better overall scores on health-related quality of life
(HRQoL) scales compared to stent placement. Most items of the generic HRQoL 
scales deteriorated during follow-up in both treatment groups, however, the
decline was more pronounced in the stent group. On the disease-specific
HRQoL scales, major improvements were seen on the dysphagia and eating 
scales, whereas the other scales remained almost stable during follow-up. This
suggests that the disease-specific scales are less sensitive in measuring HRQoL 
than the generic scales in this group of patients.
 In spite of the higher initial costs for stent placement than for brachytherapy
total medical costs were similar. Cost considerations should therefore not play
an important role in decision making on the most appropriate palliative
treatment strategy for patients with dysphagia from esophageal cancer.
In general, single dose brachytherapy is preferable to metal stent placement as the
initial treatment for the palliation of dysphagia from esophageal cancer. Our results
suggest that stent placement should be reserved for patients with severe dysphagia
in combination with a short life expectancy, who need a rapid relief of dysphagia.
215
Chapter 8 
Another group in which stent placement should be considered are patients with 
persistent or recurrent tumor growth after single dose brachytherapy.
Secondary conclusions:
 There is a wide variation in the use of diagnostic procedures and treatment 
strategies for patients with esophageal cancer in the Netherlands. This stresses
the need for a more evidence-based and uniform approach to both diagnostic 
procedures and treatment for this malignancy. 
 Patients with stenotic tumors that cannot be passed endoscopically or who 
previously underwent chemotherapy are poor candidates for single dose 
brachytherapy. For these patients alternative palliative treatment modalities
should be considered.
 Patients with dysphagia from inoperable esophageal cancer who previously
underwent radiation and/or chemotherapy can effectively and safely be treated
with stent placement.
 Re-interventions for stent-related recurrent dysphagia are effective in over 90%
of patients and these improve dysphagia. An effective treatment strategy for
both tumor overgrowth and stent migration is placement of a second stent, or, 
in some cases of migration, repositioning of the stent. Patients with recurrent 
dysphagia after palliative treatment should therefore be referred for endoscopy
as this problem is almost always amenable to treatment.
 The new design stent for the prevention of gastro-esophageal reflux, the FerX-
Ella stent with anti-reflux valve, failed to prevent gastro-esophageal reflux. In 
addition, in a relatively high number of patients the stent migrated. Changes in
the design of the stent and its anti-reflux valve are needed to improve its clinical 
usefulness.
PERSPECTIVES AND FUTURE RESEARCH
Single dose brachytherapy
In this thesis, we describe the results of our retrospective study of single dose
brachytherapy in 149 patients with dysphagia from inoperable esophageal cancer 
and the randomized trial comparing single dose brachytherapy versus metal stent 
placement. The occurrence of complications, recurrent dysphagia and survival of 
patients were similar in both studies. However, the relief of dysphagia was lower in 
the retrospective study. This can partly be explained by incomplete patient data in
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our retrospective study but also by the intensive follow-up in our comparative trial.
Patients with no improvement in dysphagia scores within a few weeks after
treatment received an additional treatment mostly consisting of stent placement.
This intensive follow-up probably leads to improved outcome data of palliative
treatment strategies.
Almost half of the patients needed an additional intervention for persistent or 
recurrent dysphagia after single dose brachytherapy. One way to improve the
results of brachytherapy is to improve the selection of patients that are eligible for 
this treatment. This was described in chapter 5B. It is uncertain whether a single
treatment of 12 Gy brachytherapy was the optimal dose for this treatment. The
biological effects of brachytherapy might be improved by increasing and/or
fractioning the delivered dose. Different doses of brachytherapy were compared in 
172 patients with advanced esophageal (mainly squamous cell) carcinoma in a study
from South Africa (1). Patients were randomized to 12 Gy in 2 sessions, 16 Gy in 2 
sessions or 18 Gy in 3 sessions. Patients who received 16 Gy or 18 Gy in two sessions
did significantly better than patients who received 12 Gy in 2 sessions in terms of
dysphagia-free survival and persistent tumor growth in the esophagus after
treatment. The treatment regimes with 16 Gy in 2 sessions and 18 Gy in 3 sessions
were again compared in a randomized trial with 232 patients with similar results for 
the two treatment regimes (2). Therefore, additional studies are needed to
investigate whether a higher and/or fractionated dose of brachytherapy will increase 
the efficacy of dysphagia relief in patients with metastatic disease and/or a poor 
general condition.
Metal stent placement
New stent designs have recently been developed or are still under development to
prevent stent-related problems and improve palliation of esophageal cancer. In
order to prevent the high fraction of recurrent dysphagia after stent placement
improved stent designs need to be developed which prevent both tumor
overgrowth and stent migration. Currently, a new type of stent is under
investigation in the Erasmus MC, the Niti-S stent, with a double layer consisting of a
covered inner layer and an uncovered outer layer. This design should reduce, if not
eliminate, the occurrence of stent migration. Other available new stent designs
which claim to reduce the occurrence of recurrent dysphagia, for example the self-
expanding plastic Polyflex stent (3), should to be compared in a randomized study.
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In this thesis we describe the results of the FerX-Ella stent designed to prevent
gastro-esophageal reflux if stents are placed across the gastro-esophageal junction. 
The FerX-Ella stent provided symptomatic relief of dysphagia, however its anti-
reflux valve failed to prevent gastro-esophageal reflux. We believe that the efficacy
of anti-reflux stents should be evaluated by 24-hour pH monitoring, although our 
study illustrates the practical difficulties in achieving such measurements.
Companies planning to introduce new stent designs with anti-reflux mechanism to 
the market would do well to wait with marketing until randomized trials have 
provided solid data for both their efficacy and their necessity.
Future new types of stents, which are currently being developed, include 
biodegradable stents, stents with a radioactive coating and drug-eluting stents.
Biodegradable stents have been developed for benign stenoses (4, 5), however a
possible application could be the initial treatment of dysphagia in patients
undergoing palliative chemotherapy or patients with severe dysphagia undergoing
neo-adjuvant chemotherapy. Since treatment results of chemotherapy for 
esophageal carcinoma have improved over the last few years (6, 7), an increased 
proportion of patients with this malignancy will likely be considered for treatment
with chemotherapy.
The incorporation of beta-emitting agents and cytotoxic agents in esophageal stents 
may increase the efficacy of stents, particularly in the prevention of (recurrent) 
tumor overgrowth at both ends of the stent. Clinical experience has been obtained 
with radio-active stents and drug-eluting stents in coronary arteries of humans. For 
the esophagus, only experience with animal models is available. In healthy dogs the
radioactive stent caused some fibrosis with radiation damage to the normal
esophagus but no serious complications such as perforation or fistula formation
occurred (8). The safety and efficacy of radio-active and drug-eluting stents in
malignant strictures in the esophagus need further evaluation in clinical trials.
Single dose brachytherapy versus metal stent placement
Study design
We preformed a randomized study in nine hospitals in the Netherlands comparing 
single dose brachytherapy versus metal stent placement for the palliation of
dysphagia from esophageal cancer. Participating centers included 3 university
centers and 6 general hospitals. In this way we were able to recruit more than 200 
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patients within 2.5 years, which is remarkable considering the relatively low 
incidence of esophageal carcinoma in the Netherlands. Patients were well-informed 
on the aim and design of the study before being randomized and only 44 (17%) of
the 253 eligible patients refused to participate. The most common reason for refusal 
was the fact that the majority of these patients had a specific preference for one of 
the two treatment modalities. In all participating centers a gastroenterology and a 
radiotherapy department were present and the physicians from these departments 
had extended clinical experience with both stent placement and brachytherapy. 
Before the start of the study several meetings were organized to discuss the design 
and logistics of the trial, in order to enhance uniform treatment strategies in each
center. During the study the study coordinators of the participating centers had 
contact on a regular basis.
Many patients needed additional treatments after both single dose brachytherapy
and stent placement. Since a specific evidence-based protocol for these re-
interventions had not been developed the choice of treatment was made by the 
responsible physician. Placement of a second stent was the most frequently used 
treatment for recurrent dysphagia after initial stent placement. In case of persistent
or recurrent dysphagia after brachytherapy placement of a stent was also the most
widely used treatment modality. By doing so these patients received, in addition to
brachytherapy, the treatment modality of the other randomization arm. Due to the
intention-to-treat set-up of the study and its analyses, all complications and costs of 
the non-assigned treatment were accounted to the randomized treatment group. In 
our recommendations for the palliative treatment of dysphagia from esophageal 
cancer we conclude that single dose brachytherapy is preferable as the initial
treatment. However, stent placement might well be used for persistent or recurrent 
dysphagia after single dose brachytherapy.
Follow-up
An important problem with multicenter trials is to obtain complete follow-up data.
In this study patients were followed by home visits from a specialized research
nurse at 14 days, 1 month and then monthly until one year after treatment. After one 
year of follow-up patients were visited every 3 months and/or telephone calls to the
patient and the patients’ practitioner were made. The specialized nurse collected
outcome data on dysphagia, complications, additional treatments, quality of life and
costs (hospital costs, interventions and extramural care). In this way we obtained
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complete follow-up data (in more than 95% of patients) which resulted in a unique 
database.
An unexpected result of this study was the enormous success of these home visits
by specialized research nurses. The research nurses were specifically trained to 
support patients with incurable esophageal carcinoma. These nurses assisted 
patients with filling out the large number of questionnaires and checklists for the
quality of life study and the cost study. However, the nurses were even more 
important in giving advice and support to this patient group with a poor survival.
Whether home visits by specialized nurses could be an alternative to regular control 
visits to the clinic for patients who have undergone treatment for esophageal cancer
is currently under investigation in a randomized study. Acceptability, quality of life
and costs are the main outcome measures of this study. 
In our study health related quality of life (HRQoL) was investigated with a variety
of validated measures. Disease specific quality of life was assessed with the
dysphagia score (9), the esophageal specific European Organization for Research
and Treatment of Cancer (EORTC) OES-23 measure (10) and a visual analogue pain
scale. Generic HRQoL was assessed with the oncology-specific EORTC QLQ-C30 
measure (11) and the EQ-5D including an index score and visual analogue scale 
(EQ-VAS) for self-rated health (12). Single dose brachytherapy gave better overall
scores on HRQoL scales compared to stent placement for the palliation of
esophageal cancer. In our opinion studies comparing different treatment modalities
for esophageal carcinoma should also incorporate quality of life questionnaires to 
determine, apart from technical aspects, whether these treatments are of benefit
from the point of view of patients.
Palliation of dysphagia from esophageal carcinoma
Recently, the guideline ‘Esophageal carcinoma’ of the Comprehensive Cancer 
Center (2003) has become available, whereas the evidence-based guideline on the
diagnosis and treatment of esophageal cancer under the flag of the Dutch institute 
for Healthcare CBO will soon become available (fall 2004). These guidelines need to
be evaluated in daily practice if they will result in a more uniform and effective
strategy for the treatment of esophageal cancer. New treatment results should be 
incorporated in regular updates of these guidelines. In addition, it is important that
implementation programs for these guidelines will be developed. 
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From this thesis we can conclude that the current recommendation for the palliative
treatment of dysphagia from esophageal cancer would be single dose brachytherapy 
as the initial treatment. Stent placement should be reserved for patients with severe 
dysphagia in combination with a short life expectancy, needing a rapid relief of 
dysphagia and for patients with persistent or recurrent tumor growth after single
dose brachytherapy.
However, the presently available treatment modalities for palliation of dysphagia 
from esophageal cancer are, as yet, not optimal in achieving fast and sustained
dysphagia relief with minimal morbidity and mortality. Metal stent are reasonably
effective in improving dysphagia, however, both the complication rate and the 
number of re-interventions necessary for recurrent dysphagia are still too high. 
Single dose brachytherapy is a more effective and safer alternative than stent
placement, although both tumor persistence and tumor recurrence have a negative
impact on the short- and long-term effect of palliation of dysphagia. It remains to be 
studied whether results of brachytherapy or stent placement can be improved by 
higher and/or fractionated radiation doses or by improved stent designs without 
jeopardizing safety.
Randomized controlled trials comparable to the trial described in this thesis are
ideally needed to compare (new) palliative treatment modalities with special 
reference to dysphagia relief, complications, interventions for recurrent dysphagia,
quality of life after treatment and costs. In addition, improvements in the selection
of patients for a particular palliative treatment modality will make a more
individualized palliative treatment strategy possible. In this way a more optimal
palliative treatment strategy for esophageal cancer will be achieved. 
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The prognosis of esophageal cancer is poor with a 5-year survival of 10-15%. In 
addition, over 50% of patients with esophageal cancer already have an inoperable
disease at presentation. The majority of these patients require palliative treatment to
relieve progressive dysphagia. Metal stent placement and single dose brachytherapy 
(intraluminal radiation) are the two most widely used palliative treatments for 
dysphagia from esophageal cancer, however, their relative merits are unknown
(Chapter 2).
In this thesis, we present the results of the first randomized trial comparing metal
stent placement with single dose brachytherapy for the palliation of dysphagia from 
inoperable esophageal cancer. Between December 1999 and June 2002, 209 patients
with dysphagia from inoperable carcinoma of the esophagus or gastro-esophageal 
junction were randomized to placement of a metal stent (n=108) or single dose 
brachytherapy (n=101). Patients randomized to stent placement received an
Ultraflex stent, patients in the brachytherapy group were treated with a single
intraluminal radiation dose of 12 Gray. We compared the two treatments with
respect to relief of dysphagia, complications, treatment for persistent or recurrent 
dysphagia, health related quality of life and costs. Participating centers included 3 
university and 6 general hospitals in the Netherlands. Patients were followed by 
monthly home visits from a specialized nurse who collected outcome data using 
standardized questionnaires. If indicated, patients were readmitted for clinical
evaluation and re-treatment (Chapter 6).
Dysphagia improvement was more rapid after stent placement than after
brachytherapy, but long term relief of dysphagia was better after brachytherapy.
Complications occurred more often after stent placement (33% vs. 21%), which was
mainly due to a higher incidence of late hemorrhage (13% vs. 5%). The number of 
patients treated for persistent or recurrent dysphagia was similar for both treatment
groups (40% vs. 43%), as was median survival (Chapter 6A).
We obtained longitudinal data on disease specific and generic health-related quality
of life. Disease specific quality of life was assessed with the dysphagia score, the
esophageal cancer specific EORTC OES-23 measure and a visual analogue pain
scale. Generic HRQoL was assessed using the oncology-specific EORTC QLQ-C30 
measure and the EQ-5D including an index score and a visual analogue scale (EQ-
VAS) for self-rated health. Treatment with single dose brachytherapy gave better
overall scores on HRQoL scales compared to stent placement. Major improvements 
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were seen on the dysphagia and eating scales of the disease specific EORTC OES-23 
after treatment, however most items of the different HRQoL scales deteriorated
during follow-up. Generic HRQoL scales were more responsive in measuring
patients’ functioning and well-being during follow-up than disease specific HRQoL
scales (Chapter 6B).
The initial costs of stent placement were higher than the costs of brachytherapy
(€1,500 vs. €570). However, total medical costs were similar (stent €11,195 vs.
brachytherapy €10,078). Total hospital stay during follow-up was 11.5 days after
stent placement versus 12.4 days after brachytherapy, which was responsible for the
high intramural costs in both treatment groups (stent: €6,512 vs. brachytherapy:
€7,982). Therefore, cost considerations should not play an important role in decision
making on the appropriate palliative treatment strategy for patients with dysphagia 
from esophageal cancer (Chapter 6C).
Brachytherapy resulted in a better relief of dysphagia during follow-up and was 
associated with fewer complications. In addition, there was a benefit in quality of
life after brachytherapy. The number of repeated procedures for persistent or 
recurrent dysphagia and costs of both treatment modalities were similar. 
Based on this randomized study single dose brachytherapy is preferable to stent
placement as the initial palliative treatment for patients with dysphagia from 
esophageal cancer. Stent placement may be reserved for patients with severe 
dysphagia in combination with a short life expectancy and for persistent or 
recurrent tumor growth after brachytherapy (Chapter 6).
In order to investigate the currently used diagnostic procedures and treatment 
strategies for esophageal cancer we sent a questionnaire to all Dutch clinicians 
(internists, gastroenterologists and surgeons) working in the field of 
gastroenterology. Almost 90% of the clinicians treated fewer than 20 patients
annually, mostly in their own hospital. Computer tomography was the most
frequently used staging procedure. Endoscopic ultrasound was less frequently used. 
The treatment choice for the presented patient vignettes varied widely among
clinicians. Factors influencing the choice to operate or not were metastases, loco-
regional tumor ingrowth, poor general health and advanced age. Stent placement
was the most frequently chosen method for the palliation of dysphagia from 
esophageal cancer. This survey indicates that at present there are wide variations in 
the strategies for diagnosis, staging and treatment of patients with esophageal
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cancer. There is a need for more evidence-based and uniform approach to both 
diagnostic procedures and treatment for this malignancy (Chapter 3).
Prior to our randomized trial between brachytherapy and stent placement, we 
performed a retrospective analysis over a 10-year period of 149 patients treated with
brachytherapy in our center. Brachytherapy was administered in one (87%) or two
(13%) sessions, at a median dose of 15 Gy. Dysphagia scores had improved from a
median of 3 (liquids only) to 2 (semisolids), however dysphagia had not improved 
in 51 (49%) patients. Procedure related complications occurred in 7 (5%) patients.
Late complications including fistula formation or bleeding occurred in 11 (7%) 
patients. Twelve (8%) patients experienced minor retrosternal pain. Median survival
of the patients was 160 days. During follow-up, 55 (37%) patients experienced
recurrent dysphagia. In 34 (23%) patients a metal stent was placed to relief
persistent or recurrent dysphagia. From this retrospective trial we concluded that
brachytherapy was a moderately effective treatment for the palliation of malignant
dysphagia. The incidence of complications was low, however, persistent and 
recurrent dysphagia occurred frequently which often required additional treatment
(Chapter 4A).
From our comparative study and the retrospective study we concluded that a 
disadvantage of single dose brachytherapy was the fact that almost half of the
patients needed additional treatment for persistent or recurrent tumor growth after
single dose brachytherapy. We investigated which baseline patient and tumor
characteristics within our study influenced the occurrence of persistent and 
recurrent tumor growth after single dose brachytherapy. We found that dilation
prior to treatment was a risk factor for persistent and recurrent tumor growth after 
single dose brachytherapy. In addition, there was a trend towards a higher risk for
persistent tumor growth in patients previously treated with chemotherapy. For
these patient alternative palliative treatment modalities should be considered 
(Chapter 4B).
In order to improve the palliation of esophageal cancer with metal stents we 
investigated several stent-related problems. An important issue of debate was 
whether prior radiation and/or chemotherapy (RTCT) increases the risk of 
complications after metal stent placement in patients with inoperable
esophagogastric carcinoma. We therefore evaluated the influence of prior RTCT on 
the outcome of stent placement in 200 prospectively followed patients. Forty-nine of
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these patients had received prior RTCT (chemotherapy n=35, radiation therapy n=8,
or both n=6). The incidence of major complications, recurrent dysphagia and 
survival were not affected by prior RTCT, however retrosternal pain occurred more 
frequently in patients who had previously undergone RTCT. Therefore, placement
of a metal stent is as safe and effective in patients with prior RTCT as in those 
without such treatment. (Chapter 5A).
Recurrent dysphagia after stent placement is also a frequently occurring problem.
We investigated the causes of stent-related recurrent dysphagia, the time interval of 
occurrence after first stent placement, the procedures used for re-intervention and 
their outcomes. Two-hundred sixteen patients underwent placement of a metal stent
(Ultraflex, n=75; Flamingo Wallstent, n=71; Z-stent, n=70) for palliation of dysphagia 
from esophageal cancer in our center and were followed prospectively. Recurrent
dysphagia occurred in almost one-third of patients after stent placement. This was
mainly caused by tumor overgrowth at the proximal and/or distal end of the stent, 
stent migration, and food bolus obstruction. Re-interventions for stent-related 
recurrent dysphagia were effective and improved dysphagia scores. The most 
effective treatment strategy for both tumor overgrowth and stent migration was
placement of a second stent or, in cases of migration, stent repositioning. Patients
with recurrent dysphagia should therefore be referred for endoscopy as this 
problem is almost always amenable to treatment (Chapter 5B).
New stent designs have been developed and are still under development to prevent
stent-related problems and improve palliation of esophageal cancer. Metal stents
deployed across the gastro-esophageal junction predispose to gastro-esophageal 
reflux. We assessed the efficacy of the FerX-Ella stent with an anti-reflux mechanism
in preventing gastro-esophageal reflux. Patients with carcinoma of the distal
esophagus or gastric cardia were randomized to receive either a FerX-Ella stent with 
a windsock-type anti-reflux valve (n=15) or a standard open FerX-Ella stent (n=15). 
We found that the FerX-Ella stent provided symptomatic relief against malignant
dysphagia, however its anti-reflux valve failed to prevent gastro-esophageal reflux. 
Changes in the design of the stent and its anti-reflux valve are needed to improve its 
clinical usefulness (Chapter 7).
It remains to be studied whether results of brachytherapy or stent placement can be 
improved by higher and/or fractionated radiation doses or by improved stent
designs without jeopardizing safety (Chapter 8).
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Samenvatting
De prognose van slokdarmkanker is slecht met een 5-jaars overleving van zo’n 10-
15%. Dit komt mede doordat meer dan de helft van de mensen met slokdarmkanker
niet in aanmerking komt voor een operatie, m.n. ten gevolge van aanwezige
metastasen of een slechte algemene conditie. Deze groep patiënten heeft vrijwel 
altijd een palliatieve behandeling nodig om voedselpassageklachten te verbeteren.
De twee meest gebruikte methoden voor de palliatie van passageklachten ten
gevolge van slokdarmkanker zijn het plaatsen van een zelf-ontplooibare stent (stent) 
of het verrichten van een inwendige bestraling (brachytherapie) in de slokdarm.
Deze twee behandeling zijn nog niet eerder met elkaar vergeleken (hoofdstuk 2).
In dit proefschrift worden de resultaten beschreven van het eerste gerandomiseerde 
onderzoek waarin stentplaatsing met brachytherapie wordt vergeleken voor de 
palliatie van passageklachten ten gevolge van slokdarmkanker. Tussen december
1999 en juni 2002 werden 209 patiënten met passageklachten op basis van een 
inoperabel slokdarmcarcinoom ten gevolge van metastasen of een slechte algemene 
conditie gerandomiseerd voor stentplaatsing (n=108) of brachytherapie (n=101). In 
de stentgroep werd een Ultraflex stent geplaatst en in de brachytherapiegroep
werden de patiënten éénmalig met 12 Gray bestraald. Eindpunten van het
onderzoek waren verbetering van de passageklachten, complicaties, kwaliteit van 
leven, het optreden van hernieuwde passageklachten en kosten. Patiënten werden 
geïncludeerd in 3 universitaire en 6 algemene ziekenhuizen in Nederland. De 
follow-up bestond uit huisbezoeken door een gespecialiseerde verpleegkundige op 
de tijdstippen 14 dagen, 1 maand en vervolgens maandelijks na de behandeling. In 
geval van complicaties of hernieuwde passageklachten werd de behandelend 
specialist geconsulteerd (hoofdstuk 6).
Hoewel er een snellere verbetering van passageklachten optrad na stentplaatsing,
was de verbetering van passageklachten over de gehele periode beter na 
brachytherapie. Het totaal aantal complicaties was hoger in de stentgroep (33%) dan 
in de brachytherapiegroep (21%), voornamelijk door meer bloedingen in de
stentgroep (13% vs. 5%). Het aantal behandelingen dat nodig was voor
aanhoudende of hernieuwde passageklachten was gelijk in beide groepen (40% vs.
43%). Ook de mediane overleving was gelijk in beide groepen (hoofdstuk 6A).
Tijdens het onderzoek werden longitudinale data verkregen van zowel de generieke 
als ziekte-specifieke kwaliteit van leven. Ziekte-specifieke kwaliteit van leven werd 
bepaald aan de hand van de passageklachtenscore, de EORTC OES-23 wat een
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vragenlijst is specifiek voor patiënten met slokdarmkanker, en een visueel analoge 
schaal waarop de mate van aanwezige pijnklachten kon worden aangegeven.
Generieke kwaliteit van leven werd bepaald aan de hand van een vragenlijst 
specifiek voor kankerpatiënten, de EORTC QLQ-C30, en de EQ-5D die een index
score geeft aan een bepaald gezondheidsprofiel en die een visueel analoge schaal 
bevat voor welbevinden. Kwaliteit van leven scores op de verschillende schalen 
waren beter na brachytherapy dan na stentplaatsing. Op de ziekte-specifieke 
EORTC OES-23 waren grote verbeteringen te zien op de ‘passageklachten’- en de
‘eten’-schaal na behandeling, maar de meeste kwaliteit van leven schalen
verslechterden tijdens follow-up. De generieke kwaliteit van leven schalen gaven
een betere weergave van het welbevinden en functioneren van de patiënt tijdens de 
follow-up dan de ziekte-specifieke kwaliteit van leven schalen (hoofdstuk 6B).
De initiële kosten voor brachytherapie waren lager dan voor stentplaatsing
(brachytherapie: € 570 vs. stentplaatsing: € 1.500), echter de totale medische kosten
waren gelijk voor beide behandelingen (brachytherpie: € 11.195 vs. stent: € 10.078).
Het totaal aantal ligdagen in het ziekenhuis voor herbehandeling of ten gevolge van 
het ziekteproces tijdens follow-up was hoog in beide groepen: 12,4 dagen na
brachytherapie en 11,5 dagen na stentplaatsing. Hierdoor waren de kosten voor
intramurale zorg de grootste kostenpost (brachytherapy: € 7.982 vs. stent: € 6.512).
Aangezien de totale kosten niet verschillend waren voor beide behandelingen,
zullen de kosten niet een belangrijke rol spelen in de keuze voor de beste palliatieve
behandelstrategie voor patiënten met slokdarmkanker (hoofdstuk 6C).
Zowel de voedselpassageklachten als kwaliteit van leven parameters waren meer 
beter na behandeling met brachytherapie dan na stentplaatsing voor de palliatieve
behandeling van slokdarmkanker. Tevens traden er minder complicaties op na 
brachytherapie. Aangezien het aantal behandelingen in verband met aanhoudende 
en hernieuwde passageklachten en totale kosten niet verschilden tussen beide 
behandelingen zijn wij van mening dat deze groep patiënten bij voorkeur behandeld
dient te worden met brachytherapie. Slechts als er sprake is van aanhoudende of 
hernieuwde passageklachten na brachytherapie als eerste behandeling is het
plaatsen van een stent geïndiceerd. Stentplaatsing kan daarnaast overwogen
worden als een snelle verbetering van passageklachten nodig is, zoals bij patiënten 
met ernstige (‘totale’) passageklachten of bij patiënten met een korte 
levensverwachting (hoofdstuk 6).
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Om een inventarisatie te maken van het huidige beleid van diagnostiek en 
behandeling van slokdarmkanker, werd een enquête verricht onder alle specialisten 
met aandachtsgebied gastroenterologie (chirurgen, internisten en maag-darm-
lever(MDL-) artsen) in Nederland. Bijna 90% van de specialisten gaf aan minder dan 
20 patiënten per jaar te behandelen, meestal in het eigen ziekenhuis. CT was de 
meest gebruikte procedure voor nadere diagnostiek van slokdarmkanker, terwijl 
endoscopische ultrasonografie minder frequent werd gebruikt. Factoren die de
keuze voor wel of geen operatie beïnvloedden, waren metastasen, lokale
tumordoorgroei, slechte algemene conditie en een hoge leeftijd. Stentplaatsing was
de meest gebruikte vorm van palliatie om passageklachten te verbeteren ten gevolge
van slokdarmkanker. Deze enquête liet zien er een grote variatie is in de diagnostiek
en behandeling van patiënten met slokdarmkanker. Er is behoefte aan een meer 
uniforme en ‘evidence-based’ aanpak voor de keuze van diagnostiek en
behandeling van slokdarmkanker (hoofdstuk 3).
Voorafgaand aan het gerandomiseerde onderzoek tussen stentplaatsing en
brachytherapie, werd een retrospectief onderzoek uitgevoerd naar de resultaten van 
149 patiënten die behandeld werden met brachytherapie in de afgelopen 10 jaar in
de Erasmus MC Rotterdam – Daniel den Hoed Kliniek. Brachytherapie werd 
toegediend als eenmalige (87%) dosis of in twee (13%) sessies, met een mediane 
toegediende stralingsdosis van 15 Gray. De passageklachtenscore verbeterde van 
een mediaan van 3 (vloeibaar) naar 2 (gemalen voeding), maar bij 51 (49%) patiënten
trad geen verbetering op van de passageklachten. Procedure-gerelateerde
complicaties traden op in 7 (5%) patiënten. Late complicaties, waaronder 
fistelvorming en bloedingen, ontstonden bij 11 (7%) patiënten. Twaalf (8%)
patiënten hadden milde retrosternale pijn. De mediane overleving was 160 dagen. 
Tijdens follow-up ontwikkelden 55 (37%) patiënten hernieuwde passageklachten. Bij 
34 (23%) patiënten werd een stent geplaatst ter verbetering van de (hernieuwde) 
passageklachten. Uit dit retrospectieve onderzoek werd geconcludeerd dat
brachytherapie een veilige behandeling was aangezien er weinig complicaties
optraden, maar de verbetering van passageklachten was matig effectief. Tevens 
hadden patiënten vaak aanhoudende of hernieuwde passageklachten waarvoor een 
aanvullende behandeling nodig was (hoofdstuk 4A).
Uit onze gerandomiseerde studie en de retrospectieve studie over brachytherapie
bleek dat een nadeel van de brachytherapie was dat bijna de helft van de patiënten
een aanvullende behandeling nodig had voor aanhoudende of hernieuwde 
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passageklachten. We onderzochten welke patiënten- en tumorkarakteristieken uit
de studie invloed hadden op het optreden van aanhoudende of hernieuwde 
passageklachten na brachytherapie. Hieruit bleek dat dilatatie voorafgaand aan
brachytherapie het risico op aanhoudende en hernieuwde passageklachten
verhoogde. Tevens bestond er een trend voor een verhoogd risico op aanhoudende
passageklachten bij patiënten die eerder een chemotherapeutische behandeling 
hadden ondergaan. Voor deze patiënten moeten alternatieve palliatieve
behandelwijzen worden overwogen (hoofdstuk 4B).
Om de toepassing van stents voor de palliatie van het slokdarmcarcinoom te
verbeteren, werden verschillende stent-gerelateerde problemen onderzocht. Een
belangrijk discussiepunt bij de toepassing van stents was of een voorafgaande 
behandeling met radiotherapie en/of chemotherapie (RTCT) het risico op
complicaties na stentplaatsing verhoogd. De invloed van voorafgaande RTCT op het
resultaat van de stentplaatsing werd onderzocht in 200 prospectief vervolgde
patiënten. Hiervan waren 49 patiënten behandeld met chemotherapie (n=35), 
radiotherapie (n=8) of beide (n=6). De incidentie van ernstige complicaties,
hernieuwde passageklachten en de overleving was gelijk voor patiënten met of
zonder voorafgaande RTCT. Retrosternale pijn kwam wel meer voor bij patiënten
die een eerdere behandeling met RTCT hadden gehad voor de stentplaatsing 
(hoofdstuk 5A).
Ook na stentplaatsing is een veel voorkomend probleem het optreden van 
hernieuwde passageklachten. We onderzochten de oorzaken van stent-gerelateerde 
hernieuwde passageklachten, het moment van optreden na stentplaatsing, welke 
behandelingen werden toegepast en het succes van deze herbehandelingen. Bij 216
patiënten werd een stent geplaatst (Ultraflex: n=75, Flamingo Wallstent: n=71, Z-
stent: n=70) voor de palliatie van passageklachten ten gevolge van slokdarmkanker.
Bij éénderde van de patiënten traden hernieuwde passageklachten op, voornamelijk 
ten gevolge van tumorovergroei aan de boven- of onderrand van de stent, migratie 
van de stent, en een voedselbrok. Behandeling voor de stent-gerelateerde 
hernieuwde passageklachten was in het algemeen effectief en verbeterde de
passageklachten. De meest effectieve behandeling voor tumorovergroei en 
stentmigratie was het plaatsen van een tweede stent. Bij stentmigratie kon de stent 
soms ook worden gerepositioneerd. Bij patiënten met hernieuwde passageklachten
na stentplaatsing moet overwogen worden om deze te verwijzen voor een 
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endoscopie, aangezien het probleem bijna altijd effectief endoscopisch kan worden 
behandeld (hoofdstuk 5B).
Momenteel zijn er nieuwe typen stents ontwikkeld en nog in ontwikkeling die stent-
gerelateerde problemen moeten voorkomen om zo de palliatie met stentplaatsing
van slokdarmkanker te verbeteren. Stents die door de onderste slokdarmsfincter
worden geplaatst, vergroten de kans op gastro-esophageale reflux. Onderzocht 
werd of de FerX-Ella stent met een anti-reflux mechanisme gastro-esophageale
reflux kon voorkomen. Patiënten werden gerandomiseerd naar de FerX-Ella stent
met anti-reflux klep (n=15) of de open FerX-Ella stent (n=15). Hieruit bleek dat de 
FerX-Ella stent wel een goede symptomatische verbetering van de passageklachten 
ten gevolge van slokdarmkanker gaf, maar dat het anti-reflux mechanisme de 
gastro-esophageale reflux niet kon voorkomen (hoofdstuk 7).
Toekomstige (gerandomiseerde) studies zullen moeten onderzoeken of de resultaten 
van de brachytherapie en stentplaatsing kunnen worden verbeterd met een hogere 
of gefractioneerde bestralingsdosis of met nieuwe typen stents zonder dat hiermee 
ook het aantal complicaties zal toenemen (hoofdstuk 8).
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Dankwoord
Mijn grootste dank en vooral medeleven gaat uit naar de patiënten die hebben 
meegewerkt aan mijn onderzoek en hun familieleden. Slokdarmkanker is naar mijn 
mening één van de ergste ziekten die men kan krijgen. De diagnose wordt veelal te 
laat gesteld, waardoor enige hoop op genezing niet meer reëel is en de basisbehoefte 
van iedere mens, namelijk eten, wordt een voortdurende strijd. De verschillende 
wijzen waarop de patiënten met deze ziekte omgingen heeft mij gefascineerd. Ik heb 
geleerd dat alles relatief is in het leven en hoewel mensen het zich vaak niet meer 
realiseren, gezondheid blijft het grootste goed. Het heeft mij ook geleerd dat de
medische begeleiding van deze mensen zeer belangrijk is, en ik zou hier graag in de 
toekomst mee door willen gaan.
Ondanks het onderwerp van mijn promotie, heb ik altijd met zeer veel plezier in het 
Dijkzigt ziekenhuis gewerkt. Dit onderzoek was uniek door de samenwerking met 
vele ziekenhuizen in Nederland, waarvoor mijn hartelijke dank, de duidelijke en 
relevante vraagstelling, het intensieve contact met patiënten en verpleegkundigen 
en de variëteit in het werk. De fameuze ‘promotiedip’ heb ik niet gekend! 
Grote dank gaat uit naar mijn begeleiders Peter Siersema en Ewout Steyerberg. De
samenwerking tussen deze twee mensen is een perfecte symbiose qua
samenwerking, de clinicus met de methodoloog, waaruit zeer veel mooie projecten 
zijn ontstaan en zullen ontstaan. Echter qua humor en ambitie doen ze niet voor
elkaar onder, heerlijk om mee samen te werken. Peter, jouw drive is aanstekelijk en 
heeft mij ambitieus gemaakt. We kennen elkaar bijna te goed! Ewout, ondanks je 
drukke programma altijd de tijd nemen voor mensen is een gave. Ik hoop in de
toekomst nog veel met jullie te kunnen samenwerken, jullie waren de perfecte
begeleiders voor mij! 
Verder wil ik mijn promotor Ernst Kuipers bedanken voor het grote vertrouwen in 
mij, de altijd positieve commentaren. En de verpleegkundigen, met name Joke
Moerman, die de patiënten thuis opzochten, hun fantastische werk! Joke, je verhalen 
en inzet maakten waren onvergetelijk.
Collega’s zijn het belangrijkst voor een leuke tijd! Rachel, Sarwa, Jan-Maarten, jullie 
zijn vrienden geworden. Grappig dat ondanks de verschillende karakters we het zo 
goed met elkaar kunnen vinden! Alle andere artsonderzoekers, Leon, Annemieke, 
Els, Marjon, Hajo, Thjon, Pieter, Bart, Monica die promotieboekjes gaan er komen!! 
Maar ook de arts-assistenten bedankt voor de leuke tijd, Abha, Ivonne, Jan Werner,
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Klaas, Tim, Pieter, Leonieke veel succes in de MDL-loopbaan. Wendy en Carla, dank
je wel voor de hulp. Alle andere MDLers en MGZters bedankt. Aangezien ik nu
weer op MGZ werk blijf jullie de komende tijd nog wel lastigvallen met mijn 
aanwezigheid!
Mijn vrienden zijn voor mij ontzettend belangrijk en gelukkig zijn ze er altijd!
Tijdens de Ardennen weekenden leer je ook jezelf kennen en als karakteristieke 
eigenschap kreeg ik de stempel ‘slim’. Mmm, het is gewoon een kwestie van doen.
Fem, leuk dat je mijn paranymph wil zijn! Jets, Mir, Maria, krijgen we ooit nog een 
iets rustiger leven dat we wel weer eens afspraken kunnen plannen? Leo, wie had 
gedacht op de kleuterschool dat je voorkant van mijn proefschrift zou maken. De 
Eindhoven groep die bijna niet meer in Eindhoven woont, Ramon, PP, Laura, Jon, 
Kirsten, Wouter, Simon, Simon, Eefje, Robbert, Hans, Wauter, en anderen, de 
feestjes blijven! 
Tijdens mijn promotietijd woonde ik in de ‘roots’ van onze familie, Schiedam, 
heerlijk vertrouwd, Dolly en Ben boven me, oma in de beurt, wat een grap. Dol, wie 
heeft er nu zo’n tante, je bent super! Erik, ik jouw getuige, jij nu mijn paranymph.
Samen met Frederic de perfecte familie, er altijd voor elkaar zijn, niet elkaars deur 
platlopen. Pap en mam, de opvoeding was perfect, grenzeloos vertrouwen, maar de 
goede adviezen altijd.
Tja, eigenlijk ben ik gelukkig met mijn leven en hopelijk dat er nog veel goede
dingen gaan komen. Dank je wel iedereen!! 
240
Curriculum Vitae 
Curriculum Vitae 
Marjolein Yvonne Véronique Homs werd geboren op 26 januari 1976 te Eindhoven
en groeide op in Son en Breugel. Ze voltooide haar VWO aan het Bisschop 
Bekkerscollege te Eindhoven en ging in 1994 ‘Voeding en Gezondheid’ studeren aan 
de Universiteit Wageningen. Tijdens haar studie voltooide ze een 
afstudeeronderzoek aan het Nederlands Kanker Instituut in het Antoni v 
Leeuwenhoekziekenhuis en ging een half jaar op stage naar de Nutrition
Department van de Otago University in Dunedin, op het prachtige zuid-eiland van 
Nieuw Zeeland. Het laatste jaar van haar studie voltooide ze een onderzoek aan de
Universiteit Wageningen en werkte daar als projectleider. Na haar afstuderen in 
1999 als voedingskundige en epidemioloog reisde ze een half jaar door India en
Nepal. Na deze avontuurlijke periode werkte ze korte tijd als junior onderzoeker bij 
de research afdeling van Unilever in Vlaardingen. In juli 2000 startte ze haar 
promotieonderzoek aan de afdeling Maag-, darm- en leverziekten van het Dijkzigt
ziekenhuis, tegenwoordig Erasmus MC. Het onderzoek betrof de palliatieve
behandeling van slokdarmkanker en vormde de basis voor dit proefschrift. Omdat 
ze echter in de toekomst klinisch onderzoek wil combineren met patiëntenzorg is ze 
in september 2003 gestart met de Master-opleiding Geneeskunde aan het
Universitair Medisch Centrum Utrecht. Als eerste lichting van 16 studenten zullen
ze binnen 4 jaar de opleiding geneeskunde gaan afronden inclusief co-schappen. 
Hierna wil ze zich verder specialiseren in de richting van de oncologie.
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